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Abstract 
The brain of Alzheimer’s disease (AD) is characterized by accumulations of β-
amyloid peptide aggregates which promote neurodegentartive dysfunction. Comprehensive 
understanding of the interaction between β-amyloid aggregates and acetylcholine (ACh) 
neurocycle is required to uncover the physiological processes related to AD and might result 
in improving therapeutic approaches for AD. Pharmacokinetics (PK) and pharmacodynamics 
(PD) techniques were applied to allow predicting the extent of the interaction of certain doses 
of AD drugs and β-amyloid inhibitors and levels of ACh as well. Although many researchers 
focused on the β-amyloid interactions, the mechanisms by which β-amyloid affects 
cholinergic neurons and reduction of ACh are still unclear.  The prediction of ACh and drug 
concentrations in the tissues and body needs an understanding of the physiology and 
mechanisms of β-amyloid aggregates processes and their compilation into a mechanistic 
model 
 In this work, two hypotheses are proposed to investigate the dynamic behavior of the 
interaction between β-amyloid peptide aggregates and cholinergic neurocycle and the 
possible therapeutic approaches through proposing pharmacokinetic/pharmacodynamics 
(PK/PD) models to represent the impact of β-amyloid aggregates in AD. The effect of β-
amyloid peptide aggregates is formulated through incorporating β- amyloid aggregates into 
non-linear model for the neurocycle of ACh where the presynaptic neuron is considered as 
compartment 1 and both synaptic cleft and postsynaptic neurons are considered as 
compartment 2. In the first hypothesis which is choline leakage hypothesis, β-amyloid 
peptide aggregates are considered to be located in the membrane of the presynaptic neuron 
and create pathways inside the membrane to allow for the intracellular choline to leak outside 
the cholinergic system. It is observed that β-amyloid aggregates via the choline leakage 
hypothesis could cause significant reductions of ACh and choline levels in both 
compartments. Furthermore, the process rates of ACh synthesis and hydrolysis have been 
affected negatively by a wide range of β-amyloid aggregate concentrations. It is found that as 
the input rate of β-amyloid aggregates to compartment 1 increases, the loss of choline from 
compartment 1 increases leading to an increase in the intracellular concentration of β-
amyloid. 
  iv 
In the second hypothesis, β-amyloid peptide aggregates are proposed to interact with 
the enzyme ChAT which is responsible for the synthesis of ACh in compartment 1; three 
different kinetic mechanisms are suggested to account for the interaction between β-amyloid 
aggregates and ChAT activity. In the first and second kinetic mechanisms, β-amyloid 
aggregate is supposed to attack different species in the enzyme. It is found that there is a 
significant decrease in the rate of ACh synthesis in compartment 1 and ACh concentrations 
in both compartments. However, it is observed that there is no effect on choline levels in both 
compartments, the rate of ACh hydrolysis in compartment 2, pH, and ACh levels in 
compartment 2.  In the third kinetic mechanism, all species in ChAT are attacked by β-
amyloid aggregates; it is observed that at very high input rates of β-amyloid aggregates, the 
oscillatory behavior dominates all components of the neurocycle of ACh. The disturbance 
observed in ACh levels in both compartments explains the harmful effect of the full attack of 
β-amyloid aggregates to all species of ChAT. It is found that to contribute significantly in 
ACh neurocycle, choline leakage hypothesis needs concentration of β-amyloid aggregates 
lower than that needed in ChAT activity hypothesis which is in agreement with experimental 
observations.  The significant decrease in ACh levels observed in both choline leakage and 
loss of ChAT activity hypotheses leads to cognitive loss and memory impairment which were 
observed in individuals with AD.  
  A one-compartment drug PK/PD model is proposed to investigate a therapeutic 
approach for inhibiting β-amyloid aggregation via choline leakage hypothesis where the 
maximum feed rate of β-amyloid (KL2 = 1) is considered.   The drug is assumed to interact 
with the tissues of the presynaptic neurons where β-amyloid aggregates are located.  The 
PK/PD model is built based on the effect of β-amyloid aggregates via choline leakage 
hypothesis where the maximum feed rate of β-amyloid aggregates is considered. The 
dynamic behavior of all concentrations of β-amyloid aggregates, choline, ACh, acetate, and 
pH in both compartments in addition to the rate of ACh synthesis in compartment 1 and ACh 
hydrolysis are investigated by monitoring the impacts of the drug on β-amyloid aggregates 
and cholinergic neurocycle over a wide range of the input drug dosage.   The PK/PD model is 
able to predict the reduction in levels of β-amyloid aggregates and the increase in choline and 
ACh, in both compartments as well as both rates of ACh synthesis and hydrolysis catalyzed.  
  v 
The parameters of the PK/PD model such as maximum concentration (Cmax), maximum time 
(Tmax), area under the curve (AUC), and maximum effect (Emax) were investigated. It was 
found that it takes a longer time (Tmax) (3-5 h) to reach Emax as the drug dose increases. 
Furthermore, AUC was found to increase with increasing drug dosage. The results of the 
current work show that drugs / therapeutic agents inhibiting β- amyloid aggregation in the 
brain represent a likely successful therapeutic approach to give systematic highlights to 
develop future trials, new diagnostic techniques, and medications for AD. This study is 
helpful in designing PK and PD and developing experimental animal models to support AD 
drug development and therapy in the future. 
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Chapter 1 
Introduction 
1.1 Background 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease. The irreversible declining 
of cognitive functions is considered the major characterizations of AD which has many 
symptoms of AD such as  memory loss, neurons dysfunction, confusion, and thinking 
disabilities. AD is the most common neurodegenerative disease in industrialized countries where 
China, Western Europe, and USA have the largest number of effected persons. The statistics 
show that there are  25 million people worldwide who have related dementia diseases,  most of 
them  are thought to have AD where  26.6 million persons worldwide had AD in 2006, and half a 
million Canadians have AD about 71,000 of them are under age 65. Also, by 2050 it is expected 
that one in every 85 persons worldwide will have AD. Therefore, AD is considered one of the 
main public health troubles that attracted researchers interests in the last decade (Lancet et al., 
2011).  There are several factors that promote the development of AD such as advancing age, 
head injury, and environmental factors like exposure to lead and aluminum which are 
neurotoxins. Furthermore, exposure to some chemicals such as toluene or benzene could 
increases the risk of AD. Genetics or family history is another serious risk factor that increases 
the odd of incidence AD three to fourfold in first- degree relative (sibling or parent) 
(Khachaturian and Radebaugh, 1996). The most common lifestyle factors causing AD are 
obesity, alcohol intake, and smoking. Chronic diseases increase the risk of occurring AD, 
including stroke, type-2 diabetes, hypertension, and hypercholesterolemia. There is information 
from many independent resources of Swedish epidemiological studies that suggest that social 
activities and social work could reduce the incidence of AD. Promotion health living conditions, 
with a strong exercise are considered the most promising approach for reducing the incidence of 
AD. The educational and occupational attainments are important factors that decrease the risk of 
AD. Since education improves  the brain’s reserve capability,  it is observed that only people 
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who achieve  low education levels have a double probability of  developing AD in comparison 
with the  those who accomplished  8 or more years of being at school (Khachaturian and 
Radebaugh,1996 ). There are four stages of AD with progressive features of cognitive and 
functional impairments and can be explained as follows: 
Stage 1- Pre-dementia:  it is characterized by forgetting recently happened events and losing 
ability to acquire new learning issues or data. 
Stage 2- Early stage: it is characterized by increasing impairment of memory and remembering 
capability. The effected person may forget how to use things, and may need supervision with the 
most cognitively demanding activities. Moreover, the patient at this stage suffers from 
difficulties in speaking and has shrinking vocabularies. 
Stage 3- Moderate stage: it is characterized by memory difficulties where patients could not 
remember close relatives such as persons of his or her family or performs daily activities. He 
also has speech difficulty due to inability to remember vocabularies and forgetting the suitable 
words for speech. 
Stage 4- Advanced stage:  In this stage the persons with AD are completely dependent on 
caregivers. Also the patients are not able to perform the simplest activities like feeding 
themselves and they lose the control of urine feeling. 
1.2 Interaction between β- amyloid peptide aggregates and AD 
The brain of Alzheimer’s disease (AD) is characterized by accumulations of β-amyloid peptide 
aggregates which promote neurodegenerative dysfunction. Amyloid plaque is aggregates of β-
amyloid peptides that deposit in the brain. β-amyloid is formed by cleavage of a transmembrane 
protein known as amyloid precursor protein (APP) by ɣ-β secratase enzymes (Goldager et al., 
1987). In addition, β-amyloid aggregates induce formation of neurofibrillary Tangles (NTF) in 
the form of accumulations of hyper phosphorylated tau protein inside nerve cell bodies.  Tau 
protein is a protein responsible for stabilizing microtubules which represent the cytoskeleton of 
the cells. Hyper phosphorylation of tau proteins leads to destabilizing and disintegration of 
microtubules, and hence collapsing the neurons and impairing axonal transport.  β-amyloid 
peptide aggregates affecting cholinergic neurocycle leading to low levels of acetylcholine (ACh) 
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and disturbances in cognition, memory, language and muscle movements.  Therefore, 
cholinergic dysfunction in communication between neurons and cell death are produced.  In AD, 
brain atrophy is characterized by loss of brain tissue and neuron cells that cause cognitive 
disorders, damage the connections between cells and decline in brain functions as indicated in 
Figure 1.1. 
The reasons of AD are still unknown; there are several hypotheses that try to explain reasons of 
AD: 
1- Amyloid hypothesis in amyloid cascade proposes that aggregation of β-amyloid which 
generates up on cleavage of amyloid precursor protein (APP) by ɣ-β secratase enzymes. 
These toxic aggregates of β-amyloid accumulate in the brain and on the surface receptors 
of neuron cells causing disturbance in neural communication by changing in the neuron 
components particularly choline and ChAT. 
2- Cholinergic hypothesis:  the idea of this hypothesis is based on decrease in synthesis of 
ACh neurotransmitter which causes AD. Cholinergic hypothesis is not strong enough 
because medications that cure ACh deficiency did not prove to be effective. 
3- Tau hypothesis: this hypothesis supposes that tau abnormality causes AD. In this 
hypothesis the hyper phosphorylated of tau protein initiates the formation of 
neurofibrillary tangles in neuron cells (NFT). Presence of NFT means disintegration and 
collapse of microtubule where dysfunction in communication between neuron and cell 
death occurs.  
4.  Other hypotheses: There are several other hypotheses. One is based on the breaking 
down of myelin in brains of elder people which initiates brain damage by iron release. 
Homeostatic myelin repair causes deposits formation called proteinaceous such as β- 
amyloid deposits. Another hypothesis is degeneration of locus coeruleus cells that 
provide norepinephrine neurotransmitter. Norepinephrine has anti-inflammatory effect in 
area around glia cells, neuron, and blood vessels in hippocampus and neocortex. In an 
experiment carried out on mice showed that norepinephrine stimulates microglia cells for 
β- amyloid phagocytosis and suppresses production of cytokine by β- amyloid. Other 
example such as oxidative stress.  
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Figure 1.1 the difference between normal brain and brain affected by AD 
(http://www.my-ms.org/symptoms_atrophy.htm) 
 
1.3 Research objectives  
In this work we investigate the nature of interaction between β-amyloid aggregates and 
cholinergic neurons to understand the pathological pathways that β-amyloid aggregates take into 
ACh neurocycle to induce AD. Then, based on this study, a therapeutic approach can be 
determined through  building a pharmacokinetics/pharmacodynamics (PK/PD)  model based on a 
cholinergic two-enzyme/two-compartment model where the presynaptic neuron is considered as 
compartment 1 and both synaptic cleft and postsynaptic neuron are considered as compartment 2. 
The main objectives of the thesis are: 
1) Describe the interaction between β-amyloid peptides and ACh neurocycle through 
incorporating the effect of  β-amyloid aggregates into two-enzyme/two-compartment 
model via proposing the following two  hypotheses: 
i) The first one is choline leakage hypothesis. It is proposed that β-amyloid aggregates 
existing in the membrane of the presynaptic neuron create channels leading to loss of 
choline (which is required for synthesizing ACh) outside the cholinergic system. 
ii) The other hypothesis is that β-amyloid aggregates interact with the enzyme ChAT 
which catalyzes the synthesis of ACh. In this hypothesis, three different kinetic 
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mechanisms are proposed to account for the interaction between β-amyloid aggregates 
and certain species in ChAT. 
2) Investigate the effect of β-amyloid aggregates on the dynamic behavior of ACh 
neurocycle in each hypothesis. The dynamics of ACh, choline, acetate, pH in both 
compartments are monitored at different concentrations of inlet β-amyloid aggregates to 
determine which state variables are affected negatively. 
3) Compare the effect of each kinetic mechanism proposed in ChAT hypothesis to identify 
which targeted species in ChAT have the most inhibiting effect. 
4) Determine if β-amyloid aggregates cause harmful effects in ACh neurocycle by 
observing concentrations of ACh, choline, acetate, rate of ACh synthesis and hydrolysis 
in each compartments by comparing the consequences of each hypothesis. 
5) Perform sensitivity analysis on the model parameters in order to choose the most 
appropriate values for kinetic constants that give results compatible with the experimental 
observations. 
6)   Build a pharmacokinetics/pharmacodynamics (PK/PD) drug model to investigate the 
dynamic effects of drug on the inhibiting effect of β-amyloid aggregates and investigate 
the dynamics of the system state variables at different doses of the drug. 
7) Determine the PK/PD parameters of the drug model such as AUC, Cmax, tmax, and Emax in 
order to determine the maximum concentration of each dose giving the maximum effect 
and the time taken to reach it. 
1.4 Thesis outlines 
This thesis comprises of six chapters: Chapter one is an introduction for AD features and factors, 
β-amyloid aggregates, and the objective of the research.  Chapter two includes a comprehensive 
literature review for the effects of β-amyloid aggregates as a major risk factor for AD with 
reference to choline leakage hypothesis, ChAT inhibition mechanism, and AD medications. 
Chapter three explains the choline leakage theory of β-amyloid aggregates. Chapter four presents 
the ChAT inhibition by β-amyloid aggregates and the consequences of this effect on declining 
ACh level. Chapter five introduces a PK/PD drug model and the dynamic effects of drug on the 
inhibition effect of β-amyloid aggregates and the dynamics of the system state variables at 
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different doses of the drug. Chapter six provides the conclusions of the study and some 
recommendations for future work. 
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Chapter 2 
Background and Literature Review 
(Introduction for the physiological processes in the 
neuron cell and their relation to Alzheimer’s disease) 
This chapter focuses on the necessary function of Acetylcholine (ACh) as a neurotransmitter in 
the process of signal transmission between neuron cells. The processes of ACh synthesis and 
release are covered before highlighting the role that β-amyloid peptides role and how they are 
formed and released and the effects of β-amyloid as a neuron defective agent on cholinergic 
neurons. In addition, pharmacokinetic and pharmacodynamics of drugs dealing with Alzheimer’s 
disease (AD) are focused. 
2.1) Acetylcholine (ACh) neurocycle 
ACh is a neurotransmitter in both peripheral nervous system (PNS) and central nervous system 
(CNS) which facilitates cholinergic transmission and regulates cognition, memory, language and 
muscle movements. ACh probably has been developed long before the appearance of a nervous 
system, since the machinery to synthesize and degrade ACh is present in microorganisms such as 
bacteria, fungi, protozoa and plants [Kazue S. (2004)]. Even in so-called higher organisms, ACh 
is present in non-neural tissues such as the placenta, suggesting that ACh has cellular functions 
other than neurotransmission [Kazue S. (2004)]. 
2.1.1) Functions of ACh 
ACh is a neuromodulator which plays necessary functions in PNS and CNS. In PNS, ACh 
activates muscle movements. As soon as ACh binds to cholinergic receptors (nicotinic and 
muscarinic receptors) on skeletal muscle, the ligand-gated sodium channels on the cell 
membrane open to permit sodium ions to go inside the muscle cell. Then, entrance of sodium 
ions triggers frequent steps that generate muscle contraction.  In CNS, ACh acts as a 
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neuromodulator where ACh has a vital role for improving of sensory recognition during wake up 
and sustaining attention. Damaging ACh cholinergic system in brain leads to memory 
dysfunction which leads to AD. 
 
2.1.2 Synthesis of ACh 
ACh is produced in the presynaptic neurons by interaction of choline and acetate in the presence 
of choline acetyltransferase enzyme (ChAT) (Eckenstein and Baughman, 1984) as shown below:  
   
      Choline + Acetyl-CoA  ChAT  ACh + CoA                               (2.1)  
Then, ACh is stored in presynaptic vesicles by the vesicular ACh transporter (VAChT) (Boucetta 
and Jones, 2009; Guyton and Hall, 2000; Tucek, 19780; Bussiere et al, 2001; Ballivet et al., 
1996].   When the presynaptic neuron is depolarized by the action potential, the calcium channels 
open to facilitate entering of calcium ions. Influx of calcium ions triggers the fusion of synaptic 
vesicle to membrane to release ACh in the synaptic cleft. ACh diffuses in the synaptic gab and 
reacts with the cholinergic receptors protein (Nicotinic and muscarinic ACh receptors) in the 
postsynaptic membrane [Ballivet et al., (1996)]. This binding with the receptors causes excitation 
or inhibition of postganglionic cell [Quinn et al, 1995; Llinas, 1999; Tucek, 1978; Ballivet et al., 
1996; Rand, J.B, 2007]. After ACh sets action on postsynaptic neuron receptors, it is hydrolyzed 
by acetyl cholinesterase (AChE) into choline and acetate. Choline is recycled to the presynaptic 
neuron for further ACh synthesis (Yael et al., 2011). The sources for the precursors required for 
ACh synthesis like acetyl-CoA and choline are as follows: 
 
A) Sources of acetyl groups for the synthesis of ACh 
Acetyl-CoA is a necessary cofactor in metabolism of glucose, fatty acids, and certain 
amino acids. It is synthesized within mitochondria matrix during pyruvate decarboxylation 
reaction. This reaction is the key process for metabolism of glucose where pyruvate coming from 
glucose metabolism is converted by pyruvate dehydrogenase complex into acetyl-CoA. The 
latter one carries carbon atoms inside acetyl group to Krebs’s cycle (TCA cycle) for energy 
generation by oxidation. Also, Acetyl-CoA can be generated by β-oxidation of long chain fatty 
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acids or during oxidative degradation for some amino acids. The immediate precursor of the 
acetyl groups of ACh in living cells is acetyl-CoA.  Acetyl-CoA is transported out of the 
mitochondria to participate in ACh synthesis. It is not clear how the acetyl groups of acetyl-CoA 
which is formed in the mitochondrial matrix from pyruvate pass into the extra mitochondrial 
space, where the synthesis of ACh occurs. The inner mitochondrial membrane is generally 
considered to be impermeable to acetyl-CoA. A number of substances (citrate, glutamate, 
acetylcanitine, acetate, acetoacetate, acetylated amino acids) have been proposed to act as 
carriers of acetyl groups from the mitochondria for metabolic reactions proceedings extra 
mitochondria [Tucek, (1978);   Vera Yip (1991)].  A probable carrier for acetyl-CoA is citrate, 
which can diffuse into the cytosol and produce acetyl CoA via citrate lyase; a possible carrier is 
acetyl carnitine, and another possibility is Ca
2+ 
induced leakage of acetyl-CoA from 
mitochondria [Cooper et al., (2003)]. 
 
B) Sources of choline for the synthesis of ACh 
Strecker is the first one who discovered choline (Ch) in 1862; then choline has got an 
important interest because of the essential role it plays in body function. For example, choline is 
one of cell membrane structures (phosphatidyl choline), and it is a precursor for ACh 
neurotransmitter. Even human body has ability for choline synthesis de novo, choline rich food is 
the most effective source for Choline. Food containing choline is necessary for prenatal memory 
growth and liver function (Lockman and Allen, 2002). Since choline is an important component 
for ACh, any shortage in choline supply sources can lead to reduction of ACh formation in the 
body, and hence AD. Lockman and Allen (2002) showed that the concentration of choline in 
plasma varies around 10 µM. Food saturated with choline or food deficient choline can either 
increase or decrease plasma choline concentration. Stabilization of choline levels in plasma 
occurs by its synthesis from catabolism of phosphatidylcholine (cell membrane component). In 
presynaptic of the neurons ACh synthesis process occurs by choline reactions with acetyl-CoA 
via ChAT enzyme to generate ACh. As soon as presynaptic is excited by action potential, ACh is 
released in synaptic cleft to bind to post synaptic neurons receptors for transmission of action 
potential. Then ACh is hydrolyzed by AChE into choline and acetyl-coA. Choline is recovered 
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back into presynaptic neuron for further ACh synthesis. Choline recycle is a rate limiting step for 
ACh formation within the neuron (Lock man and Allen, 2002; Mustafa et al., 2012). 
 
C) Choline Transport 
Choline transmission is a necessary process for physiological body operations. Because choline 
has a hydrophilic charged cation at physiological pH, it has difficulties to cross the cellular 
membrane. There are many mechanisms for choline transport (Lockman and Allen, 2002) shown 
as follow: 
1- Low–affinity choline transport mechanism:  In this mechanism choline transport occurs via 
passive diffusion, and depends on choline concentrations and independent on sodium ions 
levels. Low – affinity transporter is carrier-mediated. For instance, in rat cortical synaptosom 
choline transport has exhibited a sodium-independent carrier-mediated process. Another 
example is in basolateral plasma membrane of the rat liver where choline transport has been 
shown to be sodium-independence and carrier mediated. Low–affinity choline transporter 
occurs in hepatocytes, placenta, synaptosomes, and mitochondria tissue. Choline transport by 
this mechanism provides choline for phosphatidyl choline and Phospholipids synthesis for 
cell membrane (Lock man and Allen, 2002). 
2- High-affinity choline transport: Lockman and Allen (2002) defined the high-affinity choline 
uptake mechanism as a carrier-mediated, sodium and chloride dependent. Further, this 
transport system provides choline for ACh synthesis in presynaptic nerve ending. High 
affinity sites for this system are interpeduncular nucleus, olfactory tubercle, and caudate 
putamen. According to Yamamura and Snyder (1973) replacement of sodium with lithium 
decreased choline uptake by 95% in synaptosomes. According to Simon and Kuhar (1976) 
who showed that high-affinity mechanism of choline transport is chloride and energy 
dependent. Further, replacement of sodium with potassium or lithium lowered choline 
aggregations in human erythrocyte by approximately 60%. High-affinity choline uptake 
system is carrier-mediated sodium dependent mechanism in presynaptic cholinergic of the 
neuron. 
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3-  Unique choline transport mechanism: This mechanism occurs at blood-brain barrier as a 
basic amine transport (Lockman and Allen, 2002). Choline needs to cross blood-brain barrier 
because brain has a high need for choline to maintain physiological role in CNS. In addition, 
the ability of brain to synthesize choline de novo is low in comparison to what is needed by 
cholinergic nerve terminals to set its physiological function (Lockman and Allen, (2002; 
Ansell, G.B. et al., 1971). Choline has low permeability across blood brain barrier because of 
its cationic charged at physiological pH where brain barrier allows lipid-soluble molecules to 
diffuse cross the membrane, but the hydrophilic compounds such as choline have low 
permeation at the blood brain barrier (BBB) (Lockman and Allen, 2002; Schuberth, J et al., 
1969 and 1970). Therefore, BBB regulates the transport of choline between plasma and CNS. 
In addition, BBB is composed of endothelial cells that are joined to each other by tight 
connections at brain capillaries, and these junctions are tighter than other capillary 
endothelium junctions. The unique choline transport is a carrier mediated mechanism, and 
has the categories from both regular mechanisms and is similar to high-affinity system in 
affinity of choline, but it is sodium-independent as low-affinity mechanism. It has been 
shown that removal of sodium did not alter choline transport across capillary endothelial 
cells in mouse brain. 
2.1.3) Degradation of ACh 
 Once ACh has completed its activation duty; it becomes susceptible to degradation process. The 
main reaction is described by equation (2.2) where ACh is degraded by the acetyl cholinesterase 
(AChE) into choline and acetic acid [Tucek (1978) and (1985); Bussiere et al, (2001)]. 
R (2):          ACh + Water  
AChE
Choline +CH3COOH                    (2.2) 
Choline is recycled to presynaptic by the high affinity choline transprter-1(CHT-1) for further 
synthesis of ACh (Kim et al., 2004). 
 Figure 2.1 shows that there are two main enzymes involve in ACh producing system can be 
explained as follow: 
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i) Choline Acetyltransferase enzyme (ChAT) 
It is a single-strand globular protein, its synthesis process occurs in the body of the neurons 
(perikaryon of cholinergic neurons) and then it transported to the nerve terminals via axoplasmic 
flows. ChAT is responsible for the biosynthesis of ACh and it represents the most specific 
indicator for monitoring the functional state of cholinergic neurons in the central and peripheral 
nervous systems (Yoshio Oda, 1999). Inhibition of ChAT activity causes AD and abnormalities 
of ChAT in the brain could lead to schizophrenia (Yoshio Oda, 1999). Studying molecular and 
genetic nature of ChAT will help to understand the pathological nature of cholinergic neurons 
because ChAT plays a vital role in activation cholinergic neurons functions, such as learning, 
memory, sleep and muscle movement. The specific loss of ChAT activity was detected in AD  
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Figure (2.1) Schematic of synaptic neurons and cleft (Mustafa et al., 2009) 
(Yoshio Oda, 1999). Although ChAT activity can be measured from the rate of utilization of 
either its substrates or the synthesis of its products, the most convenient method of its assay is 
based on the measurement of ACh [Rand, J.B. et al., (1984); Marco et al., (2002)]. This is done 
using [
14
C] acetyl-CoA as substrate and measuring the radioactivity in ACh. Labeled ACh is the 
M1 M1 
M2 M2 
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most conveniently separated from labeled acetyl-CoA by extraction with tetraphenyloborn in 3-
heptane [Tucek (985);  Rand, J.B. et al., (1984); Bussiere et al.,  (2001); Marco et al.,  (2002)]. 
ii) Acetylcholinesterase [AChE] 
 AChE is an enzyme that hydrolyzes ACh into choline and acetate. All cholinesterases will 
hydrolyze not only ACh but other esters as well. Conversely, hydrolytic enzymes such as 
arylesterases, trypsin, and chymotrypsin will not hydrolyze choline esters. The problem in 
determining the number of cholinesterases is that different species and organs sometimes exhibit 
maximal activity with different substrates. The enzymes are divided into two rigidly defined 
classes: AChE (also called "true" or specific cholinesterase) and butyrylcholinesterase (also 
called "pseudo" or nonspecific cholinesterase; the term propionylcholinesterase is sometimes 
used since in some tissues propionylcholine is hydrolyzed more rapidly than butyrylcholine).  
Both of the two enzymes have similar molecular forms, but they have different entities, encoded 
by distinct genes. Current evidence suggests that in lower forms butyrylcholinesterase 
predominates, gradually giving way to AChE with evolution. When distinguishing between the 
two types of cholinesterase, at least two criteria should be used because of the aforementioned 
species or organ variation. 
 
2.1.4) Axonal Transport of ChAT, AChE and ACh 
 Most of ACh which is used for synaptic transmission is synthesized in the immediate 
vicinity of the synapses, i.e. in terminal parts of cholinergic axons [Frederick et al, (1980); Rand 
et al, (1984)]. ChAT is produced in the bodies of the neurons and is transferred to the presynaptic 
nerve endings by the mechanism of axonal transport [Marco et al., (2002)]. Axonal transport also 
delivers to the nerve endings some, most or perhaps all of ACh which is produced in the 
perikarya and neuritis of cholinergic neurons [Marco et al., (2002) and Tucek, 1985]. 
To date, the only major through studies of ACh turnover in nervous tissue were done 
originally by Macintosh and colleagues and subsequently by Collier (2003) using the superior 
cervical ganglion of the cat [Cooper et al., (2003)]. Using one ganglion to assay the resting level 
of ACh and perfusing the contralateral organ, Cooper et al, (2003) determined the amount of 
transmitter synthesized and released under a variety of experimental conditions, including 
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electrical stimulation, addition of an anticholinesterase to the perfusion fluid, and perfusion 
media of varying ionic composition [Cooper et al, (2003)]. Their results may be summarized as 
depicted by Cooper et al, (2003) as follows: 
1. During stimulation, ACh turns over at a rate of 8-10% of its resting content every minute (i.e., 
about 24-30 ng/minute). At rest, the turnover rate is about 0.5 ng/minute. Since there is no 
change in ACh content of the ganglion during stimulation at physiological frequencies, it is 
evident that electrical stimulation not only releases the transmitter but also stimulates its 
synthesis. 
2. Choline is the rate-limiting factor in the synthesis of ACh. 
3. In the perfused ganglion, Na
+
 is necessary for optimum synthesis and storage and Ca
2+
 is 
necessary for release of the neurotransmitter. 
4. Newly synthesized ACh appears to be more readily released upon nerve stimulation than 
depot or stored ACh. 
5. More than half of choline produced by cholinesterase activity is reutilized to make new ACh. 
6. At least three separate stores of ACh in the ganglion are inferred from these studies: surplus 
ACh, considered to be intracellular, which accumulates only in an eserine-treated ganglion and is 
not released by nerve stimulation but is released by K depolarization; depot ACh, which is 
released by nerve impulses and accounts for about 85% of the original store; and stationary ACh, 
which constitutes the remaining 15% that is non releasable. 
7. Choline analogs, such as triethylcholine, homocholine, and pyrrolcholine, are released by 
nerve stimulation only after they are acetylated in the ganglia. 
8. Increasing choline supply in the plasma during perfusion of the ganglion only transiently 
increases the amount of ACh that is releasable with electrical stimulation, despite accumulation 
of the transmitter in the ganglion. 
 ChAT appears to be transported slowly in mammalian nerves, at a rate of 1-6 mm/day.  
Its transport probably involves the entire enzyme in the axons and proceeds in the proximo-distal 
direction only; the transported enzyme is not associated with axonal organelles [Tucek (1987), 
Krishanu et al., (1999)]. There is, however, an alternative hypothesis which assumes that the 
transport concerns only a small part of ChAT in the axons but it proceeds at a high rate 
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[Krishanu et al., (1999)]. Contradictions on this point are difficult to resolve, since there is no 
way for determining the size of the mobile fraction of ChAT in the axons. Axonal transport of 
ChAT continues in the axons separated from nerve cell bodies, but its intensity is diminished.  It 
is blocked by ischaemia. 
ACh is also transported proximo- distally in cholinergic axons. The rate of its transport is 
estimated at 120 mm/day in mammalian nerves. The transport probably involves only the bound 
ACh in the axons, i.e. ACh contained in some unidentified axonal organelles, about 20% of the 
total ACh content. ACh supplied to the nerve endings via axonal transport represents a very 
small portion of the whole amount of ACh which is necessary for synaptic transmission [Tucek, 
(1987), Krishanu et al, (1999); Jesus et al, (2003)]. Most of ACh is synthesized in the nerve 
terminals, i.e. in the immediate vicinity of the synapse [Tucek, (1987) and (1985), Krishanu et al, 
(1999); Jesus et al, (2003)]. Axonal transport of AChE proceeds at a high rate in both directions 
[Krishanu et al, (1999)].  The transported enzyme is associated with axonal organelles and 
represents a small part of the total AChE content in the axons [O'Brien R A, (1978)]. The 
transport of AChE in the axons does not depend on the connection between the axons and the 
bodies of the nerve cells [O'Brien R. A. (1978)]. 
 
2.1.5) Organization and Control of the Synthesis of ACh in Presynaptic Nerve Endings 
Although some ACh is synthesized in all parts of a cholinergic neuron, most of it is 
produced in close proximity to the sites from which it is released by nerve impulses, i.e. in the 
terminal parts of the axon and, in some neurons, probably in the boutons en passant and in the 
axonal varicosities as well [Shawn et al, (2004)]. The enzyme is responsible for the synthesis, 
ChAT, is mainly dissolved in the cytoplasm of the nerve endings, but a proportion of it is 
probably adsorbed by the cytoplasmic side of the surface membrane and by other membranes in 
the nerve endings, including the membranes of the synaptic vesicles [Tucek (1978); Shawn et al, 
(2004)]. ACh is localized in the cytoplasm and in the synaptic vesicles. It is not clear how the 
transmitter is synthesized in the cytoplasmic compartment, is transferred to the vesicles. What 
proportion of the total ACh in the tissue is present in the vesicles is also not [Tucek (1978), 
Shawn et al., (2004)]. It is possible that much of ACh originally present in the vesicles is 
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released or diffuses from them during the homogenization and fractionation of the tissue [Tucek 
(1978); Shawn et al, (2004)].  
Most features of the release of ACh at the synapses are best explained by the vesicular 
hypothesis where nerve impulses are assumed to cause the release of ACh from the synaptic 
vesicles [Tucek, (1978); Shawn et al., (2004]. This hypothesis, providing an easy explanation for 
the fact that ACh is released in discrete quanta, is mainly supported by observations that the 
amount of vesicular ACh can be altered by stimulations, that the release of old ACh is 
accompanied by the appearance of newly synthesized ACh in those vesicles which had 
apparently undergone exocytosis, and that synaptic activity is accompanied by ultra-structural 
changes indicating exocytosis and recycling of vesicles  [Tucek (1978); Shawn et al., 2004]. 
Objections to the vesicular hypothesis, ACh release are mainly based on observations of the 
nerve impulses which more easily produce changes of the so-called free ACh with comparison to 
the bound ACh; at least some, if not all free ACh is freely dissolved in the cytoplasm, where the 
bound ACh (stable- bound ACh in mammalian preparations) is contained in the synaptic vesicles 
[Tucek (1978), Shawn et al., (2004)].  
Continuous slow synthesis of ACh proceeds in the cholinergic neurons even under 
conditions of ‘rest’ [Ballivet et al., (1996)] when the rate of ACh release is increased by nerve 
impulses. This rate of synthesis is also increased [Shawn et al., (2004)]. Recently it has been 
found that synthesized ACh is released preferentially during synaptic activity. Several 
hypotheses have been proposed to explain the mechanism of the control of the synthesis rest 
[Ballivet et al., (1996)].  The control of ACh synthesis is most probably based on the law of mass 
action, and the resting level of ACh in the compartment of synthesis corresponds to the 
concentration of ACh to be expected when the synthetic reaction is at equilibrium, lowering the 
concentration of ACh in the compartment of synthesis automatically leads to the synthesis of 
new ACh [Shawn et al., (2004)]. According to this hypothesis, the rate of synthesis and the 
equilibrium concentration of ACh are influenced by changes in the concentration of substrates, 
i.e. acetyl-CoA and choline at the site of synthesis [Shawn et al., (2004)]. The high affinity 
uptake of choline may represent an additional factor in the mechanism controlling ACh 
synthesis. Experimental observations indicate that the uptake of choline by the nerve endings is 
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augmented when the concentration of ACh in them is diminished. External (and perhaps also 
internal) ACh has an inhibitory action on the high affinity carrier of choline [Tucek (1978), Jian 
(2005)]. Further investigations are necessary to establish whether the supply of acetyl-CoA for 
ACh synthesis is influenced by the influx of Ca
+
 ions in the nerve terminals as a result of nerve 
impulses; Ca
+
 ions might act by causing the activation of pyruvate dehydrogenase phosphate 
phosphatase and by increasing the permeability of the inner mitochondrial membrane for acetyl-
CoA [Tucek (1985), Jian (2005)]. It has been suggested that the control of ACh synthesis in the 
nerve endings depends on the inhibitory action of ACh and CoA on ChAT or on the effect of 
changing ionic concentrations on the activity of ChAT, but these mechanisms do not appear to be 
physiologically importance [Tucek (1978) and (1985); Shawn et al., (2004)]. In contrast to 
adrenergic synapses, re-uptake of the released transmitters into the presynaptic nerve endings 
and its re-utilization for synaptic transmission don not play any role on cholinergic synapses 
[Tucek (1978) and (1985); Shawn et al., (2004)]. 
 
2.1.6) Changes in ChAT Activity during the Lifetime of an Individual  
It is very likely that measurements of ChAT activity in various organs and tissues 
removed from animals of the same species at different ages provide reasonably good information 
about long term changes of ACh synthesis in theses organs or tissues during the lifetime of 
individuals of the species. 
Tucek (1978) and Shawn et al., (2004) showed that prenatal and early postnatal 
development of the central nervous system and of peripheral organs receiving a cholinergic 
innervations is accompanied by a marked increase in their ChAT activity. This increase is based 
not only on the growth of cholinergic neurons, but also on the elevation of the concentration of 
ChAT in them. Transient decrease of ChAT activity observed in some tissues during 
development may be caused by the fact that during certain periods the non-cholinergic 
components of theses tissues are developed faster than the cholinergic ones. In old age the 
activity of ChAT in cholinergic neurons generally diminishes [Nakamura et al, (1996)]. 
 The activity of ChAT in neurons is very probably influenced by their functional activity. 
This is suggested by observations in salivary glands, adrenal glands and skeletal muscles, but the 
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relation between functional activity of neurons and ChAT synthesis in them requires more 
investigations. Changes of ChAT activity depending on hormonal influences have been well 
demonstrated in brain during hypothyroidism (a decrease) and after the administration of nor 
adrenaline into the brain ventricles (an increase); a sex- dependent difference in ChAT activity 
has been found in the preoptic suprachiasmatic area of the hypothalamus [Tucek (1978) and 
Nakamura et al., (1996)]. Androgenic hormones influence the activity of ChAT (and general 
development) of the levator and muscle [Tucek, (1978); Nakamura et al, (1996)]. 
A large decrease of ChAT activity leading to almost complete disappearance of its 
influence is observed during degeneration of peripheral nerves in homoeothermic animals 
generation of the axons is accompanied by the formation of ChAT in Schwann cells [Steven et 
al., (2002)]. The activity of ChAT in the axon is diminished during regeneration and for a long 
time after the regeneration has been completed [Steven et al., (2002), Tucek (1978) and Shawn et 
al., (2004)]. ChAT activity in cholinergic neurons and their axonal terminals is greatly influenced 
by the formation of synaptic contacts with postsynaptic cells [Steven et al., (2002)]. Experiments 
on hormonally induced changes in the levator indicate that ChAT activity in cholinergic nerve 
terminals is also dependent on the functional state of postsynaptic cells.  The mechanism of 
retrograde transsynaptic effect of the postsynaptic on the presynaptic cell has not been clarified 
[Tucek (1978) and (1985); Steven et al, (2002)]. 
 
2.2) β-amyloid (Aβ) peptides 
 β-amyloid is a peptide of 36-43 amino acids that is produced from Amyloid precursor protein 
(APP) via proteolytic cleavage. β-amyloid peptides are considered to be the main toxic species in 
the pathogenesis of AD (Randall et al., 2010). The self-assembly of β-amyloid first forms 
clusters known as oligomers, then oligomers chains form fibrils, the latter accumulates into 
insoluble forms of aggregates that deposit in the brain causing AD (Verdier et al., 2004).   
 
2.2.1) Amyloid precursor protein (APP)  
APP is a transmembrane glycoprotein with C- terminal cytoplasmic part and a long N-terminal 
extracellular region. APP is located in synapses of the neurons cells and other tissue. The soluble 
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monomer form of β-amyloid peptide is generated by proteolysis effect of β-and ɣ-secretase to 
around 110 kDa transmembrane of APP. These soluble β-amyloid peptides accumulate to 
insoluble form of β-amyloid peptides called senile plaque (sp) in the brain (Walter et al, 2008). 
There are some genetic risk factors that could lead to AD generation via increasing β-amyloid 
peptides levels in the brain. When lab experiments were carried on a genetically engineered mice 
that has been developed by Walter et al, 2008, the genetically engineered mice was carrying a 
human gene, a gene that is responsible for a rare kind of inherited AD, Walter et al, (2008) 
observed that the generation of β-amyloid in the mice and memory dysfunction as well (Walter 
et al, (2008)). All mutation in APP genes, presenilin1 (PS1) gene, and presenilin 2 (PS2) 
contribute to early-onset AD. These three gene defects lead to imbalance between β-amyloid 
formation and its clearance. Consequently, complex intra-and extracellular accumulations of β-
amyloid are formed leading to inflammation of neurons, synaptic changes, generation of 
neurofibrillary tangles, and loss of transmission (Verdier et al, 2004).  
Whereas, mutation the ε4 allele of the apolipoprotein E gene, on chromosome 19 lead to late-
onset AD, but expression of ε2 allele prevents AD developing (Kar et al., 2004; Holmes C, et al, 
2002, Poirier t at al., 1993).  Moreover, It is observed that changes on presenilin1 (PS1) gene on 
chromosome 14 and Presenilin 2 (PS2) on chromosome 1 initiate early onset familial cases of 
AD (under 65 years) (Kar et al, 2004).  
 
2.2.2) Formation of β -amyloid  
β-amyloid is produced by cleavage of amyloid precursor protein (APP).  APP has the following 
two pathways for cleavage as indicated in Figure 2.2:   
1- The first is non-amyloidogenic pathway by α-secretase between Lys 16 and Leu 17 amino 
acids residue to produce N-terminal soluble APPα (sAPPα) and C-terminal APP fragment. 
This pathway inhibits the formation of a complete-length β-amyloid peptide as shown in 
Figure 2.2. This pathway is not toxic and does not cause AD because of generation of more 
neurotrophic sαAPP protein (Kar et al., 2004). The sαAPP has abilities to regenerate brain 
cell particularly after sever brain injury that happens follow stroke and cerebral ischemia, and 
also sαAPP regulates excitation of neuron cells and synaptic plasticity. Additionally the 
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sαAPP has neurogenic, growth- promoting, and neuroprotective characterizations (Walter et 
al., 2008).  
2- The second pathway for proteolysis is first processed by β-secretase to yield soluble APP and 
a membrane bound β-amyloid containing C-terminal. The Second cleavage to membrane 
bound β-amyloid containing C-terminal by ɣ-secretase to produce complete Aβ1-40/42 peptide 
as shown in Figure 2.2 (Kar et al., 2004). Aβ40 peptide is more neurotoxic and linked to 
vascular endothelium. Aβ42 peptides aggregate to form the basic nucleus of senile plaque 
(SP) and then Aβ40 peptides deposit later. The catalytic ɣ-secretase is considered the rate 
limiting step for formation of β-amyloid peptides (Walter et al, 2008). The two isoforms of 
Aβ40/42 peptides are toxic because they can cause oxidative stress, neuron dysfunction, cell 
apoptosis and brain death (Walter et al., 2008). In normal cases approximately 90% of 
generated β-amyloid peptides are Aβ 1-40 which are soluble but convert to β-sheet that can be 
eliminated from the brain. On the other hand, 10% of secreted β-amyloids are Aβ1-42 that 
self-assembled to amyloid plaques are deposited in the brain to generate AD (Kar et al, 
2004). 
Recent studies showed that there is a receptor SorLA/LA11 which is a transmembrane 
lipoprotein and regulates the endocytic pathways of APP (Walter et al., 2008). SorLA/LA11 
plays an important role in determining which form of App is neurotoxic or neurotrophic up on 
proteolysis. Genetic mutations in sorting receptor result in late-onset AD.   Currently, it is clear 
that α, β, and ɣ-sectrtases-SORL1 of APP have become pharmaceutical targets strategies to 
convert neurotoxic of APP pathway to neurotrophic one (Walter et al, 2008). 
 
2.2.3) Aggregation of β-amyloid peptide 
Accumulation of β-amyloid peptide is a multistep process. First it starts with misfolded β-
amyloid to form β-Sheet, and then β-Sheet aggregates into oligomers (dimmers, trimmers, and 
dodekamers). This step of formation of oligomer is the rate limiting step called nucleation step 
(Verdier et al., 2004). After that protofibril generates until the aggregation of β-amyloid is 
insoluble form.  Finally, protofibril elongated rapidly into insoluble fibril (Silva et al., 2010; 
Verdier et al., 2004). 
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Figure 2.2: a schematic represents the two catalytic pathways for Amyloid precursor protein 
(APP) cleavage (Kar et al., 2004) 
 
2.2.4) Toxic effect of β-amyloid 
  Randall et al, (2010) showed that the appearance of insoluble β-amyloid peptides in the brain is 
considered a hallmark of AD. These insoluble plaques of β-amyloid are the key toxic risk factor 
in pathology of AD where injection of β-amyloid oligomer into rodent CNS leads to disturbance 
in cognition functions (Clearly et al, 2005; Poling et al, 2008). Also, as shown in Figure 2.3 the  
aggregations of amyloid peptides in the brain cause shrinkage of neuron cells and decrease their 
ability to synthesize and release ACh neurotransmitter through depletion of ACh precursors  like 
choline, and making complex with ChAT;  exposure SN56 cholinergic cell lines to Aβ1-40 caused 
shrinkage and cell death for these cells (Kar at al., 2004).  Verdier et al 2004 indicated that the 
toxicity of β-amyloid peptides is due to their interaction with cholinergic cell membrane and 
cellular organelles as well. This causes an impairment of cellular physiological processes. For 
example, β-amyloid peptides make leakage in cell membrane of neurons leading to choline 
leakage, and hence decreasing in ACh level (Kar et al, 2004). Moreover, β-amyloid peptides bind 
to ChAT making a complex which hiders ChAT activity process for ACh synthesis (Cheng and 
Prusoff, 1973). Also, β-amyloid peptides interact with glial cells. This stimulates production of 
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toxic mediators from glial cells and causing neurotoxicity. The toxic effects of β-amyloid 
peptides can be explained as follows: 
 
1- Changes of cholinergic functions 
  β-amyloid peptides at small concentrations (picomolar- nanomolar) can affect various steps of 
ACh synthesis and can be released as Figure 2.4 indicates. For instance, β-amyloid peptides 
cause inactivation of pyruvate dehydrogenase enzyme which is responsible for production acetyl 
coenzyme A (acetyl-CoA) from pyruvate (Kar et al., 2004). This effect of β-amyloid peptides is 
consistent with lab experiment observations where an exposure of nanomolar concentration of 
Aβ 1-42 peptides to rat septal neurons reduced ACh formation and decreased activity of acetyl-
CoA production by decreasing activity of pyruvate dehydrogenase enzyme (PDH) (Kar et al, 
2004; Pedersen, 1997)). Also, β-amyloid peptides could reduce high-affinity uptake of choline; 
incubation of hippocampal synaptosomes with nanomolar β-amyloid which stopped the 
depolarization that stimulates high-affinity choline uptake (Kar et al, 2004 and 1998).  Moreover, 
high-dose exposure to β-amyloid peptides reduces activity of ChAT. β-amyloid peptides have an 
effect on reducing ACh release from synaptic vesicles (SV). When β-amyloid peptides were 
injected into rat, ACh release from hippocampus was decreased (Kar et al., 2004; Harkany et al., 
1995). The inhibition effect of β-amyloid peptides on ACh release was regenerated by ginseng 
saponins (Lee et al., 2001; Kar et al., 2004). Furthermore, Kar et al., (2004) reported that β-
amyloid peptides have the ability to impair muscarinic M1 like signaling; incubation of nM-mM 
concentrations of Aβ1-40 with rat cortical cultured neurons decreased the carbachol produced 
GTPase activation effect (Kar et al., 2004; Kelly, 1996). Moreover, increasing choline 
conductance from PC12 cells after long exposure to micromolar Aβ1-40 is due to choline depletion 
by decreasing choline uptake and increasing choline leakage from the neurons (Kar et al., 2004). 
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Figure 2.3: β-amyloid induced toxic effect through different mechanisms (http://www.sharpbrains.com/wp-
content/uploads/2012/01/plaques_and_tangles_border.jpg) 
 
2- Neurofibrillary Tangles (NFTs) Formation 
 β-amyloid peptides aggregations in the brain generate neurofibrillary tangles (NFTs): 
neurofibrillar tangles (NFTs) are paired of helical filaments that include hyper phosphorylated 
tau protein. Tau is a protein that is responsible for stabilizing microtubules (the cytoskeleton of 
the cells) via reversible enzymatic mechanisms including phosphorylated and dephosphorylated 
reactions. When phosphorylated tau is not able to undergo dephosphorylated by action of β-
amyloid peptides, as a result hyper phosphorylation form of tau proteins is generated. 
Accordingly, the tau would lose its ability to bind and stabilize microtubule. This leads to 
destabilizing microtubule, impairing of axonal transport and cell death. This is confirmed with 
the experimental results in which β-amyloid plaques increase the phosphorylation of tau protein 
in SN56 cholinergic cell lines (Kar et al., 2004). 
 
3 -Formation of free radicals 
 When β-amyloid peptides bind to p75 receptors of neuron cells, free radicals are formed leading 
to apoptosis and loss of cholinergic neurons. This results in decreasing neurotransmitters 
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secretion from these cells. Since the level of p75 is highest in cholinergic neuron cells of the 
basal forebrain, the highest decrease would be in ACh level. This is consistent with experimental 
research where binding β-amyloid peptides to p75 receptors of rat brains showed colocalizations 
of p75 receptors (Ehrenstein et al., 1997; Peng et al., 1994). 
 
 
 
Figure 2.4:  A graphical representation of β-amyloid peptides targets in cholinergic neuron cells 
(Kar et al., 2004) 
 
4-Decreasing concentration of ACh through Positive feedback mechanism 
 The reduction in ACh concentration causes increase in β-amyloid aggregates concentration 
through two pathways: 1- Low ACh concentrations increase the synthesis of amyloid precursor 
protein (APP) in cerebral cortex by inducing high level of APP mRNA (Wallace et al, 1993). 2- 
Small level of ACh stimulates the cleavage of APP via β-amyloid pathway (Buxbaum et al., 
1994; Hung et al., 1993). These two pathways lead to another increasing in β-amyloid peptides 
levels and hence a further decreasing in ACh levels. The positive feedback loop explains why 
some medications that increase ACh level such as AChE inhibitors have a limited success for 
AD treatment. This is because the decrease in ACh concentration is a continuous process due to 
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loss of choline by leakage action of β-amyloid peptide. Although the drug increases ACh level, 
β-amyloid peptides reduce it by depletion of its precursor like choline (Ehrenstein et al, 1997).  
5-Leakage effect of β-amyloid peptides 
The aggregates β-amyloid peptides in cholinergic cells cause formation pathways for leakage of 
choline and ions such as Calcium out of cholinergic neurons (Galdzicki et al., 1994). Because 
choline is the rate limiting substrate for ACh synthesis (Mustafa et al., 2009), leakage of choline 
out of cholinergic neurons induces a reduction in ACh concentrations, and hence AD. 
 This effect is as toxic as 2,4-dinitrophenol which causes a leakage pathway for protons to cross 
out cell  membrane and leading to uncoupling of electron transport from ATP synthesis 
(Galdzicki et al., 1994). Choline leakage effect is consistent with experimental observations 
where the incubation of β-amyloid peptides with Pheochromocytoma PC12 cells increases 
choline conductance which is proportional to β-amyloid peptides concentrations (Galdzicki, 
1994). In such case of low choline levels the cholinergic neurons try to provide choline from 
other sources like membrane phosphatidylcholine to compensate choline loss by leakage and to 
be able to synthesize ACh. This behavior of neuron cells is known as autocanabolism effect. The 
autocanabolism effect causes changes in phospholipids formation and thus in the lipid 
composition of cell membrane. This leads to neurodegeneration in which the membrane turnover 
and becomes unable to transmit chemicals impulses (Kar et al., 2004).   
 
2.3) AD Pharmacotherapy 
  The numbers of patients with AD increase every day where there are 25 million people have 
dementia related disease, and this number is expected to reach to 81 million by 2040. The risk 
increases in the developed countries. For instance, in the US every 71 seconds there is one case 
of AD is estimated, and the cost of healthcare is around $180 billion annually (Walter Lukiw, 
2008). Thus most of pharmaceutical research objectives are to develop medications for 
preventing and reducing AD. Until now there are no effective medication to arrest the 
developing progression of AD, but drugs provide only symptomatic relief and not useful as long 
term therapy (Walter J Lukiw, 2008). There are many drugs used for improving the quality of 
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life and behavior of AD Patients. These drugs are classified according to its molecular targets 
into different categories as follows: 
 
1- Acetyl cholinesterase inhibitors ( AChEIs) 
AChEIs therapy is the drug of choice to treat AD. These medications are used to cure mild to 
moderate AD and considered the most widely prescribed drugs. Such kinds of medications were 
introduced more than 20 years ago. AChE is responsible for the degradation of ACh in synaptic 
cleft. As AD is characterized by low levels of ACh, some medications can be used to increase 
level of ACh by inhibition of AChE. Therefore, cholinergic neurotransmission in brain gets 
improving. Examples of these medications approved by FDA are donepezil (Aricept), 
galanthamine, revastigmine (Exelon), and tacrine. However, AChEIs have many side effects 
such as cardiovascular, cerebrovascular, urinary, and cognitive complications. Also, tacrine is 
withdrawal by FDA after severe adverse effects that are associated with its use where it is 
hepatotoxic leading to acute liver failure. Although a long of these (AChEIs) group Donepezil 
(Aricept) is the most common and favored drug, some researches in Canada and US have 
approved that the efficacy of this medication is not perfect and limited. Totally, using AChEIs 
have a definite effect as medicinal agents in AD treatment because the positive feedback effect 
which low level of ACh causes a further increase in β-amyloid peptides and as a result more 
decreasing in ACh level in the neurons (Ehrenstein et al., 1997). 
  
2-N-methy-D-aspartate receptor (NMDAR) antagonists: 
According to Walter Lukiw, (2008) β-amyloid peptides prevent glial cells from regulation of 
glutamate re-uptake and recycling resulting in glutamate over excitation and excitotoxicity. This 
leads to hyperstimulation and neural dysfunction which participates in etiopathogenesis of AD. 
Using NMDA receptor antagonist such as memantine (Namenda) plays a vital role in masking 
over stimulation effects of glutamate receptors. Memantine also has anticonvulsant and anti-
parkinsonism properties. Recent studies show that NMDA antagonists have some neurotoxic 
effects and this depends on dose and patient age. 
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 3-β-amyloid as a molecular target 
 There are different subcategory medications for β-amyloid peptides as follow:  
A-γ-Secretase Inhibitors such as Semegacestat and Begacestat are used to inhibit 
amyloidogenic pathway for cleavage of amyloid precursor protein (APP). Ly450139, as another 
ɣ-Secretase inhibitor, is subjecting to clinical trials and it is expected to have a good ability in 
treatment of AD where single 140 mg dosage decreases Aβ40 in plasma by 73%. Another 
compound is JLk6 which is also under research stage and it showed a good result in inhibition of 
Aβ 40 and Aβ42 in HEk293 cells. However, ɣ-Secretase inhibitors have some concerns where they 
have some adverse reactions such as gastrointestinal bleeding, hyperplasia, immunological 
disturbance, and needed to large dosage to be able to cause a significant effect (Lukiw, 2008). 
 
B- β-Secretase Inhibitors such as OM99-2 which is a high molecular weight peptide 
(peptidomimetic) with potent β-Secretase inhibition effects. 
 
C- β-amyloid Aggregation Inhibitors 
Native β-amyloid peptide is misfolded to form β-Sheet which aggregates into oligomer and 
protofibril. The latter is self-assembly to form insoluble fibril. Fibril deposits in the brain of AD 
patient to form β-amyloid plaques. Some medications are natural products obtained from plant 
source can inhibit aggregation of β-amyloid such as curcumine. 
 
D- Immunization against β -amyloid peptides 
 Immunization against Aβ1-42 peptides will be an effective solution for reducing Aβ1-42 peptide 
levels resulting in reducing pathology of AD. Amyloid over expressing transgemic PDAPP mice 
showed a good result in decreasing progression and level of neuropathology in AD. On the other 
hand, the human’s clinical trials have not showed a significant success because of human patient 
body develops complex adverse reactions and meningo-encephalitic cellular inflammation 
effects. Immunotherapeutics possess significant properties to be used as a therapy for mild-to-
moderate AD is under clinical phase III program (Lukiw, 2008). 
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3- Tau hyperphosphorylation inhibitors as a molecular target 
 Tau is a microtubule-associated protein in the CNS and promotes tubulin self-assembly into 
microtubules. Microtubules (MTs) are components of eukaryotic cellular cytoskeleton. 
Stabilization of microtubules depends on tau protein. Hyperphosphorylation of tau protein by β-
amyloid peptides leads to microtubule disintegration and formation of neurofibrillary tangles 
(NFTs) which is a significant mark of AD. These aggregations of NFTs cause destabilization and 
disintegration of microtubule leading to collapsing the neurons and impairing axonal transport. 
Curcumin, Indirubin derivatives and Orange-G are considered good medications for tau 
hyperphosphorylation inhibition. 
4-Oxidative stress as a molecular target 
Oxidative stress is an imbalance between the formation of  free radicals (reactive oxygen species 
(ROS)) such as nitric oxide (NO
.
), hydrogen peroxide (H2O2), peroxynitrite (ONOO
-
), 
superoxide (O2
.
), and hydroxyl radical (OH
.
) inside the cells, and the ability of cells to protect 
themselves by scavenging through using detoxifying enzymes or antioxidants. Some metals 
(aluminum, zinc, copper, iron) can generate the production of free radicals. ROS can promote the 
generation of amyloid aggregations and neurofibrillary tangles in the brain which causes AD.  
Moreover, ROS can modify lipids, proteins, nucleotide by oxidation causing cell dysfunction and 
death. Some medications act as metal chelators or antioxidants used to protect cells against ROS 
such as desferrioxamine, curcumin, clioquinol, resveratrol, and vitamin-E (Branham, K.J. et al., 
2004). 
5 -Monoamine oxidase-B (MAO-B) as a molecular target for AD 
 
Monoamine oxidase-B is an enzyme responsible for degradation of the neurotransmitter 
dopamine. As a result of degradation reaction of dopamine by MAO-B, toxic H2O2 and reactive 
quinone generate as metabolites of dopamine degradation. These toxic metabolites cause 
neurodegeneration in the CNS. So MAO-B Inhibitors act as neuroprotective agents in AD. 
Examples for drugs used for this purpose are Tacrine and Rasagiline. 
   29 
6- G-protein Coupled Receptor 3 as a therapeutic target in AD 
G-protein coupled receptor3 (GPR3) is an orphan receptor expressed in brain. GPR3 is a 
potential therapeutic target in AD because the over expression of GPR3 stimulates β-amyloid 
production, and hence causing AD. The genetic removal (deletion) of GPR3 in AD mouse model 
prevents β-amyloid aggregation in the brain (Bobba.et al., 2009). 
7- Gamma- Secretase Activating Protein as a molecular target for AD treatment 
 Gamma-secretase activating protein (GSAP) is a protein that regulates gamma secretase 
processed cleavage of amyloid precursor protein (APP). Deletion of GSAP in mouse model of 
AD shows a reduction in β-amyloid formation. The anticancer imatinib (Gleevec) drug has a 
GSAP inhibition characters (Gen He et al., 2010). 
8-Sirtuins are a therapeutic target for AD 
Sirtuins (SIRT) are a group of enzymes involved in aging and longevity. Over expression of 
SIRT1 prevents oxidative stress and β-amyloid accumulation in AD. Activation of SIRT1by the 
antioxidant resveratrol is considered an effective goal for treatment ageing and Alzheimer 
disease (Bonda et al., 2011). 
9- Other potential AD drug targeted against β-amyloid peptide generation 
 Some compounds are being under research and believed to have good roles in AD treatment. 
For instance, tramiprosate (Alzheimer NC-51; homotaurine) is a glycosaminoglycan-mimetic 
compound and it inhibits β-amyloid accumulation. Also, non-steroidal anti-inflammatory drugs 
(NSAIDs) have anti-inflammatory, antiamylodgenic characterizations like Flurbiprofen 
(Tarenflurbil; MPC-7869; flurizan) is attractive agent because it reduces Aβ42 and it inhibits ɣ-
secretase. Further, some herbs they would be expected to play a significant role in treatment of 
mild-to-moderate AD. For example, ginkgo biloba and uncararia rhynchophylla have antioxidant 
and antiangiogenic properties as well, also both of them could prevent β-amyloid aggregations. 
Other examples for herbal medications are tetrahydrcannabinol (THC) and marijuana both of 
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them are competitive AChE inhibitors. Also, satvia officinalis could improve cognitive 
impairment (Lukiw, 2008). 
10 – Cholesterol lowering agent and their actions on β-amyloid peptide 
Recent studies show that there is a relation between increasing weight and late-onset AD. In vitro 
and in vivo model lab researches have reached that contribution of high serum cholesterol 
concentration in pathology of AD where high cholesterol level increases processing APP into 
neurotoxic Aβ40 and Aβ42. Cholesterol lowering agents such as statins have ability to reduce 
cholesterol biosynthesis pathway by prevention HMG-CoA reductase enzyme, an enzyme that is 
responsible for production of cholesterol in liver, (Lukiw, 2008). 
11-Omega-3 fatty acid (docosahexaenoic acid; DHA) 
Omega-3 fatty acids have antioxidant, anti-inflammatory, and cholesterol lowering agent’s 
properties. Docosahexaenoic acid (DHA) is a neuroprotective compound where it reduces APP 
processing into neurotoxic amyloidogenic pathway. In vitro studies using human brain cell tissue 
culture showed that depletion of DHA causes ROS production, and hence oxidative tissue 
damage. In animal studies using DHA supplementation results in lowering β-amyloid peptides 
aggregation, quenching ROS oxidative effect, and improving damaged synaptic contacts. This 
leads to improve cognitive impairment (Lukiw, 2008). 
 
2.4) Pharmacokinetics (PK) and Pharmacodynamics (PD) of Drugs 
2.4.1) Pharmacokinetics definition of drugs 
It is very important to determine drug doses reaching its target site in the body and how long the 
drug takes. These questions give us fundamental definition of pharmacokinetic of drug (PK). The 
pharmacokinetics terms refers to the action of body on the drugs. In other words, a description 
for drug stages inside the body to reach its site of action as Figure 2.5 refers to. 
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Accordingly, for drugs to be accessible in the action site, they should pass through the following 
stages: 
I) Adsorption: in which drug is transported from compartment of application to systemic 
circulation (blood plasma). 
II) Distribution: equilibrium drug concentration between blood plasma and rest of organs. 
III) Metabolism: this process happens usually in liver or kidney. Some drugs subject to 
metabolism by specific mechanisms according to drug nature structure. This process is important 
to make a drug in an easy form to be able to give its action or it is able to excrete easily out of the 
body. 
 
 
 
 
  
 
Figure 2.5: Pharmacokinetic principle of drug  
IV) Elimination: excretion of drug outside the body via urine, sweat, breast milk or feces. 
These four stages are for drugs that are not administered through intravenously (IV). In case of 
IV, the drug is injected directly into the blood stream; drugs do not need to be absorbed. In such 
case the bioavailability (percent of the drug that reaches to systemic circulation) of the drug is 
100%. Whereas, for drug taken by other routes like oral their bioavailability is less than 100%. 
This is because the drug might be exposed to metabolism in liver before it becomes accessible in 
the systemic blood this is called first- pass effect. 
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2.4.2) Pharmacokinetic terms 
There are many terms that should be determined in PK and PD study. These terms are: 
1- Area under the curve (AUC): it measures plasma drug concentration time 
2-  Bioavailability (F): amount of given dose to reach systemic circulation. 
3-  Clearance (CL): rate of drug eliminated to its concentration in blood plasma. 
4-  Elimination half-life (t1/2): the time needed for decreasing plasma drug concentration by 
half. 
5-  Maximum concentration (Cmax):  maximum drug concentration in plasma.  
6-  Time to maximum concentration (Tmax):  time needed for reaching maximum plasma 
concentration after taking the dose. 
7- Volume of distribution: a relation between amount of drug in the body and concentration 
of drug in the plasma. 
2.4.3) Pharmacodynamics (PD) definition 
PD refers to the drug effects on the body. Most of the drugs set their action after binding to 
receptors of cell membrane surface, but others can affect the receptors inside the cell or the cell 
organelles. 
2.4.4) Pharmacodynamics terms 
There are many terms that should be determined in PD study. These terms are: 
1- Agonist: drug that binds to its characterized receptor and generates its specific effects. 
2- Antagonist: drug binds to receptor but does not produce effect by prohibiting a specific 
active agent from access to the receptors. 
3-  Potency:  molar drug concentration required to give a specific high effect. 
4-  Efficacy (Intrinsic activity): maximum effect the drug can get. 
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5-  Affinity: strength (intensity) of binding between drug and receptors. 
6-  Selectivity: separation between favorable and unfavorable drug action. 
7-  Therapeutic Window: the most safe and effective drug concentration that exists between 
effective dug concentration and toxic drug concentration.  
8-  Therapeutic Index: the ratio of toxic dose to effective dose (TD50/ ED50). 
9-  Dose-response: simple relation between the mount of drug (dose) and the response        
(effect) that the drug does. All substances are toxic, the only thing that differentiates 
between effective and toxic effect is the right dose. 
2.4.5) Pharmacokinetics/Pharmacodynamics (PK/PD) model 
 
The application of mathematical modeling for pharmacokinetics/pharmacodynamics (PK/PD) 
analysis is very important for drug development and optimum therapy for patients.   A  PK 
model investigates the dynamics of drug levels in the body tissues such as blood, plasma livers, 
and heart while a PD model describes the dynamics of drug impacts (Tang et al., 2012). 
Furthermore, PD models could help for identification the most important factors for increasing 
the drug efficiency. PK/PD model can help in the design experiments on the large scale to 
understand the drug pharmacology acted inside biological systems (Gustafason and Bradashaw-
pierce, 2011). 
 
2.4.6) PK/PD modeling terms 
There are many terms that should be determined in PK/PD modeling study. These terms are: 
1- Pharmacokinetics (PK) models  
PK models are mathematical models used for giving data about drug concentration in body vs. 
time. These mathematical equations are used to describe drug concentration in plasma and other 
tissues using different dosage regimes. Also by mathematical models all of absorption, 
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distribution, metabolism and elimination can be estimated. Differential equations are used to 
describe the dynamic behavior of drug from plasma compartments to tissue compartments and 
vice versa (Gustafason and Bradashaw-pierce, 2011).  
2- Compartmental modeling is based on separating the body into different sections 
(compartments). Theses compartments have the same drug follow, blood flow, binding and 
similar elimination rate. These models are used for determining plasma concentration with 
time. There are two types of compartments models as follows: 
A- One-compartment model 
It is used to describe the distribution and the elimination of drug in the body using a single 
central compartment as shown in Figure 2.6. This compartment assumes that the change in blood 
concentration represents a suitable change in drug concentration in the tissue.  
 
 
 
 
 
 
Figure 2.6: One-compartment model graph  
 
 
B- Multi-compartments model  
It is used to describe the drug eliminated by different mechanisms with different rate, and the 
drug that does not decay linearly with time. In this model the drug transports from a central 
compartment to peripheral compartments and vice versa with a first-order rate constant.  For 
example, in two- compartment model there is no equilibrium in distribution of drug between 
blood and tissues. This means that the drug has bidirectional movement pathway between 
peripheral and central compartments as shown in Figure 2.7. 
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Figure 2.7 two-compartment models Scheme.   
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Chapter 3 
Modeling the Effect of β-Amyloid as Direct Cholinergic 
Neuromodulator via Choline Leakage Hypothesis 
 
3.1) Introduction 
Alzheimer’s disease (AD) is an advanced neurodegenerative disease that is considered one of the 
most dangerous diseases after cancer and heart attack in Canada and the USA.  The aggregation 
of β-amyloid (Aβ) peptides and their plaques deposition in the central nervous system cause loss 
of neurons and lack of acetylcholine (ACh) which are considered the main symptoms of AD 
(Selkoe, 1999). Aβ is formed from its poly peptides called amyloid precursor protein (APP) by 
cleaving via β-secretase and γ –secretase enzymes (Craft 2002). Therefore, Aβ is considered one 
of the main reasons leading to AD where it rises the level of  calcium ions inside the neurons by 
making a leakage pathways for Ca
+2
 to enter inside of the neurons (Hardy and Higgins, 1992). 
This leads to loss of neurons plasticity (Arispe et al., 1993). In addition, β-amyloid causes 
harmful effects on the function of cells. For example, it could prevent glutamate transport in 
cultured astrocytes and could alter salts and nutrients concentrations through cellular membrane 
as well (Allen et al., 1997). In this paper, we investigate the interaction between Aβ and ACh 
neurocycle through the choline-leakage mechanism leading to AD proposed by Ehrenstein et al., 
(1997). It is assumed that Aβ causes leakage in the plasma membrane leading to diffusion of 
choline outside the presynaptic membrane, and hence the rate of ACh production decreases. The 
effect of Aβ will be added to the two-enzyme/two-compartment model (2E2C) built by Mustafa 
et al., (2009) leading to a system of nine-first-order differential equations system. There are two 
sources for the choline substrate required for ACh synthesis in the brain: the first one is from 
compounds containing choline such as phosphatidylcholine and sphingomyelin and the other 
source is from the blood plasma which contains unbounded choline (Mustafa et al., 2009; Tucek 
1985). Choline cannot be synthesized inside the neurons; however, it is produced from the 
hydrolysis of ACh and it is recycled to the presynaptic membranes via specific transporters 
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mechanisms existing in the membranes such as high affinity choline transporter mechanism 
(Bussiere et al., 2001) where the electrochemical gradient of salts like K and Na plays an 
important role for transporting choline from the synaptic cleft to the presynaptic membrane via 
high affinity choline transporter (Ehrenstein et al., 1997; Koliatsos and Price, 1991). Therefore, 
the brain gets choline in the form of either free or bound choline in phospholipids (Mustafa et al., 
2009; Shawn et al., 2004).  Tucek et al., (1985, 1987) showed that the brain can produce free 
choline where it was found that the blood stream entering the brain has choline levels lower than 
that in the leaving stream. Weckler (1988) showed that the experimental observations supported 
the importance of both forms of choline either free choline in the blood plasma or bound form 
such as lipoproteins and lysophospahtetidylcholine. Both forms provide the required amount of 
choline for ACh synthesis (Mustafa et al., 2009). In addition, the process of ACh degradation 
catalyzed by acetyl cholinesterase (AChE) in synaptic cleft is the most important source for 
providing the presynaptic neuron with choline (Tucek, (1985). Therefore, Choline recycled has a 
necessary function in ACh synthesis (Mustafa et al., 2009). Therefore, there are three main 
sources for choline supplied for ACh synthesis: free choline in the plasma of blood, bound 
choline in phospholipids, and choline coming from ACh hydrolysis process (Mustafa et al., 
2009). Accordingly, if there is a shortage of choline resulting from ACh hydrolysis due to any 
reason such as AChE inhibition or Aβ aggregates, ACh concentrations in the presynaptic neuron 
will be affected significantly. This is because the choline is the rate limiting substrate for ACh 
synthesis in vivo (Mullen et al., 2007; Mustafa et al., (2009). Mustafa et al., (2012) showed that 
the choline recycled from the synaptic cleft to the presynaptic neuron is the rate limiting step in 
the whole neurocycle of ACh. 
Mustafa et al., (2009) indicated that ACh concentrations in the presynaptic and postsynaptic 
neurons and synaptic cleft are affected directly by the level of feed choline substrate 
concentrations (Mustafa et al., (2009)). In addition, the feed choline is much more important than 
acetyl-coA where choline is the only substrate which is not synthesized in the brain as mentioned 
earlier (Mustafa et al., (2009)). Furthermore, the low levels of choline content lead to the less 
efficiency of the process of ACh synthesis and may lead to irregular cholinergic neurocycle 
behavior (Mustafa et al., 2009). 
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Ehrenstein et al., (1997) showed that the leakage of choline outside the presynaptic neuron is due 
to the high levels of Aβ leads to decreasing the internal concentrations of choline substrate. In 
addition, choline had been proved as the rate limiting substrate for synthesizing ACh (Mustafa et 
al., 2009; Tucek et al., 1985). Therefore, the final levels of the product ACh in the presynaptic 
neuron will be affected. Ehrenstein et al., (1997) presented experimental observations supporting 
the interaction between Aβ and leakage of intracellular choline where Aβ can cause ionic leakage 
in PC12 cells (Galdzicki et al., 1994). In addition, it is  observed that the low levels of 
intracellular choline concentrations in the presynaptic neurons is one of the symptoms of AD 
even if the rate of choline transfer to the presynaptic neurons is high (Slotkin et al., 1990, 1994; 
Ehrenstein et al., 1997).  
The main aim of this paper is to investigate the effect of β-amyloid via choline leakage 
hypothesis on the concentration of ACh, choline, and acetate in both compartments. In addition, 
we will study how the behaviors of the rate of ACh synthesis in compartment 1 catalyzed by the 
enzyme ChAT and the rate of ACh hydrolysis catalyzed by the enzyme AChE and pH levels in 
both compartments are affected by different Aβ levels. It is important to determine whether the 
choline leakage hypothesis on mechanism of cholinergic neurocycle inhibition AD is able to 
produce pronounced results compatible with physiological symptoms such as low level of ACh 
concentration. 
 
3.2 Cholinergic cells and β-amyloid peptides  
In cholinergic cells ACh neurotransmitter is responsible for transmission of chemical impulses 
from presynaptic neurons to postsynaptic neurons (Galdzicki et al., (1994)). ACh 
neurotransmitter is synthesized in the presynaptic neurons by interaction of choline (Ch) and 
acetyl-coenzyme A (AcCoA); the reaction is catalyzed by choline-acetyl transferase (ChAT) 
enzyme. AcCoA is the only substrate produced in axon terminal of presynaptic in the 
mitochondria, but the other substrates are supplied through different transport mechanisms 
(Mustafa et al., 2009). After ACh induces the effect on muscarinic receptors of post synaptic 
cell, it is hydrolyzed by acetylcholinesterase (AChE) into choline, acetate, and protons. The 
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choline is recovered back to the presynaptic neuron for further synthesis of a new ACh 
(Galdzicki et al., 1994). 
Formation of Aβ plaques in the brain is considered a significant symptom of AD where the 
accumulation of Aβ in the brain can affect many stages of ACh synthesis and release.  In vitro, 
observation of low concentration of Aβ (picomolar or nanomolar) lowers ACh production in rat 
hippocampal (Kar et al., 1998). Moreover, the continuous infusion of Aβ into rats was observed 
to reduce ChAT activity in frontal cortex (Nitta, 1994). 
The high levels of β-amyloid plaques in the central nervous system are one of the well-known 
pathological characteristics for AD patients (Galdzicki et al., 1994). The interaction of β-amyloid 
with cholinergic neurocycle has attracted many researchers’ interests  such as  Yankner  et al., 
(1990), Galdzicki et al., (1994), Allen et al., (1997), Kar et al., ( 2004), and Mustafa  et al., 
(2009, 2012). One of the mechanisms explaining the destructive effect of β-amyloid is that the 
leakage pathway built by the sticking of β-amyloid in the membrane of the presynaptic neurons 
leading to disruption of membrane transport and substrate diffusion such as choline out of the 
neurons and infusion of calcium ions into presynaptic neurons (Galdzicki et al., 1994; Aripse et 
al., 1993). 
In this paper, we will focus on leakage pathways in the presynaptic neurons caused by β-amyloid 
aggregates and supported by many researchers such as Galdzicki et al., (1994) and Enshretein et 
al., (1997). The effect of β-amyloid aggregates on the dynamic behavior of ACh neurocycle is 
investigated where the dynamics of levels of ACh, choline, acetate, pH in both compartments are 
monitored at different concentrations of β-amyloid to determine which state variables are 
monitored with the various concentrations of β-amyloid. The kinetic parameters are evaluated in 
order to choose the most appropriate values that give results compatible with the experimental 
observations. In cell biology there are similar phenomena for the leakage pathways provided by 
inhibitors such as dinitrophenol to allow for ions to transport through the cell membranes and 
result in obstacles in ATP synthesis (Galdzicki et al., 1994). In the cholinergic neurocycle β-
amyloid leakage pathways could explain the low levels of ACh concentrations in AD patients.  
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3.3) Modeling the effect of β-amyloid via the choline leakage 
hypothesis   
The effect of β-amyloid on ACh neurocycle is investigated considering the choline leakage 
hypothesis from compartment 1. According to Ehrenstein et al., (1997) and Mustafa et al., 
(2009), the availability of choline is the rate-limiting step in the synthesis of ACh. Therefore, the 
loss of choline due to the leakage could produce significant effects on ACh levels in neurons 
resulting in low ACh concentration inside the cholinergic neurons. Depletion of choline makes 
neurons search for other sources of cholin such as phosphatidycholine of cell membrane. 
Furthermore, the membrane becomes turned over and unable to transport chemical impulses 
(Wurtman., 1992; Ehrenstein et al., 1997). Another negative effect is the increase β-amyloid 
aggregates levels by positive feedback. In such case the low ACh level leads to increase average 
of amyloid precursor protein (APP) mRNA and thereby β-amyloid (Ehrenstein et al., 1997; 
Wallace et al., 1993). Moreover, low ACh level stimulates cleavage of APP through 
amyloidogenic pathway (Ehrenstein et al., 1997; Buxbaum et al., 1994). These effects lead to an 
increase in Aβ levels and hence more choline leakage pathways and low ACh production. The 
latter case is known as a positive feedback mechanism. It had been observed that activating 
muscarinic receptors in rat hippocampus by ACh increases the regulation of nerve growth factor 
(NGF) mRNA and NGF protein (Knipper et al., 1994) while low ACh concentration could lead 
to neuron death by reduction of NGF. Ehrenstein et al., (1997) investigated the interaction 
between ACh and β-amyloid and found that the rate of reduction in ACh is proportional to the 
rate of production Aβ. Therefore, a reduction in ACh could cause low NGF (Ehrenstein et al., 
1997; Knipper et al., 1994). 
 
To incorporate β-amyloid into 2E2C model to induce the choline leakage effect the following 
modifications are performed: First the loss of intracellular choline is included  by the addition of 
the term (- KbA3 bA) which is different from that considered by  Ehrenstein et al., (1997) who did 
not consider mathematically  the interaction between intracellular choline (Ch) concentration in 
compartment 1( S2(1)), and Aβ. This interaction can be formulated as below:  
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Where bA is extracellular Aβ concentration and KbA3 is rate constant. This will yield significant 
effects because ACh is formed in compartment one and choline is the limiting substrate for 
formation of ACh. The second modification to 2E2C model is the introduction of extracellular 
Aβ (bA) as a new state variable by adding a new differential equation as shown below: 
  bAKsKK
dT
dbA
LLL 41132                         (3.2) 
Equation (3.2) describes that the net increase in extracellular concentration of β-amyloid is 
proportional to each of  KL2 which is the inlet concentration formed from APP, consumption by 
extracellular ACh  (- KL3s1(1)), and decreasing  in extracellular concentration of β-amyloid by 
acting through both absorption into neuronal membranes and enzymatic breaking down reaction 
(-KL4bA).  
The term KL2 refers to the rate of β-amyloid peptides generation. The numerical values of rate 
constants KL1, KL2, KL3 and KL4 are in the dimensionless form as shown in Table 1. To simplify 
the calculations, KL1, KL3 and KL4 are expressed as a function of KL2.  
The third modification is based on the assumption that the rate of ACh reduction caused by 
decrease in choline levels in compartment 1 is proportional to the rate of β-amyloid production. 
Therefore, the effect of β-amyloid on ACh concentrations in compartment 1 can be formulated 
according to the following equation: 
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                                                            (3.3) 
Equation (3.3) describes the rate loss of intracellular ACh (s1(1)) which is assumed to be 
proportional to membrane concentration of β-amyloid (bA). 
 
The 2E2C model considers that the presynaptic neuron is compartment one and both of the post 
synaptic neuron and the synaptic cleft as compartment two as shown in Figure 3.1. In 2E2C 
model every compartment is considered as a constant volume, isothermal continuous stirred tank 
reactor (CSTR) with constant flow rate, stable recycle ratio, and separated by a permeable 
membrane. S1 refers to is ACh, S2 is choline (Ch), h1 hydrogen protons concentration, and S3 
   42 
refers to acetate (Ac). The feed streams of hydrogen, ACh, choline, and acetate (Q) are brought 
together in a stable stream to meet the choline recycle flow (RQ) before entering the presynaptic 
neuron. Also both the feed stream rate into compartment 1 and the outlet flow rate from 
compartment 2 are assumed to be constant values Q (1+R) as indicated in Figure 3.2. 
 
  
Compartment 1 
Compartment 2 
 ACh 
diffuse
 
Choline  
 
Choline  
ACh 
ACh 
 
Figure 3.1: Two-enzyme/ two-compartment (2E2C) Model. Presynaptic neuron is compartment one, both 
synaptic cleft neuron and post synaptic is compartment two (Mustafa et al., 2009) 
 
After incorporating the effect of β-amyloid through equations (3.1), ( 3.2), and (3.3), the two-
enzyme two-compartment model consists of nine first-order differential equations as shown in 
Table 3.1 where the parameters and the ordinary differential equations of the nine state variables 
h(1), h(2), s1(1), s1(2), s2(1), s2(2), s3(1), s3(2) , and bA are expressed  in the dimensionless form. 
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Figure 3.2:  Schematic representation for two-enzyme/ two-compartment model 
 
3.4) Model Assumptions 
The following assumptions are considered in order to help simplify calculations.  All 
assumptions made for investigating the effect of β-amyloid are compatible with the literature 
such as those studied by Mustafa et al., (2009). More justifications and assumptions are clarified 
as below: 
1) The presynaptic of cholinergic nerve terminal is described by compartment 1 where ACh 
is synthesized by the reaction of choline and acetyl CoA in presence of the catalytic 
effect of ChAT enzyme. 
2)  Both postsynaptic neurons and synaptic cleft are considered as a compartment two. It is 
observed that both of them are unified to be in one compartment instead of two or three 
compartments because both of them are harmonized and interactive and also to simplify 
the model; particularly to reduce the dimensionality. 
3)  Both compartments are assumed to be separated by a permeable membrane. 
4) The internal mass transfer in compartment one between synaptic vesicles and cytoplasm 
and in compartment two between ACh and postsynaptic receptors are neglected because 
every compartment is assumed to be homogenous.  
5) All substrates in the presynaptic neuron are transported to the postsynaptic cleft via 
passive diffusion where all concentrations in compartment 1 should be higher than that in 
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compartment 2; however choline uptake from the postsynaptic cleft to the presynaptic 
neuron is performed by facilitated diffusion via high affinity choline uptake transporters 
(HACUTs). 
6) The concentrations of all state variables in compartment two are the average of 
concentrations in the postsynaptic neuron and synaptic cleft. 
7) Temperature is considered constant where the system is assumed to be isothermal and 
there is no effect for any temperate changes on the system. 
8) In this paper we consider that the choline leaked out from the presynaptic neuron caused 
by β-amyloid aggregates is not transported to compartment 2 but it is leaked outside the 
two-enzyme/two-compartment system. 
9) Transport of β-amyloid from compartment 1 to compartment 2 is neglected.  
10) The initial concentration of β-amyloid is assumed to be zero. 
11) Both feed flow rate to compartment one and outlet flow from compartment two are 
considered to be constant with a flow rate of q(m
3
/sec). 
12)  The reactions that are carried out in connected compartments by ChAT and AChE  are  
the following: 
In compartment one; ACh is produced as indicated in the reaction below in presence of 
  CoAineAcetylcholCoAAcetylCholineR
ChAT  :1                                              (3.4) 
In compartment two, ACh is hydrolyzed as the following reaction shows by AChE catalytic 
enzyme: 
 
  HAcetateCholineWaterineAcetylcholR AChE:2                               (3.5) 
Both reaction rates R (1) and R (2) are assumed to be hydrogen ions dependent and substrate 
inhibited (Mustafa et al., 2009). The first order ordinary differential equations (ODEs) of the 
modified two-enzyme/two-compartment model are summarized in Table 3.1. The concentrations 
of choline and β-amyloid in cholinergic brain cells are not known either for healthy neurons or 
AD patients (Galadzicki et al., (1994). The values of kinetic parameters of the models and their 
sources are given in Table 3.2. Kinetic parameters related to β-amyloid effect such as kbA1, kbA2, 
kbA3, KL1, KL2, KL3, and KL4 are obtained by parameter estimation process and the remaining 
parameters are obtained from the literature as stated in Table 3.2. 
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Table 3.1: Dimensionless forms of the ordinary differential equations of choline leakage 
effects by β-Amyloid aggregates 
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2bAK  2075.0 LK  
1bAK  206.0 LK  
 
Table 3.2:  Kinetic Parameter Values 
Parameter Value Reference 
 1 5.2(0.1) Hersh & Peet (1977) 
 2 12 Hersh & Peet (1977) 
 3 1000 Hersh & Peet (1977) 
 4 5 Hersh & Peet (1977) 
 5 1 Hersh & Peet (1977) 
  0.5 Garhyan et al., (2006); Ibrahim et al., 
(1997); Elnashaie et al., (1984) and 
(1995))   
  1 Garhyan et al., (2006); Ibrahim et al., 
(1997); Elnashaie et al., (1984) and 
(1995)   
Ka(kh) 1.066*10
-6 
kMole/m
3
(µMole/mm
3
) 
Garhyan et al., (2006); Ibrahim et al., 
(1997); Elnashaie et al., (1984) and 
(1995)   
Ks1 50.33 µMole/l Garhyan et al., (2006); Ibrahim et al., 
(1997); Elnashaie et al., (1984) and 
(1995) 
S2ref 100 µMole/l Guyton and Hall, (2000) 
S3ref 1 µMole/l Guyton Hall, (2000) 
1B  
510033.5  kMole/m
3
(µMole/mm
3
) Garhyan et al., (2006) 
2B  
510033.5  kMole/m
3
(µMole/mm
3
) Garhyan   et al., (2006) 
H
  2.25 Elnashaie et al., (1984) 
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OH
  0.5 Elnashaie et al., (1984) 
1S
  1.5 Elnashaie et al., (1984) 
2S
  1.5 Elnashaie et al., (1984) 
3S
  1 Elnashaie et al., (1984) 
RV  1.2 Elnashaie et al., (1984) 
fpH  8.2 Guyton, 2000 
fs1  15 Garhyan   et al., (2006) 
fs2  1.15 Garhyan et al., (2006) 
fs3  3.9 Garhyan et al., (2006) 
1  0.01 Garhyan et al., (2006); Ibrahim et al., 
(1997); Elnashaie et al., (1984) and 
(1995) 
R 0.8 Tucek (1978) 
KbAref 20  nM/h Ehrenstein et al., (1997) 
KL2 assumed Dimensionless form 
KL1  3KL2 Dimensionless form 
KL3  0.035KL2 Dimensionless form
 
KL4  1.76KL3 Dimensionless form 
Tref 0.1 h Assumed 
BAref  20 nM/l Kar et al., (2008) 
 
3.5) Results and Discussion 
The effect of Aβ on ACh neurocycle is investigated considering the choline leakage hypothesis 
from compartment 1. According to Mustafa et al., (2009) and (2012), the availability of choline 
is the rate limiting step in the synthesis of ACh. Therefore, the loss of choline due to the leakage 
pathways occurring in the membranes could produce significant effect on ACh concentration in 
neurons.  
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3.5.1) β- amyloid accumulation  
The accumulation of β-amyloid in brains determines the onset of Alzheimer’s symptoms (Lee et 
al., 2007). Figure 3.3 shows the dynamic behavior of the concentration of β-Amyloid. It is found 
that as  the feed rate of β-amyloid (KL2), which is the rate of β-amyloid formation representing 
the input of β-Amyloid to compartment 1, increases bA increases where it is produced from 
amyloid precursor protein (APP) in cerebral cortex. It is observed that no β-amyloid is generated 
at KL2 = 0 where bA is relatively zero which means healthy neurons. “KL2 = 0” means that there 
is no generation of Aβ in the neurons and ACh neurocycle behaves normally.  The value of KL2 = 
0 could be considered the control value of healthy neurons without Aβ aggregates. When KL2 
increases to 0.5 in the dimensionless form (corresponding to 10 nM/h), bA increases rapidly in 
the time period (0-100) in the dimensionless form corresponding to (0-10 h), then bA reaches a 
plateau at bA = 9 in the dimensionless form (corresponding to 180 nM/h). When Kl2 increases to 
0.75 and 1 (corresponding to 15 and 20 nM/h respectively), bA increases  fast to 9.5 and 9.8 in 
the dimensionless form (corresponding to 190 and 196 nM/h respectively) and then settles down 
in the end of the previous plateau period. These results are compatible with the theoretical results 
obtained by Ehrenstein (1997) who showed that the synthesis of APP promotes high 
concentrations of β-amyloid and creates pathways in the membranes of presynaptic neurons. The 
behavior of ACh neurocycle would be investigated at the previous different values of KL2 where 
all state variables in both compartments are studied in order to understand the physiological 
phenomena of the cholinergic neurocycle and their response to different values of β-amyloid 
inlet concentrations as will be shown later. 
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Figure 3.3 A graphical representation for Aβ concentration with time at different KL2 values 
 
 
3.5.2) ACh concentrations in compartments 1 and 2 
 
The dynamic behavior of ACh concentration in compartment 1 is investigated at different rates 
of Aβ production from APP (KL2). The healthy normal cholinergic neurons is characterized by 
no existence of bA which corresponds to KL2 = 0. In this case no Aβ is produced inside the 
neuron as mentioned previously (Figure 3.3) and ACh level is normal where ACh1 = 8.5 in the 
dimensionless form corresponding to 425 µM which represents a healthy concentration. On the 
other hand, as KL2 increases, there is a significant decrease in ACh1 concentration in the period 
(0-100 h) until it reaches 5.8 in the dimensionless form corresponding to 290 µM at the end of 
the plateau period (100-300) in the dimensionless form corresponding to (10-30 h). 
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When KL2 increases to 0.75 and 1 (corresponding to 15 and 20 nM/h respectively), it is observed 
that there is a further significant decrease in ACh1, where in the period of (0-100) in the 
dimensionless form, ACh1 decreases fast to reach 5 and 4 in the dimensionless form 
(corresponding to (250 and 200µM). Then, ACh1 decreases to reach the plateau at (4.7 and 3.8) 
in the dimensionless form corresponding to (235, and 190 µM) respectively. These values are 
lower than the healthy ACh levels in the end of plateau period as shown in Figure 3.4 (a). In the 
latter cases of KL2 = 0.75, and 1, it is observed that there is a much pronounced decrease in 
ACh1. This can be explained by the mechanism of choline leakage pathways caused by high β-
amyloid concentrations, as shown in Figure 3.3, which leads to decrease of choline 
concentrations in compartment 1 as will be studied later. The results are consistent qualitatively 
with the experimental results obtained by Kar et al., (1998) who showed that the small 
concentrations of β- amyloid lead to reduction of ACh concentrations in the presynaptic and 
postsynaptic neurons in rat hippocampal slices and guinea pig cortical synaptosomes. It is 
observed that reduction in ACh synthesis is accompanied by reduction in ACh hydrolysis. 
As shown in Figure 3.4 (b) ACh2 concentration in compartment two decreases as a consequence 
of decreasing ACh1 in compartment one because the decrease in synthesis of ACh1 leads to a 
reduction in ACh transport from the presynaptic neuron to the  synaptic cleft.  As shown in the 
figure ACh2 has an exponential behavior and the more increase in the inlet rate  of Aβ aggregates 
(KL2), the more decrease in ACh2 level in compartment 2. For example, at KL2 = 0 the level of 
ACh2 is relatively high which is around 0.23 in the dimensionless form (corresponding to 11.5 
µM) and this case represents the normal physiological condition where no bA is produced. 
However, at KL2 = 0.5 in the dimensionless form (corresponding to 10 nM/h), the level of ACh2 
decreases rapidly to 0.18 through the period of (0-100) in dimensionless form (corresponding to 
(0-100 h) until it reaches a plateau at 0.16 (corresponding to 8 µM). At KL2 = 0.75 
(corresponding to 15 nM/h), ACh2 has the same behavior as at KL2 = 0.5, but ACh2 reaches a 
plateau at 0.15 (corresponding to 7.5 µM) at time t = 300 in the dimensionless form 
(corresponding to 30 h). At the maximum Aβ inlet rate KL2 = 1 (corresponding to 20 nM/h), 
ACh2 concentration settles down at 0.12 (corresponding to 6 µM) at the end of the period which 
is much lower than the healthy ACh concentration. 
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The observed reduction  in ACh1 and ACh2 concentrations at higher values of KL2  in 
comparison to the normal condition at KL2 = 0 is attributed to that the rate of production of Aβ is 
relatively high which leads to leaking choline (Ch1) from compartment 1.  As the choline is the 
limiting substrate for ACh synthesis, with continuous leakage of choline, the net amount of 
choline available for synthesis of ACh decreases leading to lower generation of ACh1. This low 
level of ACh release is compatible with experimental observations obtained by Kar et al., (2004)   
and Tohgi et al., (1994) who observed lower levels of ACh in guinea pig cortical synaposomes 
and rat neurons after incubation with Aβ and consistent with the observations of low levels in 
ACh concentration in cerebrospinal fluid (CSF) of AD patients (Ehrentein et al., 1997; Tohgi et 
al., 1994). 
Ehrenstein et al., 1997   confirmed the reduction in intracellular ACh level observed in SN56 
cells of cholinergic hybrid after two days incubations with small concentrations of Aβ1-42. This 
reduction of intracellular ACh1 level is due to shortage in availability of biosynthesis substrate 
material such as choline and acetyl-CoA, where Aβ peptide causes leakage of choline outside of 
the neuron (Ehrenstein et al., 1997) and Aβ reduces acetyl-coA synthesis in the neuron.  
Moreover, Kar et al., (2003) and Harkany et al., (1995) showed that a decrease in ACh release 
from hippocampus of rat occurs after its injection with Aβ1-40. As shown in Figure 3.4, ACh2 
concentration in compartment two decreases as a consequence of  decreasing its level in 
compartment one  because reduction in  ACh1 synthesis leads to a decrease in ACh transport via 
presynaptic membrane to synaptic cleft, and hence lowering ACh2 level.  
 
3.5.3) Choline concentrations in compartments 1 and 2 
As indicated in Figure 3.5 (a), there is a significant reduction in choline concentration in both 
compartments of 2E2C model (Ch1) and (Ch2) respectively due to choline leakage by the action 
of Aβ. Figure 3.5 (a), for instance, in compartment one at healthy neurons where KL2 = 0 (no 
inlet of Aβ peptides), choline concentration in compartment 1 (Ch1) does not leak out of the 
presynaptic neuron. Accordingly, its level is normal and reaches 2.8 in the dimensionless form 
(Corresponding to 280 µM) at the end of the period of 300 corresponding to 30 hr. 
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Figure 3.4: A schematic representation for ACh1 and ACh2 concentrations with time at different KL2 
values. 
 
At KL2 = 0.5 in the dimensionless form (corresponding to 10 nM/h), the level of ACh2 decreases 
rapidly to 0.18 through the period of (0-100) in the dimensionless form (corresponding to ((0-10 
h) until it reaches a plateau at 0.16 (corresponding to 8 µM). However, as shown in Figure 3.5 
(a) when KL2 increases to 0.5 (corresponding to 10 nM/h), it is clearly observed that Ch1 
decreases to 2.3 (corresponding to 230 µM/h), at time (0-100) in dimensionless form 
(corresponding to 0-10 h). Then, Ch1 is prolonged in reduction until it takes a plateau at 2 
(corresponding to 200 µM) at the end of the period 30 h. While at KL2 = 0.75 (corresponding to 
15 nM/h), Ch1 reduces more significantly and settles down at 1.5 (corresponding to 150 µM/h) at 
the end of the period  30 h. When Aβ production rate propagates to KL2 = 1 (corresponding to 20 
nM/h), Ch1 decreases fast to reach 1 (corresponding to 100 µM/h) at the end of the period 300 
(corresponding to 30 h). These results are in agreement with the theoretical and experimental 
results obtained by Ehrenstein et al., (1997) and Nitsch, (1992) who showed that the decrease in 
ACh levels in frontal cortex of AD patients was attributed to a decrease in choline concentration 
in the presynaptic neuron. Also our results are consistent with the experimental results obtained 
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by Kar et al (2004) who showed that an increase in choline conductance from PC12 cells after 
long exposure to molar concentrations of Aβ1-40 was due to leakage of choline out of cells and 
low choline up-take. The leakage of choline from brain cell of AD patients is compatible with 
choline leakage from their red blood cells (Butterfield et al., 1985). Also, Aβ causes ionic 
leakage in PC12 cells (Galdzicki et al., 1994) and a further reduction in high-affinity choline 
uptake occurs after incubation of nanomolar concentration of Aβ1-40 with hippocampus 
synaptosomal (Kar et al., 1998 and 2003). 
 Since the availability of choline in compartment two depends on the amount of ACh release 
existing in compartment 2 which depends on ACh transported from compartment 1 by 
membrane diffusion, choline level in compartment two (Ch2) as shown in Figure 3.5 (b) 
decreases subsequently. This is because ACh in compartment two is susceptible to hydrolysis in 
synaptic cleft giving rise to choline, acetate and hydrogen ions. Accordingly, the reduction in 
ACh2 leads to a corresponding reduction in Ch2, as shown in Figure 3.5 (b). In the absence of β-
amyloid production at KL2 = 0 as in healthy neurons, it is observed that the concentrations of Ch2 
is high. At KL2 = 0.5, Ch2 decreases rapidly to 0.85 (corresponding to 42.5 µM/h) at the end of 
the period (0-100) in the dimensionless form (corresponding to 10 h). Then, Ch2 reaches a 
plateau at 0.81 (corresponding to 40.5µM/h) at the end of 30 hr. It is observed that Ch2, at KL2 = 
0.75 (corresponding to 15 nM/h), behaves in the same way as at KL2 = 0.5 but it reaches a 
plateau at 0.62 (corresponding to 31 µM/h) after 300 hr.  Figure 3.5 (b) at KL2 = 1 (corresponding 
to 20 nM/h) shows that the rate of Ch2 reduction is fast and rapid and reaches nearly 0.4 
(corresponding to 20 µM/h), after 30 hr which is less than healthy concentration which is 300 
µM/h (Allen et al., (1997). However, the results in Figure 3.5 (b) are not compatible with 
observations obtained by Nitsch et al. (1992) and Slotkin et al., (1990), who observed that 
choline leakage could lead to increase in extracellular choline level noticed by high level of 
choline in cerebrospinal fluid (CSF). This discrepancy is because of our assumption that the 
choline leaked through β-amyloid pathways from compartment 1 does not enter to compartment 
2. However, the result in Figure 3.5 (a) are in agreement with their observation which is low 
levels in Ch1 is a result of choline leakage effect by β-amyloid (Ehrenstein et al., 1997; Elble et 
al., 1989; Nitsch et al. 992; Slotkin et al., 1990, 1994). Because ACh synthesis is based on 
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choline content in the presynaptic neuron, the reduction in Ch1 via choline leakage pathways will 
affect significantly the rate of ACh synthesis and ACh1 as well. 
These results are compatible with those obtained by Galdzicki et al., (1994) who illustrated that 
the reduction of intracellular concentration of choline increases by the presence of β- amyloid 
aggregates and this could help explain the low concentrations of ACh in the tissue brains of AD 
patients (Galdzicki et al., (1994); Davis et al., 1982). Furthermore, These results are in agreement 
with the experimental results obtained, in-vitro, by Galdzicki et al., (1994) who showed that the 
interaction between PC12 cells and β-amyloid-(1–40) leads to reduction in free choline and 
increase in choline conductance which would result in increasing the concentration of β- 
amyloid.  Furthermore, Galdzicki et al., (1994) illustrated that βA would decrease the choline 
levels in the presynaptic neurons; thereby ACh synthesized by the enzyme ChAT would decrease 
significantly where the decrease of concentrations of ACh is clearly one of the main symptoms 
existing in the central nervous system of AD patients (Galdzicki et al., 1994). 
3.5.4)  Acetate (Ac) concentrations in compartments 1 and 2 
According to equation (3.4), the intracellular acetate substrate in the form of acetyl-CoA reacts 
with choline to produce ACh in the presence of catalytic effect of choline acetyl transferase 
(ChAT). Figure 3.6 (a) shows the dynamic behaviour of acetate level in compartment 1 (Acetate 
1) at different values of KL2. It is observed that at KL2 = 0 which represents healthy neurons 
without β-myloid effect, Acetate 1 decreases gradually from 8.5 in the dimensionless form 
(corresponding to 8.5 µM) and settles down to a plateau at 6.5 in the dimensionless form 
(corresponding to 6.5 µM) which represents the minimum concentration of Acetate 1 in 
comparison to its values at KL2 = 0.5, 0.75, and 1. It can be explained by that at KL2 = 0 , no β- 
amyloid is produced as shown in Figure 3.3, no pathways are built in the membrane of the 
presynaptic membrane to allow for  choline to be leaked outside the presynaptic neuron allowing 
for Acetate 1  to be consumed by the enzyme ChAT to synthesize ACh according to equation 
(3.3).  
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Figure 3.5: Ch1 and Ch2 concentrations with time at different KL2 values 
 
However, at  KL2 = 0.5 (corresponding to 10 nM/h) as shown in Figure 3.6 (a),  Acetate 1 
decreases gradually from 8.5  to reach 6.7 after passing time of  50 (corresponding to 5 hr)  to be 
stable at 6.8 (corresponding to 6.8 µM) which is higher than Acetate 1 at KL2 = 0.0. It is 
observed that as KL2 increases β- amyloid aggregate is produced and builds leakage pathways 
allowing for choline to transport outside compartment 1 and reduction of intracellular choline 
concentration (Ch1) and accumulation of intracellular acetate (Acetate 1). In addition, it is 
observed that Acetate 1  at KL2 = 0.75 (corresponding to 15 nM/h) decreases to reach 7 after a 
time of 50, then it increases to reach a plateau of around 7.4 (corresponding to 7.4 µM) at the end 
of the period 300 (corresponding to 30 hr), as illustrated in  Figure 3.6 (a). However, at KL2 = 1 
(corresponding to 20 nM/h), Acetate 1  decreases from 8.5  to around 7.8 (corresponding to 7.8 
µM) at the end of the period 300 which is higher than that of  KL2 = 0, 0.5, and 0.75 due to 
accumulation of Acetate 1  and low intracellular choline and choline leakage pathways of β-
amyloid effect Figure 3.6 (a).   
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Figure 3.6 Dynamic behavior Ac1 and Ac2 concentrations at different KL2 values 
 
Figure 3.6 (b) shows the dynamic behaviour of the acetate concentration in compartment 2 
(Acetate 2) at different KL2 values. It is observed that the dynamic behaviour of Acetate 2 is 
different from that of Acetate 1 which increases with increasing of KL2. This is due to the lower 
concentration of ACh2 as shown in Figure 3.4 (b) where ACh2 is the source for producing 
Acetate 2 according to the hydrolysis reaction (equation 3.5) catalyzed by AChE. As shown in 
Figure 3.6 (b) at KL2 = 0 (where no β-amyloid  is produced) and ACh2 has the maximum range, 
Acetate 2 settles down around 6.25 (corresponding to 6.25 µM) at the end of  the period 300 
(corresponding to 30 hr); however, as KL2 increases to 0.5, 0.75, and 1, Acetate 2 decreases  to 
reach 5.52, 5.4, and 5.3 respectively (corresponding to 5.52 µM, 5.4 µM, and 5.3 µM 
respectively) at the end of  the period 300 (corresponding to 30 hr). These concentrations are 
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lower than the healthy range and show the harmful effect of choline leakage pathways because of 
increase in β-amyloid aggregates concentrations. 
 
3.5.5) Effect of β-amyloid on Synthesis and Hydrolysis Rates in compartments 1 and 2 
 
The dynamic behaviors of ACh synthesis rate (Rate 1) catalyzed by ChAT in compartment 1 and 
ACh hydrolysis rate (Rate 2) catalyzed by AChE in compartment 2 are shown in Figure (3.7). 
Figure 3.7 (a) shows that Rate 1 does not change in the healthy range of KL2 = 0 where Rate 1 
decreases from 0.0175 in the beginning of the reaction to settle down around 0.015 of  the end of 
the period 300  (corresponding to 30 h). However, as KL2 increases to 0.5, 0.75 and 1 in the 
dimensionless form, Rate1 decreases continuously to reach a plateau at 0.01, 0.008 and 0.005 in 
the dimensionless form, respectively. As shown previously in Figure 3.5 (a), the intracellular 
choline concentrations (Ch 1) decreases with the increase of KL2, and according to Table 3.1, 
Rate 1 depends on choline substrate concentration. In this case, ChAT activity decreases 
negatively with the increase in production of β-amyloid aggregates with an increase in KL2 as 
shown previously in Figure 3.3. 
Figure 3.7 (b) shows that Rate 2 in compartment 2 which is catalyzed by AChE enzyme at 
different values of KL2. It is observed that Rate 2 decreases slightly from 0.16 at the beginning of 
the reaction to reach 0.12 at the end of the plateau period of 30 hr.  However, as KL2 increases to 
be 0.5, 0.75 and 1 in the dimensionless form, Rate 2 decreases significantly and reaches 0.78, 
0.63, and 0.61, respectively. To explain the reduction of Rate 2, the hydrolysis rate in 
compartment 2 (r(2)) in Table 3.1 depends on ACh2 , which decreases  with the increase in KL2  as 
shown in Figure 3.7 (b) leading  to the reduction of Rate 2.  
 
3.5.6) pH levels in compartments 1 and 2 
 
Figure 3.8 shows the change of pH levels in both compartments at different KL2 values. As 
shown in Figure 3.8(a), at KL2 = 0 the level of pH1 decreases very fast from 8.5 at the beginning 
of the period to reach the plateau where pH1 is 5.5 at the end of the period 300 corresponding to 
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30h. At KL2 = 0.5, Figure 3.8(a) illustrates that pH1 takes the same behaviour as at KL2 = 0 but 
settles down to a plateau at a high value of pH1 = 5.75. In addition, at KL2 = 0.75, Figure 3.8 (a) 
shows that pH1 settles at a high value of 6 at the end of the period 300 (corresponding to 30 hr). 
When Kl2 increases to 1 (corresponding to 20 nM), it is observed that pH1 stabilizes at a high 
value of 6.6 as shown in Figure 3.8(a). The phenomenon of increasing pH levels in compartment 
1 with the increase of β-amyloid formation rate in terms of Kl2, can be attributed to the decrease 
in concentration of hydrogen protons in compartment 1(H
+
) because of the increase in the 
difference between hydrogen ions levels in compartments 1 and 2 where hydrogen proton in 
compartment two (H
+
) decreases as shown in Figure 3.8(b). The latter difference represents the 
driving force for transfer of hydrogen protons from compartment 1 to compartment 2. 
 
Figure 3.8 (b) shows the dynamics of pH2 in compartment 2 (pH2).  It is observed that at KL2 = 0 
where no β-amyloid is produced, pH2 decreases rapidly from 6.8 at the beginning of the period to 
settle down at 5.3 at the end of the period 300 (corresponding to 30 hr). When KL2 increases to 
0.5, β-amyloid aggregate is generated leading to an increase of pH2 which stabilizes around 5.6. 
As KL2 increases to 0.75 and 1 (corresponding to 15 and 20 nM respectively), it is observed that 
pH2 settles down around 5.75 and 6.1 respectively as shown in Figure 3.8 (b). The reduction of 
pH2 with the increase in β-amyloid aggregate production in terms of KL2 is attributed to the 
decrease in the rate of ACh hydrolysis as shown in Figure 3.7 (b) which is due to low available 
ACh2 for hydrolysis. 
From this study, it is clear that all system variables in addition to rate of ACh synthesis, rate of 
ACh hydrolysis - in all of presynaptic, postsynaptic cleft, and postsynaptic neurons have been 
affected significantly by lack of choline reflecting the sensitivity of cholinergic neurocycle in 
AD (Wurtman et al., 1990). As mentioned before, phospholipids in neuronal membranes are one 
of choline sources for ACh synthesis (Marie et al., 1985). A portion of membranes choline is 
proposed to transport into the presynaptic neuron to compensate the shortage of intercellular 
choline levels (Galdzicki et al., 1994; Wurtman et al., 1990). Therefore, the lipid composition of 
cell membranes could be affected leading to destruction of cholinergic neurons membranes 
[Ginsberg et al., 1993, Galdzicki et al., 1994; Wurtman et al., 1990).  It has been found that low 
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levels of choline concentration and neuron cells membrane destruction are common features in 
the brain tissues of AD sick persons (Galdzicki et al., 1994). 
 
 
Figure 3.7 Dynamic behavior of ACh synthesis rate catalyzed by ChAT (Rate 1) and ACh hydrolysis rate 
catalyzed by AChE (Rate 2) at different KL2 values 
 
Allen et al., (1997) investigated the neurotoxic effect on the membranes of PC 12 cells.  They 
found that choline transport rate through PC 12 cells increases when exposed to a wide range of 
β-amyloid (1-40) concentrations. Allen et al., (1997) showed that the high levels of β-amyloid in 
cholinergic neurons could lead to loss of choline inside the neurons. Our results are in agreement 
with those obtained by Ehrenstein (1997), who showed that there is a mutual effect between the 
reduction of ACh concentration and the levels of β-amyloid. Where the synthesis of APP in the 
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neuron tissues of AD brain patients will be induced by the low levels of ACh and as a result 
more choline leakage pathways might be promoted (Buxbaum et al., 1994; Ehrenstein 1997). 
Therefore, the increase of β-amyloid will lead to a further decrease in ACh levels. This cycle of 
increasing β-amyloid and decreasing ACh continues resulting in a pronounced reduction in ACh 
in compartment 1. Furthermore, the results of the choline leakage model are compatible with 
those obtained by Tohgi et al., (1994) who observed low levels of ACh in the brains tissues of 
AD patients. 
 
Figure 3.8 pH1 and pH2 levels with time at different KL2 values 
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3.6) Summary and Conclusions 
Based on the results of the effect of β-amyloid on ACh neurocycle through the two-enzyme/two-
compartment model, it is concluded that β-amyloid induces choline leakage from the brain 
presynaptic neurons (compartment 1) leading to a decrease of choline concentration in 
compartment 1 and compartment 2 as well. These reductions in choline concentrations in both 
compartments are promoted with the increase in the inlet β-amyloid (KL2) where the portion of 
choline transported outside the presynaptic membrane increases.  Additionally,   the rates of ACh 
synthesis catalyzed by ChAT and rate of ACh hydrolysis in the post synaptic neurons 
(compartment 2) catalyzed by AChE decrease. Furthermore, the levels of ACh in both 
compartments are lowered as well as the levels of β-amyloid production (KL2) increase in the 
range (0-1). However, the acetate concentration in compartment 1 increases in parallel with the 
increase of KL2 but the acetate level in compartment 2 decreases. As shown in Figure 3.3, β-
amyloid production also increases with the increase of KL2 causing a more harmful effect. The 
results of the model show that choline leakage, induced by β-amyloid, could cause a reduction in 
choline and ACh concentrations in each of the presynaptic neuron and the synaptic cleft neuron, 
rate of ACh synthesis by ChAT, rate of ACh hydrolysis by AChE, and significant changes in pH 
levels and acetate concentrations in both compartments. The results are in agreement with that 
reported by Allen et al., (1994) and Kar et al., (2004) who showed that β-amyloid aggregates 
could lead to increase in choline loss from neurons and reduction in generated ACh levels. 
Also, the results are in agreement with those obtained by Kar et al., (1998) who showed that 
when neuron tissues are exposed to low concentrations of β-amyloid for a while, choline uptake 
is reduced significantly. Therefore, ACh levels in the post synaptic cleft can be affected 
negatively. In addition, β-amyloid could influence ACh in compartment 1 by affecting transport 
rate of ACh in the presynaptic neuron and the fusion of synaptic vesicles with the membranes 
and thereby inhibiting ACh release. These results are compatible with the low levels of both ACh 
and choline in the neuron tissues of AD brains. Furthermore, our observations are consistent with 
the experimental findings such as those obtained by Kar et al., (1998, 2004), Galdzicki et al., 
(1994), and Allen et al., (1997) on PC 12 cells and with theoretical results obtained by 
Ehrenstein et al., (1997) and reflect the significance effect of β-amyloid in cholinergic disease 
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through choline leakage hypothesis. From this study it is proposed that medications should 
inhibit β-amyloid leakage effect as will be discussed in the next chapter to improve the choline 
recycle. 
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Chapter 4 
Modeling the Interaction between β-Amyloid Peptides 
and Choline Acetyltransferase Activity and Its 
Relation with Cholinergic Dysfunction 
4.1) Introduction 
Cholineacetyltransferase (ChAT) is a single–strand globular protein, and it was discovered in 
rabbit brain by Nachmansohn and Machado in 1943 and catalyzes biosynthesis reaction of ACh 
neurotransmitter (Lips et al., 2007).  ChAT is present in two forms in nerve terminal: (i) non-
ionic membrane-bound and (ii) soluble form. ChAT synthesis occurs in the rough endoplasmic 
reticulum in cholinergic neuron cells. Then, it is transferred to axon terminal for ACh synthesis 
via rapid and slow axoplasmic flow (Oda, 1999). ChAT plays an essential role in cholinergic 
neuron cells and non-neuron cells. In neuron cells ChAT expression is a special marker for 
cholinergic system improvement during brain growth and development where ChAT is involved 
in activation of multiple neuropsychic functions such as memory, cognition, sleep, learning, and 
movement (Abreu-Villaca et al., 2011).Therefor, any disturbance in ChAT levels inside neuron 
cells could generate serious negative consequences. For example, (i) down-regulation of ChAT 
activity causes serious cholinergic disease such as dementia, schizophrenia, and Huntington’s 
disease (Mustafa et al., 2009; Nuns Tavares et al., 2000), (ii) ChAT abnormalities in the brain 
could lead to sudden death in infants (Oda, 1999), (iii) ChAT inhibition leads to generation of 
Alzheimer’s disease because ChAT is the enzyme that is responsible for ACh synthesis. 
Therefore, ChAT inactivation results in a decline of ACh levels in brain. Decreasing ACh 
concentration is the most common early stage features of AD. However, in non-neuron cells 
ACh generated by ChAT catalytic effect is secreted in extracellular space. ACh in extracellular 
space is necessary for maintaining homeostasis of cells, and for modulating many of the essential 
cell functions such as cell division, mitosis, cytoskeleton organization, interactions between 
cells, and maintaining the immune functions (Abreu-Villaca et al., 2011). As shown in Figure 4.1 
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ChAT is concentrated in the presynaptic neuron of the cholinergic neuron because of its 
necessity for ACh synthesis (Mustafa et al., 2009; Brandon et al., 2004) where  ChAT catalyzes 
the reaction between choline (taken from extra cellular fluid by high-affinity transporter carrier) 
and acetyl-CoA (produced during glucose metabolism in mitochondria) to produce ACh; ChAT 
facilitates the transfer of acetyl moiety from acetyl-CoA to choline to give ACh and enzyme-
CoA as indicated in equation 4.1. 
    CoASHOCOCHCHCHNCHCOSCoACHOHCHCHNCH ChAT  

3223332233
 
      
 
There are various factors that could affect negatively on ChAT activity such as excitatory amino 
acids (EAAs), reactive oxygen species (ROS), and β-amyloid peptides. The most serious 
defective factor is β-amyloid peptides (Zambrzycka et al., 2002). Incubation of nanomolar 
concentration of β-amyloid peptides with 50% cultured cholinergic neurons caused a complete 
ChAT inhibition (Nilson Nunes-Tavares et al., 2012). ChAT inhibition by β-amyloid peptides 
induces several cholinergic problems such as memory dysfunction, neuron impairment, and 
cognition declining. Since ChAT is an important indicator for healthy of cholinergic neurons and 
plays a necessary role for activating multiple neuropsychic functions, many researches focused 
on ChAT investigation such as Mustafa et al., (2009), Nunes-Tavares et al., (2000), and Waser et 
al., (1989).  
The main goal of this chapter is to investigate the effect of wide range of concentrations of β-
amyloid aggregates as inhibitor on ChAT activity in brain tissues and the consequences on the 
cholinergic neurocycle behavior such as concentrations of ACh, choline levels, acetate levels, 
and the rate of ACh synthesis and ACh hydrolysis in compartment 1 and compartment 2, 
respectively. In this study three different kinetic mechanisms describing the interaction between 
β-amyloid aggregates and ChAT activity are investigated and the results of each mechanism are 
compared to each other in order to understand how β-amyloid aggregates could affect ChAT 
activity. The rate of ACh synthesis catalyzed by ChAT and affected by β-amyloid inhibitor and 
derived from each kinetic mechanism is incorporated into the two-enzyme/two-compartment 
model explained in Chapter 3 to account for the effect of β-amyloid peptides. 
(4.1) 
ACh Choline Acetyl coenzyme A 
   65 
 
 
 
 
  
Compartment 1 
Compartment 2 
 ACh 
diffuse
 
Choline  
 
Choline  
ACh 
ACh 
 
Figure 4.1: Schematic representation of ChAT catalytic role in ACh synthesis: two –enzyme/ two-
compartment (2E2C) Model (Mustafa et al., 2009) 
 
4.2 Formulation of the interaction between β-Amyloid peptides and 
ChAT kinetics through 2E2C Model 
The ACh neurocycle is shown in Figure 4.1 where the presynaptic neuron represents the plant for 
ACh synthesis where it contains the enzyme ChAT, choline, and acetyl CoA. The presynaptic 
neuron is considered as compartment 1 while both synaptic cleft and postsynaptic neuron 
represent compartment 2. It is observed that choline is the only component produced from the 
hydrolysis which is recycled to compartment 1 and  reused for ACh synthesis (Mustafa et al., 
2009). Tucek (1985) showed that both ACh and acetyl-CoA are synthesized in compartment 1. 
Figure 4.2 shows a simple form of the feedback model of ACh cholinergic neurocycle shown in 
Figure 4.1. Every compartment is considered a constant volume and isothermal continuous 
stirred tank reactor (CSTR) with a constant flow rate and constant recycle ratio. Also, the two 
compartments are separated by a permeable membrane.  β-amyloid peptides interact with ChAT 
inside compartment 1.  Nunes-Tavares et al., (2012) reported that there is a strong relation 
ChAT 
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between β-amyloid peptides and cholinergic dysfunction which is one of the main symptoms of 
Alzheimer disease (AD). Furthermore, β-amyloid could inhibit the activity of the enzyme ChAT 
leading to reduction in the levels of ACh and memory impairment (Nunes-Tavares et al., 2012). 
ChAT activity could be completely reduced significantly with β-amyloid. 
  
4.2.1 Model Assumptions 
All assumptions made for investigating the effect of β-amyloid compatible with literature such as 
those cited by Mustafa et al., (2009) are shown in Chapter 3. More justifications and assumptions 
are clarified below: 
1) The presynaptic of cholinergic nerve terminal is described by compartment 1. Inside this 
compartment ACh is synthesized by the reaction of choline and acetyl CoA in the 
presence of catalytic effect of ChAT enzyme. 
2)  Postsynaptic of neurons together with synaptic cleft are considered as compartment two. 
Both postsynaptic and synaptic cleft are unified to be in one compartment instead of two 
or three because both of them are harmonized and interactive and also to simplify the 
calculations in solving the model particularly when the dimensionality is too high. 
3)  Both compartments are assumed to be divided with a permeable membrane. 
4) The internal masses transfer in compartment one between synaptic vesicles and 
cytoplasm and in compartment two between ACh and postsynaptic receptors are 
neglected because every compartment is assumed to be a homogenous  
5) All matters in the presynaptic neuron are transported to the postsynaptic cleft via passive 
diffusion where all concentrations in compartment 1 should be higher than that in 
compartment 2; however, choline uptake from the postsynaptic cleft to the presynaptic 
neurons is performed by facilitated diffusion via high affinity choline uptake transporters, 
(HACUTs). 
6) It is observed that concentrations of all state variables in compartment two are the 
average of concentrations in postsynaptic and synaptic cleft. 
7) Temperature is considered constant where the system is assumed to be isothermal and 
there is no effect for any temperate changes on the system. 
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8) Transport of β-amyloid from compartment 1 to compartment 2 is neglected. To justify, it 
is noted that transport of β-amyloid from compartment 1 to compartment 2 is by passive 
diffusion and the transport rate is extremely lower than that from the cytoplasm to 
compartment 1. The latter transport (from cytoplasm to compartment1) addresses the 
blood brain barriers (BBB) according to saturable mechanism such as Monod and 
Michaelis-Menten kinetics (Craft et al., 2002; Zlokovic et al., 1993; Martel et al., 1996). 
9) The initial concentration of β-amyloid is assumed to be zero. 
10) Feed stream rate to compartment one and outlet flow from compartment two are 
considered to be constant with a value of q (m
3
/sec). 
 
Figure 4.2:  Schematic representation for two-enzyme/ two-compartment model 
 
4.2.2 Competitive Inhibition of ChAT in Two Enzyme/Two Compartment Model 
ChAT and AChE are the two cholinergic enzymes considered in the 2E2C model. ChAT 
is responsible for synthesis of ACh in compartment 1 of the 2E2C model, while AChE catalyzes 
the degradation of ACh in compartment 2. It is found that incorporation of β-amyloid into rat 
brains in vivo (Nitta, 1994) and at nano to pico molar concentrations into SN56 cell line in vitro 
(W.A. Pederson, 1996), shows significantly a decrease in ChAT activity and ACh production. 
However, detection of change in AChE activity was readily observed and reported (Auld, 1998). 
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This finding suggests that β-amyloid may act as a general modulator of ChAT enzyme activity 
leading to a reduction in ACh synthesis (Ehrenstein 2000).  
 The exact mechanisms of ChAT modulation by β-amyloid are still currently unknown. It 
is possible that β-amyloid aggregates may directly inhibit ChAT activity by competitively 
binding to active sites, or perhaps limit the activity of secondary proteins responsible for ChAT 
synthesis and regulation. Since level of intracellular ChAT is generally maintained at a 
concentration much higher than that of the reactants for ACh production (Blusztajn, 2000), 
modification of the 2E2C model to incorporate inhibition of ChAT activity is required to 
understand the mechanisms of the interaction between ChAT and β-amyloid aggregates. 
    To examine the phenomenon of ChAT activity inhibition by β-amyloid in a simpler model, β-
amyloid is considered to act directly as a competitive inhibitor of ChAT enzyme.  
 
Figure 4.3 illustrates a modified version of pH-dependent enzyme synthesis reaction model used 
in the two enzyme/two compartment model. The modification (represented in square brackets) 
takes into account two possible pathways in which β-amyloid may bind competitively to 
intermediate complexes, thereby inhibiting  their ability to progress to the main reaction direction 
(in the vertical pathway) towards ACh synthesis. In such case β-amyloid may bind directly to the 
active form of the enzyme E2H to generate the inactive E2H [bA] complex (Figure 4.3 (a)), thus 
limiting the availability of active enzymes to carry out ACh synthesis and decrease net enzyme 
activity.  Similarly, it is also possible that β-amyloid may bind to the enzyme intermediate 
complex X2 thereby preventing ACh release from the complex (Figure 4.3 (b)). 
The generation of β-amyloid is modeled by adding another differential equation identical to that 
of choline leakage hypothesis. However, note that the leakage term was not incorporated into the 
choline differential equation for compartment 1. The accumulation of Aβ is described by 
equation (4.2). 
bKsKK
dT
db
LLL 4)1(132                          (4.2) 
The value of KL2 is assumed to produce significant effects on other variables and the numerical 
relationships between KL3 and KL4 were kept the same as in the choline leakage hypothesis. The 
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numerical derivation of the rate equation for the modified pH-dependent ACh synthesis model 
with competitive inhibition of β- amyloid is shown below.   
  
 4.3. Kinetic Mechanism 1: Competitive inhibition of Aβ with all 
species activated enzyme complex E2H  
4.3.1 Formulation of Kinetic Mechanism1:  
The synthesis rate for competitive inhibition of β- amyloid with activated enzyme complex E2H 
can be derived as follow: 
X1 and X2 are related to each other through the following equation: 
1211 )(  kXkChX  or  2
1
1 X
Ch
K
X                          (4.3) 
where 111 / kkK   
By the assumption of rapid equilibrium, E2H and X1 can be related by: 
1222 )( XkHEAcCoAk   or   2
21
2
)(
X
ChAcCoA
KK
HE                    (4.4) 
Where 222 / kkK   
By rapid equilibrium assumption, E2H [bA] complex can be expressed as 
][)( 22 bAHEkbAHEk ii   or ))((][ 22 HEbAKbAHE i                     (4.5) 
Where iii kkK  /  
From the ionization of E2H 
bb kHEkHHE


  22 )(  or                
 
bK
HHE
HE

 
)( 2
2                     (4.6)  
From the deionization of E2H 
  aa kHEkHE   22  or                 
 
H
HEK
E a
)( 2
2                                    (4.7)  
From equation (4.3), (4.4), (4.5), (4.6) and (4.7) we get, 
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X2 and X3 are related by: 
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Where bA is the generated Aβ concentration in the dimensionless form and KI1 is the dimensionless 
equilibrium rate constant for the first proposed inhibition mechanism (Figure 4.3 (a)). Table 4.1 
summarizes the nine ordinary-differential equations of 2E2C model considering ChAT- 
inhibition effect by β-amyloid based on the previous kinetic mechanism (1), and Table 4.2 gives 
the values of kinetic parameters. 
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Figure 4.3: Possible competitive inhibition mechanisms for β-amyloid ([bA]) during pH-dependent ChAT synthesis 
of  ACh (areas of inhibition are displayed in square brackets). The  reaction route occurs in the vertical direction. 
E2H is the active form of the enzyme; E2H
+
 and E2
-1
 are the protonated and de-protonated inactive forms. X1, X2 and 
X3 are enzyme intermediate complexes. a) β- -amyloid competitively binds to active enzyme complex E2H; b) β- -
amyloid competitively binds to enzyme intermediate X2. 
 
AcCoA 
+ 
E 2 H 
k 
-2 k 2 
K a   
(H 
+ ) - 
E 2 
-1 
E 2 H 
+ 
X 1 Ch 
ACh 
X 3 AcCoA 
X 2 
k 
-1 k 1 
+ 
K 
2 
\ 
k 
-3 
k 
3 
+ 
E 2 H[bA] 
k i   (bA) 
K 
b  (H + 
) 
k-i 
k-b 
k-a 
(a) 
 AcCoA 
+ 
E 2 H 
k -2 k 2 
K a   (H 
+ ) - 
E 2 
-1 
E 2 H 
+ K b  (H 
+ ) 
X 1 Ch 
ACh 
X 3 AcCoA 
X 2 
k -1 k 1 
+ 
K 2 
\ 
k -3 k 3 
+ 
X 2 [bA] 
K i  ([bA]) 
ki 
(b) 
 
   72 
 
Table 4.1: Dimensionless forms of the ordinary differential equations of ChAT inhibition by β-
amyloid aggregates 
Item Compartment Differential equation 
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Table 4.2: Values of the kinetic parameters 
Parameter Value Reference 
 1 5.2(0.1) Hersh & Peet (1977) 
 2 12 Hersh & Peet (1977) 
 3 1000 Hersh & Peet (1977) 
 4 5 Hersh & Peet (1977) 
 5 1 Hersh & Peet (1977) 
  0.5 Garhyan et al., (2006); Ibrahim et al., (1997); 
Elnashaie et al., (1983b), ( 1984), and (1995) 
  1 Garhyan et al., (2006); Ibrahim et al., (1997); 
Elnashaie et al., (1983b), ( 1984), and (1995) 
Ka(kh) 1.066*10
-6 
kMole/m
3
(µMole/mm
3
) Garhyan et al., (2006); Ibrahim et al., (1997); 
Elnashaie et al., (1983b), ( 1984), and (1995) 
Ks1 50.33 µMole/l Garhyan et al., (2006); Ibrahim et al., (1997); 
Elnashaie et al., (1983b), ( 1984), and (1995) 
S2ref 100 µMole/l Guyton and Hall, (2000) 
S3ref 1 µMole/l Guyton Hall, (2000) 
1B  
510033.5  kMole/m
3
(µMole/mm
3
) Garhyan et al., (2006) 
2B  
510033.5  kMole/m
3
(µMole/mm
3
) Garhyan   et al., (2006) 
H
  2.25 Elnashaie et al., (1984) 
OH
  0.5 Elnashaie et al., (1984) 
1S
  1.5 Elnashaie et al., (1984) 
2S
  1.5 Elnashaie et al., (1984) 
3S
  1 Elnashaie et al., (1984) 
RV  
1.2 Elnashaie et al., (1984) 
fpH  
8.2 Guyton, 2000 
fs1  
15 Garhyan   et al., (2006) 
fs2  
1.15 Garhyan et al., (2006) 
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fs3  
3.9 Garhyan et al., (2006) 
1  
0.01 Garhyan et al., (2006), Elnashaie et al., 
1983a; Elnashaie et al., 1983b; Elnashaie et 
al., 1984; Elnashaie et al., 1995; Ibrahim et 
al., 1997) 
R 0.8 Tucek (1978) 
KbAref 20  nM/h Ehrenstein et al., (1997) 
KL2 assumed  
KL1  
 
3*KL2 Assumed 
KL3  
 
0.035KL2 Assumed 
KL4  
 
0.176KL3; Assumed 
KI1  10.015 Assumed 
KbA1 0.05 Assumed 
Tref 0.1 h Assumed 
BAref  20 nM/l Kar et al., (2008) 
 
 
4.3.2 Results of Kinetic Mechanism 1   
Based on the first kinetic mechanism of β-amyloid-ChAT competitive inhibition shown in Figure 
4.3(a) and the derived ACh synthesis rate equation r1 equation (4.11), the dynamic behavior of 
2E2C model is investigated at different rates of β-amyloid production from APP (KL2) as 
explained below.  
 
4.3.2.1) β-Amyloid Generation 
Figure 4.4 shows the dynamic behavior of β-amyloid concentrations. It is observed that at KL2 = 
0, no β-amyloid is produced.  However, when KL2 increases to 0.5 (corresponding to 10 nM), the 
concentration of generated β-amyloid increases in the period 0-150 (corresponding to (0-15hr) to 
reach the plateau at 9.75 (corresponding to 185 nM). However, when KL2 = 2.5 (corresponding to 
50 nM), the produced β- amyloid increases rapidly to reach the plateau at the previous 
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concentrations which is 185 nM but through a shorter time which is 15 (corresponding to 1.5 hr) 
and remains constant until the end of the incubation period which is 30 (corresponding to 30 hr). 
When KL2 increases to reach the maximum value which is 25 (corresponding to 500 nM), the 
generated bA increases with a rate faster than the previous rates at Kl2=0.5 and 0.75 to reach the 
plateau in a period of 5 (corresponding to 0.5 hr only). 
 
 
Figure 4.4: Time course of β-amyloid at different KL2 according to kinetic mechanism 1 
  
4.3.2.2 Rate of ACh synthesis and hydrolysis 
Figure 4.5 (a) shows the dynamics behavior of ACh synthesis (Rate 1) catalyzed by the enzyme 
ChAT. It is observed that rate 1 reaches steady state at a high value which is 0.01375 at KL2 = 0  
where no β-amyloid is produced; however, when KL2  increases to 0.5, 2.5, and 25, rate 1 
decreases significantly to reach a  steady state  around 0.0104. It is observed that the final value 
of Rate 1 at the end of the period (0-300) corresponding to (0-30) hr does not change with KL2 
reflecting the neglected effect of the generated β-amyloid in this period. The rate of ACh 
synthesis is lowered by 25% through the effect of β-amyloid on ChAT.  Figure 4.5 (b) shows that 
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there is no effect of KL2 on the rate of hydrolysis (rate 2) indicating that rate 2 is independent of 
the change of KL2 in the kinetic mechanism. 
These results are compatible with the experimental results obtained by Nunes-Tavare et al., 
(2012) who showed that β-amyloid peptides could bind to a significant portion of cholinergic 
neurons and reduce ChAT activity. It is observed that the reduction in Rate 1 decreases from 
0.0105 to 0.000125 which refers to a reduction in ChAT activity of 99.7% with an increase in 
KL2 from 0 to 25 (corresponding to 500 nM). In addition, Nunes-Tavares et al., (2012) showed 
that β-amyloid peptides have a very limited effect on the activity of AChE in comparison to 
ChAT activity which is in agreement with our results shown in Figures 4.5 (a) and (b).  
 
4.3.2.3 ACh concentrations in compartments 1 and 2 
One of the main physiological symptoms of AD is a reduction of ACh production in cholinergic 
neurons (Blusztajn, 2000). Therefore, the first step towards validating β-amyloid inhibition 
model is to see whether this physiological effect is reflected in the simulation results or not. As 
shown in Figure 4.6, it is an evidence of decreasing ACh concentration in compartment 1 (ACh 
1) level in compartment1.  Figure 4.6 (a) shows the dynamics of ACh1 which reaches steady 
state at a high value at KL2 = 0 where ACh1 settles down around 4.4 (corresponding to 221.5 
µM) where no β-amyloid is produced, but when KL2 increases to 0.5, 2.5, and 25, it is observed 
that ACh1 decreases slightly to reach the steady state at 4.28 (corresponding to 215 µM). It is 
noted that the final value of rate at the end of the period (0-300) corresponding to (0-30 hr) does 
not change with KL2 reflecting the neglected effect of the generated β-amyloid in this period.  
These results are compatible with experimental results obtained by Kar et al., (1998) who 
indicated that the decrease in ChAT activity leads to a reduction in ACh generated in the 
presynaptic neurons. Furthermore, Zheng et al., (2002) indicated that exposure of culture neurons 
to β-amyloid leads to decrease in ChAT activity. However, Pedersen and Blusztajn (1997) 
showed that only acetyl-coA not ChAT activity is affected negatively when exposed to β- 
amyloid leading to reduction of generated ACh similarly to the rate of ACh hydrolysis shown in 
Figure 4.5 (b) which exhibits no effect of KL2 where ACh2 does not change with any change in 
KL2. The absence of any observable effects in ACh2 is mostly likely due to the relative magnitude 
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of the ACh synthesis rate (r1) compared to the magnitude of other transport phenomena within 
the model. Focusing on the kinetics in compartment 2, ACh2 level is governed mainly by two 
processes; membrane diffusion of ACh from compartment 1 and the rate of ACh degradation (r2) 
 
Figure 4.5: Time course according to kinetic mechanism 1 of: a) Rate of ACh Synthesis (Rate 1),      
          b) Rate of ACh hydrolysis (Rate 2) at different KL2 
 
in compartment 2. The transport of ACh into compartment 2 through membrane diffusion is 
observed to slighly decrease due to reduced ACh1 levels from β-amyloid inhibtion. On the other  
hand,  the rate of ACh break-down is maintained the same. It is expected  that the influx of ACh 
into compartment 2 is approximately an order of magnitude higher than the consumption of ACh 
(r2) in that compartment. This means that although the influx of ACh into compartment 2 is 
limited by β-amyloid inhibition, the fact that r2 is so small in comparison infers that the overall 
level of ACh2 will not be affected much.  
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4. 3.2.4) Choline concentrations in compartments 1 and 2 
Figure 4.7 (a) and Figure 4.7 (b) show the dynamic response for choline concentrations in 
compartment 1 (Ch1) and 2 (Ch2) respectively. It is observed that there is no effect of KL2 on the 
behavior of Ch1. This reflects that the uptake of choline to compartment 1 is not affected by any 
change in β-amyloid through the interaction between ChAT and β-amyloid via the relevant 
kinetic mechanism. This result is compatible with the experimental results obtained by Nunes et 
al., (2012) who showed that there is no effect of β-amyloid oligomers on choline uptake. Figure 
Figure 4.6: Time course according to kinetic mechanism 1 of: a) ACh concentration 
in compartment 1 (ACh 1), b) ACh concentration in compartment 2 (ACh 2)   at 
different KL2 values 
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4.7 (b) shows that KL2 does not affect Ch2. In other words ChAT inhibition β-amyloid in 
compartment 1 does not affect AChE activity in compartment 2. 
 
4. 3.2.5) Acetate concentrations in compartments 1 and 2 
Figure 4.8 shows the dynamic response for acetate concentrations in compartments 1 (Ac1) and 
2 (Ac2). Figure 4.8 (a) shows that Ac1 increases from 8.25 at the beginning of the period  then it 
reaches the steady state value which is 9.51 ( corresponding to 9.51 µM) when KL2  increases to 
0.5 , 0.75, and 1. Ac1 increases slightly due to ChAT inhibition and accumulates due to low 
consumption of acetates by ChAT for synthesizing ACh. However, KL2 does not affect Ac1 since 
the steady state behavior of Ac1 is obtained when KL2 is higher than zero.  Figure 4.8 (b) shows 
that there is no influence of KL2 on Ac2  which is the same as Ch2 and Rate 2 reflecting the 
negligible effect of KL2  on  compartment 2 through the proposed kinetic mechanism 1. 
 
4. 3.2.6) pH in compartments 1 and 2 
Figure 4.9 shows the dynamic response of pH in both compartments (pH1) and 2 (pH2). Figure 
4.9 (a) shows that pH1 is affected very slightly with changes in KL2 indicating that the inhibition 
of ChAT activity with the proposed kinetic mechanism 1 has a low effect on changing pH1. 
Figure 4.8 (b) shows a negligible effect of KL2 on pH2 which is the same as the behaviors of Ch2 
and Rate 2 explained previously. According to kinetic mechanism 1, β-amyloid promotes a 
major reduction in ChAT activity while all other components in ACh cholinergic system remain 
unaffected. 
The effect of β-amyloid inhibition on the remaining variables (pH and Ac) is observed to be 
negligible within the time frame studied. One likely explanation is that the feed concentrations of 
these chemical components into the 2E2C system are all much larger in magnitude compared to 
that of ACh. While they all have an indirect dependence on the activity of ChAT through 
changes in ACh1 concentration, the reduction in ACh is too small to produce a significant effect 
on the concentration of these components. 
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Figure 4.7: Time course according to kinetic mechanism 1 of: a) Choline concentration in compartment 1 (Ch 1), b) 
Choline concentration in compartment 2 (Ch 2)   at different KL2 values 
 
Figure 4.8: Time course according to kinetic mechanism 1 of: a) Acetate concentration in compartment 1 (Ac 1),    
b) Acetate concentration in compartment 2 (Ac 2)   at different KL2 values 
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Figure 4.9: Time course according to kinetic mechanism 1 of: a) pH in compartment 1 (pH1), 
b) pH in compartment 2 (pH2)   at different KL2 values 
 
4.4 Kinetic Mechanism 2: Ccompetitive inhibition of β-amyloid with 
enzyme intermediate complex X2 
4.4.1 Formulation of kinetic mechanism 2 
In this kinetic mechanism, there is a competitive inhibition of β-amyloid with enzyme 
intermediate complex X2. during ACh synthesis as shown in  (Figure 4.3 (b)), the modified rate 
equation can be derived as shown below.  
X1 and X2 are related through the following expressions: 
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Where 222 / kkK   
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Where bA is the concentration of generated β-amyloid in the dimensionless form and KI1 is the 
dimensionless equilibrium rate constant for the second proposed inhibition mechanism shown in 
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Figure 4.3 (b). In the next section, the results presented are based on the previous equation of r1 
replacing that r1 in Table 4.1 while all other equations remain the same as the kinetic parameter 
values in Table 4.2. 
 
4.4.2 Results of Kinetic Mechanism 2 
Incorporating the rate of ChAT synthesis r1 (equation 4.20)  inhibited by β-amyloid 
peptides  derived from  the kinetic mechanism (2) into the 9
th
 dimension 2E2C model shown in 
Table 4.1, the effect of  β-amyloid peptides on ACh neurocycle is investigated to check the 
feasibility of kinetic mechanisms as a descriptor for the interaction between ChAT activity and 
β-amyloid peptides. 
 
4.4.2.1) β. Amyloid Generation 
Figure 4.10 shows the dynamic behavior of β-amyloid produced in compartment 1. It is clear that 
at KL2 = 0 where there is no inlet β-amyloid, there is no generation of β-amyloid. However, when 
KL2 increases to 0.5 (corresponding to 10 nM), β-amyloid is produced to reach 10 (corresponding 
to 200 nM) after a time of 150 (corresponding to 15 hr), then it becomes constant where there is 
no more generation until the end of the incubation period (300) corresponding to 30 hr. In 
addition, Figure 4.10 shows that when KL2 increases to 2.5 (corresponding to 50 nM),  β-amyloid 
is generated faster than that at KL2 = 0.5 where β-amyloid reaches the stationery steady state after 
15 (corresponding to 1.5 hr) then it does not change until the end of the incubation period. 
Furthermore, at KL2 =25 (corresponding to 500 nM), β-amyloid is produced much faster than 
before where it reaches the steady state value only after a dimensionless time of 7 (corresponding 
to 42 minutes).  Comparing the dynamic behaviors of β-amyloid in kinetic mechanism 2 and 
kinetic mechanism 1, it is observed that the final steady state value of kinetic mechanism 2 is 
higher than that of kinetic mechanism 1.  The increase of final β-amyloid might lead to changes 
in other state variables of the system.  
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Figure 4.10: Time course of generated β-amyloid at different KL2 (according to kinetic mechanism 2) 
 
4.4.2.2) Rates of ACh synthesis and hydrolysis 
Figure 4.11 shows the dynamic behavior of rate of ACh synthesis catalyzed by ChAT (Rate1) 
and rate of ACh hydrolysis catalyzed by AChE (Rate 2). Figure 4.11 (a) shows that Rate1, at no 
β-amyloid production where KL2 = 0,   decreases from 0.016 at the beginning of process to reach 
0.0138 after passing 20 (corresponding to 2 hr), then it becomes constant until the end of the 
period. However, when ChAT activity is reduced according to kinetic mechanism 2 at KL2 = 0.5 
(corresponding to 10 nM), Rate 1 decreases significantly as shown in Figure 4.11 (a) to reach 
0.0103 at the end of the period but it reaches the steady state slower than that at KL2 = 0 where it 
takes time of 100 (corresponding to 10 hr) to reach the plateau. Furthermore, when KL2 increases 
to 2.5 and 50 (corresponding to 50 and 1000 nM, respectively) the generated β-amyloid takes the 
same behavior where both of them decrease with the same rate but faster than that at KL2 = 0.5.  
It is observed that the reduction in Rate 1 decreases from 0.01375 to 0.0105 which refers to a 
reduction in ChAT activity of 24.7% with an increase of KL2 from 0 to 25 (corresponding to 500 
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Figure 4.11: Time course of: a) Rate of ACh Synthesis (Rate 1), b) Rate of ACh hydrolysis (Rate 2) at different KL2 
(according to kinetic mechanism 2) 
 
nM). Figure 4.11 (b) shows that the effect of changing KL2 on Rate 2 is negligible according to 
the kinetic mechanism 2 indicating the same behavior as kinetic mechanism 1 as shown 
previously in Figure 4.7 (b). 
 
4.4.2.3) ACh concentrations in compartments 1 and 2 
Figure 4.12 (a) shows the dynamics of ACh1 with the rate of ChAT activity inhibition r1 based 
on kinetic mechanism 2. It is observed that at KL2 = 0.5 ACh1 reduces from 4.3 (corresponding 
to 216.419 µM) at the beginning of β-amyloid incubation to reach to 3.15 (corresponding to 
158.5µM) after passing 100 (10 hr) and it keeps at this value until the end of the period which is 
300 (corresponding to 30 hr). Comparing ACh1 at KL2 = 0.5 to that in the first kinetic 
mechanism in Figure 4.6 (a), it is observed that the rate of ChAT activity affected by the 
interaction between competitive inhibitions of β-amyloid with enzyme intermediate complex X2 
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in kinetic mechanism 2 leads to a more reduction in ACh1. At KL2 = 2.5 and 50, the reduction of 
ACh1 is faster than that at KL2 = 0.5 where it occurs after passing 15 and 10 (corresponding to 
1.5 and 1 hr respectively), then ACh1 remains at steady state around 3.15 (corresponding to 
158.5µM) indicating that inhibition of ChAT activity by β-amyloid reached its maximum limit. 
Figure 4.12 (b) shows that ACh2 is not affected significantly with the change of KL2; which is 
the same as in kinetic mechanism 1 as shown in Figure 4.6(b). 
 
 
 
 
 
 
Figure 4.12: Time course of: a) ACh concentration in compartment 1 (ACh 1),  
b) ACh concentration in compartment 2 (ACh 2)   at different KL2 values 
(according to kinetic mechanism 2) 
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Figure 4.13: Time course of: a) Choline concentration in compartment 1 (Ch 1), 
b) Choline concentration in compartment 2 (Ch 2)   at different KL2 values (according to kinetic mechanism 2) 
 
4.4.2.4) Choline concentrations in compartments 1 and 2 
Figure 4.13 (a) and Figure 4.13 (b) illustrate the time course of choline concentrations in 
compartments 1 and 2 respectively. It is observed that KL2 has no effect on both Ch1 and Ch2 
indicating that the inhibition of ChAT activity by β-amyloid does not affect choline uptake in 
compartment 1 and choline produced from hydrolysis in compartment 2 following the same 
behavior in kinetic mechanism 1 as shown previously in Figure 4.7 (a) and (b). 
 
4.4.2.5) Acetate concentrations in compartments 1 and 2 
Figure 4.14 (a) shows the effect of changing KL2 in terms of the inhibition of ChAT activity 
according to kinetic mechanisms 2 on intracellular concentration of acetate. At KL2 = 0, Ac1 
increases through the first 30 (3 hr) and reaches steady state around 9.52 (corresponding to 9.52 
µM) indicating that inhibition of ChAT activity by β-amyloid reached its maximum limit. 
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However, after incorporating β-amyloid generation in terms of KL2 = 0.5, 2.5, and 50 
(corresponding to 10, 25, 1000 nM), there is a significant decrease in Ac1, where the final steady 
state concentration of Ac1 is around 8.95 (corresponding to 8.95 µM). It is clear that competitive 
inhibition of β-amyloid with enzyme intermediate complex X2 in kinetic mechanism 2 has 
moreeffect on Ac1 than that in kinetic mechanism 1. Figure 4.14 (b) shows that Ac2 is affected 
clearly with any increase in inlet β- amyloid concentrations (KL2) where at KL2 = 0, the steady 
state of Ac2 = 6.4 (corresponding to 6.4 µM) while with the increase of KL2 to 0.5, 2.5 and 50, 
the steady state value of Ac2 will be around 5.6 and not varying with changing KL2 as illustrated 
in Figure 4.14 (b). This indicates again that inhibition of ChAT activity by β-amyloid reaches the 
maximum effect. 
 
 
Figure 4.14: Time course according to kinetic mechanism 2 of: a) Acetate concentration in compartment 1 
(Ac1), b) Acetate concentration in compartment 2 (Ac 2)   at different KL2 values 
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4.4.2.6) pH in compartments 1 and 2 
Figure 4.15 (a) shows the dynamics of pH1 with changing KL2. It is observed that at KL2 = 0, pH1 
decreases from 8.5 at the beginning to settle down around 6.2 at the end of the period. However, 
as KL2 increases to 0.5, 2.5, and 50, pH1 decreases clearly to settle down around 7.75 indicating 
that the inhibition of ChAT activity by β-amyloid reaches the maximum limit.  It is concluded 
that the rate of transport of hydrogen protons from compartment 1 to compartment 2 is still 
higher than the rate of accumulation of hydrogen protons due to the inhibition of ChAT catalytic 
effect according to kinetic mechanism 2.  Figure 4.15 (b) shows the dynamic behavior of pH2 
where pH2 increases from 5.85 at KL2 = 0 to the steady state value of 6.23 with increasing KL2 
from 0.5 to 50. 
It clear that kinetic mechanism 2 in terms of competitive inhibition of β-amyloid with enzyme 
intermediate complex X2 has more effect on pH1 and pH2 than that in kinetic mechanism 1. It is 
observed that after time 100 (corresponding to 10 hr), there is no effect for any further change of     
β-amyloid production rate (KL2 from 0.5 to 25), where all state variables reach the same steady 
state values indicating that the activity of ChAT is fully inhibited. These results are compatible 
with that obtained by Nunes-Tavares et al., 2012) who showed that there is no significant effect 
for any further β-amyloid concentration more than 100 nM. According to kinetic mechanism 2, 
β-amyloid peptides promote a major reduction in ChAT function, ACh1, acetate 1 and acetate 2, 
pH1, and pH2 while all other components in ACh cholinergic system remain unaffected. 
 
 
4.5 Kinetic Mechanism 3: Non-competitive inhibition of β-amyloid with 
all species ChAT  
4.5.1 Formulation of kinetic mechanism 3 
β-amyloid inhibitor behaves as a non-competitive inhibitor  and  could  attack  all  ChAT  species  
in  the  synthesis reaction in compartment 1 with  the  same  affinity  if  the   reaction follows  
either  a  rapid  equilibrium  random  mechanism or an  ordered  sequential (Cheng and Prusoff, 
1973). Figure 4.16 shows the kinetic mechanism 3 for the synthesis reaction catalyzed by ChAT 
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where all species in ChAT can be exposed to β-amyloid peptide, where E = ChAT, I = β-
amyloid, A = Choline, B = Acetyl-coA.  In the same way as the previous kinetic mechanisms 1 
and 2 were derived, the final form of the rate of ACh synthesis derived is shown as below:  
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Figure 4.15: Time course according to kinetic mechanism 2 of:  a) pH in compartment 1 (pH 1),  
b) pH in compartment 2 (pH 2)   at different KL2 values 
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By using equation (4.21) for the rate equation r1 in 2E2C of Table 4.1 and keeping all other 
equations the same and incorporating KI1 into Table 4.2, the effect of β-amyloid peptide as an 
inhibitor for ChAT activity on 2E2C model can be simulated as discussed in the next section: 
 
 
Figure 4.16: Possible non-competitive inhibition mechanisms for β-amyloid during pH-dependent ChAT synthesis 
of ACh: E = ChAT, I = β-amyloid, A = Choline, B = Acetyl-coA, Products = ACh 
 
 
4.5.2 Results of Kinetic Mechanism 3 
 
4.5.2.1) β-Amyloid Generation 
Figure 4.17 shows the dynamic response at different KL2 values. At KL2 = 0 where there is a 
normal ChAT activity without inhibition, it is observed that there is no β-amyloid generated 
where β-amyloid concentration = 0. At KL2 = 0.5, β-amyloid is produced significantly and 
increases to 10.2 (corresponding to 204 nM) after passing time of 100 (corresponding to 10 hr), 
where it reaches steady state at this value. At KL2 = 25 (corresponding to 500 nM), it is observed 
that β-amyloid oscillates in a narrow range (10-10.2) corresponding to (200-204 nM). The 
oscillatory behavior is an interesting phenomenon because it may affect other state variables of 
the system as will be investigated below. 
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4.5.2.2) Rate of ACh synthesis and hydrolysis 
Figure 4.18 (a) shows the effect of varying inlet β-amyloid KL2 on ACh synthesis rate 1 under 
the condition of ChAT fully inhibited according to equation (21).  At normal ChAT synthesis  
where there is no β-amyloid generation, rate 1 decreases from 0.014 at the beginning to 0.0105 
which is the steady state value after passing time 200 (corresponding to 20 hr). However, when 
KL2 increases to 0.5 and 25 (corresponding to 10 and 500 nM), rate 1 decreases from 0.014 at the 
beginning of β-amyloid incubation to reach a very small value close to zero indicating that ChAT 
activity is completely inhibited by β-amyloid peptides which attack every species in ChAT 
enzyme.  It is observed that the reduction in Rate 1 decreases from 0.0105 to 0.000125 which 
refers to a reduction in ChAT activity of 99.7% with increasing KL2 from 0 to 25 (corresponding 
to 500 nM). This result is consistent with the experimental results obtained by Nunes-Tavares et 
al., 2012) who showed that β-amyloid could inhibit ChAT completely. 
Figure 4.18 (b) shows that a very interesting phenomenon which is the oscillatory behavior at a 
high inlet β-amyloid KL2 = 25 where rate 2 oscillates in the range (0.05-0.32). This oscillatory 
behavior reflects the disturbances occurring in the cholinergic system at which β-amyloid is 
generated at a high rate as shown in Figure 4.17 and acts severely as an inhibitor ChAT.  
 
4.5.2.3) ACh concentrations in compartments 1 and 2 
Figure 4.19 (a) shows that ACh1 is synthesized with a high rate at KL2 = 0 where ACh1 settles 
down to around 4.35 (corresponding to 219 µM) at the end of the time T = 200 (corresponding to 
30 hr). When KL2 = 0.5 (corresponding to 10 nM), the levels of ACh1 decrease to 2.7 
(corresponding to 136 µM) after passing T = 100 (corresponding to 10 hr) then ACh1 remains 
constant at the latter concentration until the end of the incubation period which 30 hr. As KL2 
increases to 25 (corresponding to 500 nM), the interesting oscillatory phenomenon appears 
where ACh1 oscillates in a wide range from 2.6-3.4 corresponding to 131-322 µM. This range 
shows that the ACh1 moves in a disturbance and could be related to irregular behavior leading to 
impaired memory. Figure 4.19 (b) shows that at the highest value of KL2 =25, ACh2 fluctuates in 
a wide range (0.1-1.38) corresponding to (5-69.5) µM.  The latter fluctuation shows the irregular 
behavior of ACh2 released in compartment 2 and could lead to unreasonable electrical and 
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chemical messages to the postsynaptic receptors and finally dysfunctions of the memory. The 
latter disturbances show the harmful effect of high concentration β-amyloid and the 
consequences of inhibition action with all species in ChAT. 
 
Figure 4.17: Time course of β-amyloid at different KL2 (according to kinetic mechanism 3) 
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Figure 4.18: Time course of: a) Rate of ACh Synthesis (Rate 1), b) Rate of ACh hydrolysis (Rate 2) at different KL2 
(according to kinetic mechanism 3) 
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Figure 4.19: Time course of: a) ACh concentration in compartment 1 (ACh1), 
b) ACh concentration in compartment 2 (ACh)   at different KL2 values (according to kinetic mechanism 3) 
 
4.5.2.4) Choline concentrations in compartments 1 and 2 
Figure 4.20 (a) shows that there are no observable effects in the bahavior of  Ch1. This refelcts 
that there is no effect of ChAT-inhibition by β-amyloid on intracellular choline concentration 
indicating that both choline uptake and choline transport  between compartments 1 and 2 are able 
to keep balanced  intracellular choline concentration. It is observed that Ch1 decreases from 3.22 
(corresponding to 322 µM) at the beginning of incubation to 2.55 (corresponding to 255 µM).  
Figure 4.20(b) shows a limted efect of varying KL2 on Ch2. Ch2 increases very fast at the 
beginning of the reaction from 1.15 (corresponding to 115 µM) to 1.36 (corresponding to 136 
µM) in just a short time T = (0-2) corresponing to (0-0.2 hr) then decreases to settle down at 
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1.16. Figure 4.21 (a)  shows that Ch1 decraeses from 3.2 (corresponding to 320 µM) to 2.52 
(corresponding to 252µM) after passing T = 20 (corresponing to 2 hr). Figures 4.22 (a) and (b) 
are enlargement of Figures 4.20 (a) and (b) where it is observed that Ch1 oscilates in a narrow 
range (2.532-2.538) (corresponding to 253.2-2538 µM)  at KL2 = 25 (corresponding to 500 nM)  
as shown in Figure 4.22 (a). Figure 4.22 (b) shows that Ch2 oscialtes through a limted range of 
1.1548-1.1558 (corresponding to 115.48-155.8 µM). 
 
Figure 4.20: Time course of: a) Choline concentration in compartment 1 (Ch1), 
b) Choline concentration in compartment 2 (Ch2)   at different KL2 values (according to kinetic mechanism 3) 
 
The limited effect of Aβ inhibition on Ch1 and Ch2 is found to be negligible within the time 
frame studied. One likely explanation is that the choline uptake and the rate of ACh hydrolysis 
are all much larger in magnitude compared to that of ACh. While they all have an indirect 
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dependence on the activity of ChAT through changes in ACh1 concentration, the reduction in 
ACh is too small to produce a significant effect on the concentrations of these components. 
 
4.5.2.5) Acetate concentrations in compartments 1 and 2 
Figure 4.23 (a) shows the dynamic behaviors of Acetate 1 at different KL2 values. It is observed 
that at KL2 = 0 where no β-amyloid is produced, Acetate 1 increases to settle down at the 
stationery state value of 9.6 (corresponding to 6.6 µM). As KL2 increases to 0.5 (corresponding 
to 10 nM), Acetate 1 settles down at a lower value of 9.45 (corresponding to 9.45 µM). When 
KL2 increases to the highest value of 25 (corresponding to 500 nM), Acetate 1 fluctuates in the 
range of 9-9.5 (corresponding to 9-9.5 µM). 
Figure 4.23 (b) shows that Acetate 2, at KL2= 0, takes steady state behavior which is around 6.4 
(corresponding to 6.4 µM). While KL2 increases to 0.5 (corresponding to 10 nM), Acetate 2 
deceases to settle down around 5.6 (corresponding to 5.6 µM) which is lower than that at no 
inhibition KL2 = 0). When KL2 increases to 25 (corresponding to 500 nM), the oscillatory 
behavior dominates the system where Acetate 2 fluctuates in the range 5- 5.63 corresponding to 
5-5.63 µM. 
 
4.5.2.6) pH in compartments 1 and 2 
Figure 4.24 (a) shows the dynamic response of pH1 at different KL2 values. It is observed that at 
KL2 = 0 where no β-amyloid is produced, pH1 decreases rapidly from 8.5 to settle down at 6.2. At 
KL2 = 0.5, pH1 decreases from 8.5 to 6.75 in the period 0-5 corresponding to (0 - 0.5 hr) then it 
increases to settle down around 8.4 which is the steady state value. When KL2 increases to the 
high value of 25 (corresponding to 500 nM), pH1 oscillates in the range of 7.8-8.6. 
Figure 4.24 (b) shows that at KL2= 0, pH2 settles down of  around 5.8;  when KL2 increases to 0.5 
(corresponding to 10 nM), pH2 decreases from 6.65  to 6.1 in the period 0-5 corresponding to (0 - 
0.5 hr) then  it  increases to  settle down around the steady state value of 6.8. It is observed that at 
KL2 = 25, pH2 fluctuates in a wide range of 6.35-8.2 causing disturbances to the cholinergic 
system. 
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Figure 4.21: Magnification to Figure 4.20: a) Choline concentration in compartment 1 (Ch 1),  
b) Choline concentration in compartment 2 (Ch 2)   at different KL2 values (according to kinetic mechanism 3) 
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Figure 4.22: Magnification to Figure 4.20: a) Choline concentration in compartment 1 (Ch 1),  
b) Choline concentration in compartment 2 (Ch 2)   at different KL2 values (according to kinetic mechanism 3) 
 
4.6 Discussion 
The effect of β-amyloid inhibition on ChAT activity is investigated through proposing three 
different kinetic mechanisms. The first kinetic mechanism is that β-amyloid binds to active 
enzyme complex E2H in ChAT for producing ACh while in the second kinetic mechanism β-
amyloid competitively binds to enzyme intermediate X2. In the third kinetic mechanism, β-
amyloid binds all species in ChAT enzyme. In each kinetic mechanism, a rate equation of ACh 
synthesis (r1) is derived and incorporated into the two-enzyme/ two –compartment model to get 
a cholinergic system with nine first-order ordinary differential equations. The concentrations of 
all state variables in compartments 1 and 2 in addition to the rates of ACh synthesis and ACh 
hydrolysis are investigated at different rates of β-amyloid generation (KL2) and compared with 
normal cholinergic neurons where there is no inhibition with β-amyloid.    
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Figure 4.23: Time course of: a) Acetate concentration in compartment 1 (Ac 1),  
b) Acetate concentration in compartment 2 (Ac 2)   at different KL2 values (according to kinetic mechanism 3) 
 
It is found that for all kinetic mechanisms the concentration of generated β-amyloid increases 
with increasing β-amyloid peptides production until it reaches saturation levels where there is no 
further increase with any additional increase of KL2. In the first kinetic mechanism where β-
amyloid attacks only the active enzyme complex E2H in ChAT, it is found that each of the rate of 
ACh synthesis and the concentration of intracellular ACh (ACh1) decrease significantly with an 
increase in KL2 referring to the inhibition effect of ChAT activity while all of the other rates of 
ACh hydrolysis are not affected. In addition, ACh concentration in compartment 2 (ACh2), 
choline concentrations in compartments, pH in both compartments, acetate concentrations in 
both compartments are not affected by any change in KL2. Therefore, the interaction between β-
amyloid peptides and enzyme complex E2H in ChAT has a limited effect on most of elements of 
ACh neurocycle. One of the main explanations is that the limited effect of β-amyloid peptide on 
substrates such as choline and acetyl CoA in kinetic mechanism 1 is because that supply of these 
substrates such as choline from compartment 2 to compartment 1 and choline transport from 
compartment 1 to compartment 2 and acetate transport from compartment 1 to compartment 2 
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can compensate any reduction due to the inhibiting effect of β-amyloid on the active site E2H. 
However, the significant reduction in ACh concentrations due to ChAT activity inhibition is one 
of the hallmarks in cholinergic dysfunctions. 
 
Figure 4.24: Time course of: a) pH in compartment 1 (pH 1), 
b) pH in compartment 2 (pH 2)   at different KL2 values (according to kinetic mechanism 3) 
 
The results of the second kinetic mechanism where β-amyloid competitively attacks the 
enzyme intermediate X2 are similar to that of the first kinetic mechanism except that acetate 
concentration in compartments 1 and 2 decrease significantly while pH1 and pH2 in both 
compartments increase with the increase in KL2 where the attack of β-amyloid on intermediate 
X2 of ChAT leads to a decrease in the consumption of acetyl-CoA in compartment 1 and the 
lower production of acetate in compartment 2. The reduction in Rate 1 or ChAT activity in 
kinetic mechanisms 1 and 2 decrease with around 25 % with increase KL2 from 0 to 25 
(corresponding to 500 nM). 
   102 
In the third kinetic mechanism where β-amyloid binds to all species in ChAT, it is found 
that at low values of KL2, the behavior of  cholinergic  ACh looks like that of the second kinetic 
mechanism. However, at  high values of KL2 (e.g. 25), an interesting phenomenon arises for all 
state variables of the system where all variables fluctuate in a wide range (as shown from Figures 
4.17 to 4.22) leading to irregular behavior of the cholinergic system. These disturbances 
occurring in the cholinergic system is one of the main features of AD (Nunes-Tavare et al., 
2012). According to kinetic mechanism 3, β-amyloid peptides promote a major reduction in 
ChAT activity. Kar et al., (2004) indicated that decline of intracellular ACh concentration is due 
to reduction in ChAT catalytic action. Moreover, it was observed that long incubation of rat 
primary septal culture neurons with micro molar concentration of β-amyloid peptides caused a 
reduction in ChAT function and cell death (Kar et al., 2004; Olesen of et al., 1998). 
  The results of kinetic mechanism 3 are compatible with the experimental results obtained 
by Nunes-Tavare et al., (2012) who showed that β-amyloid peptides could bind to a significant 
portion of cholinergic neurons and reduce ChAT activity completely. It is observed that the 
reduction in Rate 1 in kinetic mechanism 3 decreases from 0.0105 to 0.000125 which refers to a 
reduction in ChAT activity of 99.7% with increasing KL2 from 0 to 25 (corresponding to 500 
nM). The results are in agreement with the experimental results obtained by Nunes-Tavares et 
al., 2012) who showed that β-amyloid could inhibit ChAT completely. 
It is observed that after time 100 (corresponding to 10 hr), there is no effect for any further 
change of β-amyloid production rate (KL2 from 0.5 to 25), where all state variables reach the 
same steady state values. These results are compatible with those obtained by Nunes-Tavares et 
al., 2012) who showed that there is no significant effect for any further β-amyloid concentration 
higher than 100 nM. It is also observed that ChAT inhibition by β-amyloid could cause severe 
consequences for the rate of ACh synthesis and ACh concentrations in compartments 1 and 2 as 
well where ChAT inhibition could reach 100 % as shown in Figure 4.18 (a). 
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4.7 Summary and Conclusions 
In this chapter, the  effect  of  β-amyloid peptide as  an inhibitor on ChAT activity for ACh 
synthesis through the two enzyme/two compartment (2E2C) model in a variety  of  situations  is  
analyzed through suggesting three different kinetic mechanisms for the inhibition effect. Overall, 
numerical solutions to the modified 2E2C with β-amyloid were in accordance with three 
significant, widely reported symptoms of AD; loss of ChAT activity (Pederson 1996), reduced 
choline uptake (Kar 1998) and reduced ACh production (Pederson 1996). This in turn means that 
the direct inactivation of ChAT by β-amyloid may be a probable mechanism contributing to the 
development of AD.  The incorporation of ChAT inhibition by β-amyloid into the 2E2C model is 
able to yield dynamic solutions for concentrations of generated β-amyloid, ACh, choline, acetate, 
and pH in addition to the rates of ACh synthesis and ACh hydrolysis in compartment 1 and 2. 
This correlates well to the physiological understanding since the production of β-amyloid is not 
generally known to be highly reversible.  One of the most significant physiological symptoms of 
AD is the reduction of ACh neurotransmitter concentration within cholinergic neurons.  In this 
investigation, the effect of ChAT activity inhibition via β-amyloid is considered an individual 
basis in order to evaluate the validity of each kinetic mechanism. Since it is highly likely that 
physiologically more than one single mechanism can contribute to the generation of AD 
symptoms. In comparison to the effect of β- amyloid via choline leakage hypothesis, it is 
observed that ChAT activity needs a high concentration of β-amyloid production rate (KL2). This 
is in agreement with the experimental results obtained by Kar et al., (1998) who showed that the 
exposure to small concentrations of β-amyloid has no impact on ChAT activity in cortex tissues. 
However, the results are in agreement with those obtained by Zambrzycka et al., (2002) who 
showed that when neurons tissues exposed to high concentrations of β- amyloid for a while, 
ChAT activity is reduced significantly. The results of kinetic mechanism 3 are in agreement with 
that obtained by Mustafa et al., (2012) who indicated the oscillatory behavior of ACh neurocycle 
at low ChAT activity. 
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Chapter 5 
Pharmacodynamics/Pharmacokinetics, Modeling, and 
Simulation for the Effect of Drugs on β-amyloid 
Aggregates and Cholinergic Neurocycle 
5-1 Introduction 
Alzheimer’s disease (AD) is a progressive neurodysfunction illness and responsible for high 
mortality rate worldwide and is considered the main cause of dementia. Loss of memory, 
cognition impairment, and behavioral deficits are common characterizations of AD.  AD is 
considered the fourth reason of death in the United States. In addition, the number of AD patients 
increases every day; now 25 million worldwide have AD, 4 million of them are in the USA.  AD 
etiology is still unknown accurately; however, many researchers such as Hardy and Higgins, 
(1992) supported the hypothesis of β-amyloid cascade as the main reason of AD where β-
amyloid aggregates are deposited in the brain slices (Lu, 2012).  β-amyloid is produced through 
sequential enzymatic cleavages of APP. Lowering of β-amyloid aggregates in the brain is 
considered a strategy for AD therapeutics (Pettersson et al., 2011; Lu, 2012). These aggregates of 
β- amyloid are formed by proteolytic cleavage of a transmembrane protein known as amyloid 
precursor protein (APP). There are two possible ways for cutting APP: (1) via α- secretase to 
produce sAPPα which is non amyloidogenic and neuroprotective agent. This is because sAPPα 
induces expression of transthyretin (TTR), a transport protein in cerebrospinal fluid (CSF) and 
blood, which prevents β-amyloid aggregation; (2) via β- and ɣ- secretase. The latter pathway is 
amyloidogenic because it releases β- amyloid that deposits as fibrillar aggregates in the brain and 
known as senile plaques (Liu and Murphy, 2006). Senile plaques are dense plaque cores of β- 
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amyloid deposits plus activated microglia and active astrocytes, where they together form 
damaged neutrophil (Teplow, 1998). Aggregates of amyloid plaques in the brain of AD patients 
cause negative consequences in cholinergic neurons. Examples for sever neurodegenerative 
disorders are: (1) disturbance in choline level a rate limiting substrate for ACh synthesis,  in  
cholinergic neurons by inducing a leakage  in the presynaptic membrane as indicated in Chapter 
3, (2) Inhibition of ChAT activity, an enzyme responsible for ACh synthesis, as presented in 
Chapter 4, (3) Other effects such as formation of neurofibrillary tangles (NFT) which are 
aggregation of  hyper phosphorylated  tau protein: an enzyme that is responsible for stability of 
microtubules and enhances assembly of tubulin into microtubules, the cytoskeleton of cells, and 
hence hyper phosphorylation of tau protein causes instability and disintegration of microtubules 
that results in neuron cells degeneration and death (Mandelkow E.M., and Mandelkow, E. 
(2012)). 
 From Chapter 3, it was found that the lower concentration of β- amyloid aggregates could cause 
significant reductions in the levels of choline and ACh. Therefore, therapeutic agents have 
become extremely important to abrogate the toxicity effect of β- amyloid aggregates and inhibit 
aggregation. Since β-amyloid plaques are the key to neurons damage which initiates AD, the 
challenge for research is to find a promising and safe therapy for preventing β-amyloid formation 
and accumulation. Examples for promising drugs candidate that are currently under studies for 
developing an effective therapy for AD: 
(1) Transthyretin (TTR), a transport protein in plasma and cerebrospinal fluid (CSF) with 
molecular weight 55 kDa, is able to reduce dementia in AD patient by binding to β- amyloid and 
preventing its toxicity and aggregation. The hopeful research is to find a compound that mimics 
TTR or increases level of TTR in CSF. Stein et al., (2002) and (2004); Lui and Murphy,(2006) 
showed that incubation of 50 µM of β- amyloid with hippocampal slices caused cell death, but 
this effect is completely abolished after the addition 3 µM of TTR. Also, processing APP by α- 
secretase to produce sAPPα increases TTR expression, and hence increase TTR. 
(2) β- amyloid vaccination helps stop β- amyloid aggregation and moves it from brain to blood. 
In 2000 the immunization therapy showed good results in enhancement memory function of 
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participants but did not achieve the required objectives due to problems related to brain 
inflammation and bleeding in brain besides cerebral blood vessel disease (Teplow, 1998; Liu and 
Murphy, 2006). Currently, there is a product produced by researchers at Cardiff University 
namely 2B12 which is antibody that binds to amyloid precursor protein (APP) and prevents its 
cutting by amyloidgenic β-secretase. 2B12 inhibits β- amyloid aggregation in culture cells. This 
product is still under lab trials for human use (Teplow, 1998; Liu and Murphy, 2006). 
(3) Nicotine for AD treatment: Researchers at Lancaster University found that nicotine is able to 
arrest β-amyloid aggregation. An optimist result had been obtained in lab trial on nicotine using 
animal model (Pollack et al., 2005). 
Overall, the key element for AD treatment is to understand its etiology and pathobiology. 
Since the main pathological feature of AD is the presence of β-amyloid aggregation in the brain, 
a drug that could prevent β-amyloid formation and accumulation could achieve the greatest 
success in AD cure (Teplow, 1998). Using traditional trials for improving and testing new drugs 
is based on carrying a series of experiments on number of healthy volunteers in order to 
determine the correlation between potential doses and medical effects for testing drug. Moreover, 
the traditional resources of research are money, time, and effort consuming besides risk effects 
due to adverse drug interactions. Therefore, the need for developing new methods for drug 
testing and development become necessary. An example for these new techniques is the 
application of computational modeling for the analysis of pharmacokinetics (PK) and 
pharmacodynamics (PD) of drugs. 
 PK/PD modeling helps to understand the mechanisms leading to intimation and 
development of diseases and develop therapeutics of different diseases and integrate with 
experimental knowledge and improve in vivo /vitro clinical potentials (Lu, 2012). However, not 
all factors of all aspects of AD can be considered in mathematical models. These factors such as 
temperature, environment, diet, and presence of any other disease could have a significant effect 
on PK and PD of drugs. PK models can predict and define time course of drug concentration in 
different body compartments such as blood, brain, and plasma, but PD models describe time 
course of drug effect at the site of action.  Both PK and PD models play an important role in 
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current drug research. However, the accuracy of these models is limited because they did not 
consider the biophysical properties of different body tissues and the interstitial space.  
In AD, PK/PD models are helpful in predicting the time course of β- amyloid 
concentrations after treatment. PK/PD models have many advantages: they can predict the 
reduction of β- amyloid aggregates, ACh and choline levels as will be shown from PD time 
course.  The prediction of time course of β- amyloid aggregates facilitates selection of 
appropriate doses and sampling time points to ensure that the outcomes are informative. 
Moreover, PK/PD models help design preclinical studies and clinical experiments. In addition, 
modeling and simulation are good tools for hypothesis testing. The simulations of β- amyloid 
aggregates profiles after treatment are then compared with observations from a subsequent 
preclinical study. Therefore, modeling and simulations could provide a good feedback that could 
speed-up drug development. 
Because the importance and necessity of AD therapy and the big need for improving and 
developing drug techniques, we propose an integrated mechanistic model for AD drug that 
integrates PK and PD of drug and elucidate the relationship between dose and drug action at 
cholinergic neuron cells in brain. This is an effective way in determining the best strategies for 
AD treatment. Our model describes the dynamic concentration of AD drugs, β- amyloid 
aggregates, and ACh neurocycle components with time.  
This Chapter is based on Chapter 3 at which the interaction between β- amyloid and ACh 
neurocycle was investigated through incorporation of the effect of β- amyloid aggregates into 
two-enzyme/two-compartment model via choline leakage hypothesis. The presynaptic neuron 
was considered as compartment 1 while both synaptic cleft where ACh hydrolysis process occurs 
by the enzyme AChE and postsynaptic neuron are considered as compartment 2. Furthermore, it 
was found that β-amyloid aggregates formed from APP interact with ACh synthesized in 
compartment 1 and the membrane of the presynaptic neurons lead to formation of pathways in 
the membranes and allowed the opportunity for choline content in compartment 1 to leak out of 
the cholinergic system. Therefore, choline substrate reduction in compartment 1 affects the levels 
of produced ACh.  Furthermore, it was found in Chapter 3 that as the rate of β- amyloid 
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production (KL2) increases, the number of channels formed in the membranes increase and levels 
of ACh and choline in both compartments decrease significantly.  
In this chapter, a PK and PD one-compartment model is proposed to study the drug 
behavior in the presynaptic neurons. It is proposed that the drug interacts only with one 
compartment which is compartment 1 where ACh is synthesized by the catalytic effect of the 
ChAT enzyme.  It is suggested that the drug interacts with β- amyloid peptides to prevent 
formation of β- amyloid aggregates (polymers) more than monomers. Therefore, β- amyloid 
aggregates will not be able to form pathways in the membranes of the presynaptic neurons 
allowing saving choline levels inside the presynaptic neurons.  
The main objective of this chapter is to evaluate the impact of AD drugs on β- amyloid 
levels, ACh, choline, acetate, pH, and rates of ACh synthesis and hydrolysis in ACH cholinergic 
system. This is performed by incorporating the proposed one-compartment PD/PK model into 
the two-enzyme/two-compartment model built in Chapter 3. The effect of drugs on the percent of 
β- amyloid aggregates removal is investigated at different feed drug rates. The maximum 
concentration of drug content in the presynaptic tissues giving the maximum effect is 
investigated with the area under the curve (AUC) for drug concentration with time.   
 
5.2) Formulation of PD/PK model of the ACh system  
It is very important to understand the effect of drug feed rates on its pharmacokinetic and 
pharmacodynamics behavior because it helps to maximize the drug effect (Wakelkamp et al., 
1998). Controlling the drug input rate can help to develop advanced drug delivery systems to 
accomplish the best efficiency Wakelkamp (1997). In this chapter PD and PK model is used to 
evaluate the impact of AD drugs on β- amyloid aggregates levels, ACh, choline, acetate, pH, and 
rates of ACh synthesis and hydrolysis in two-enzyme/two compartments of cholinergic neurons. 
The drug concentrations inside neuronal tissues are calculated through one-compartment model 
which is the presynaptic neuron where both β- amyloid inhibitor and the produced ACh exist.  
The feed production of the drug (KU2) is assumed to be zero-order. However, the clearance rate 
is assumed to be first order that is proportional to the accumulation concentration of drugs 
(Wakelkamp et al., 1998). The drug consumption rate is assumed to be second order where it is 
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proportional to the concentrations of accumulated drugs and β- amyloid (Wakelkamp et al., 
1998).  The first order differential equation for the drug concentration can be formulated as 
follows: 
    UKUbAK
e
K
dT
dU
Clet
U 


1
2                                                           (5.1) 
It is observed that KU2 is multiplied by the sigmoid function which is a special case of logistic 
functions. The sigmoid function helps to simulate the cholinergic cycle system. This saturates 
after a long period of time. Gibbs (2000) used sigmoidal functions in different natural processes 
characterized by continuous development from low levels to the saturation through time. Lu 
(2012) and Group et al., (2013) used the sigmoidal function to modify the input rate of the 
inhibitory effect. 
It is expected that the drug could prevent the aggregation of β-amyloid and inhibit pathways 
formation in the presynaptic membrane according to choline leakage hypothesis investigated in 
Chapter 3. Therefore, the intracellular choline concentration could be kept inside the presynaptic 
neuron to react with acetyl-coA to form ACh. The final concentration of β- amyloid aggregates 
existed in the presynaptic neurons after incorporation of drugs through oral input is obtained as 
follows: 
    UbAKUbAKsKK
dT
dbA
LLL 1141132                                         (5.2) 
The potency and efficacy of lowering β-amyloid aggregates can be defined by the function % Xs 
which measures the average β-amyloid aggregates reduction after treatment. It defines the 
intrinsic PK/PD relationship for the drug which is equivalent to the relationship between an 
exposure and time-weighted-average β-amyloid aggregates lowering after treatment: 
 
   
 
100
0
0
% x
bA
fbAbA
X S

                      (5.3) 
Where bA(0) refers to the initial concentration of β-amyloid aggregates at time (zero) where 
there is no drug added, and bA (f) refers to the final concentration of β- amyloid aggregates after 
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incorporating the drug. The last term refers to the reduction of β-amyloid aggregates 
concentrations due to interaction with the drug (U).  It is noticed that the latter reduction is 
proportional to the concentrations of drugs and β- amyloid aggregates as well. Furthermore, the 
reduction of intracellular choline concentration will be lowered due to interaction of β- amyloid 
aggregates with the drug. The final concentration of choline in compartment 1 can be formulated 
as follows: 
 
         UUbA
refernce
Sf KbAKr
S
B
sssRs
dT
ds
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1
22122222
12
1*
1
          (5.4) 
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
              (5.5) 
The term KUU refers to the effect of the drug on the intracellular choline concentrations. It takes 
the form of Monod kinetics to show the dynamic effect of the drug. It is observed that the drug 
should be kept in a certain range where it should be neither too low in order to give the required 
effect nor too high to avoid the toxicity (Moore et al., 2004). The form of KUU is obtained 
through assuming values for Vm (the maximum effect of the drug), and the constants Ksm and KsU 
in order to give reasonable effect for the drug. 
Equations from equation 5.1 to 5.5 of PK/PD model are incorporated into two-enzyme/two-
compartment model to evaluate the impact of Alzheimer’s drug on β- amyloid levels, ACh, 
choline, acetate, pH, and rates of ACh synthesis and hydrolysis in two-enzyme two-compartment 
model of cholinergic neurons via β- amyloid-choline leakage mechanism studied in Chapter 3.  
The response of the cholinergic system through the time course of β- amyloid aggregates levels 
in compartment 1 in addition to concentrations of  ACh, choline, acetyl CoA concentrations  and 
pH levels in both the presynaptic neurons (compartment 1) and the postsynaptic cleft 
(compartment 2)  are investigated. Furthermore, the impact of the drug on the rate of ACh 
synthesis catalyzed by the enzyme ChAT in compartment 1 and the rate of ACh hydrolysis 
catalyzed by the enzyme AChE in compartment 2 are investigated.  
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Table 5.1 provides a summary of ordinary differential PK/PD equations where there are ten-first 
order differential equations through the 2E/2C cholinergic ACh system and one compartment for 
the drug effect. The effect of AD drugs is assumed to be only one compartment which is 
compartment 1 because β- amyloid aggregates which cause choline leakage exist only in 
compartment 1. In addition, it will help to focus on choline leakage hypothesis and how AD 
drugs affect β- amyloid aggregates in the presynaptic neurons in addition to simplify the 
calculations of the system. Table 2 shows the values of PK/PD parameters and other kinetic and 
operating parameters used previously in Chapter 3. 
Model Assumptions: 
Each compartment is assumed to be isothermal continuous-stirred tank reactor (CSTR); the 
components in each compartment are assumed to be well-mixed and homogenous. In addition, it 
is assumed that choline  which is leaked due to the pathways caused by the β- amyloid 
aggregates in the membrane of compartment 1, is settled out of the two-enzyme/two-
compartment systems where it is not settled down in compartment 2 or compartment 1 as shown 
in Figure 5.1.  
A one-compartmental model is enough to describe the pharmacokinetics of orally administered 
drugs where KU2 represents zero-order rate constant for drug feed rate, Kcl is the first order rate 
constant for drug clearance. In addition, it is assumed that drug exerts action by inhibiting β- 
amyloid aggregation. Transport of both β-amyloid aggregates and drug from compartment 1 to 
compartment 2 are neglected. To justify these considerations, we note that the transport of β-
amyloid and drugs from compartment 1 to compartment 2 is by passive diffusion and the 
transport rates are extremely lower than those from the cytoplasm to compartment 1 
(Wakelkamp (1997)). The latter transport (from the cytoplasm to compartment 1) addresses brain 
boundary barriers (BBB) according to saturable mechanism such as Monod and Michaelis-
Menten kinetics (Craft et al., 2002; Zlokovic et al., 1993; Martel et al., 1996). 
 
One of the main assumptions is this Chapter is that the drugs are administered orally to let the 
drug absorption be as fast as possible and could give a direct effect on the neuron tissues in the 
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brain. In addition, the drug is assumed to be on a single-dosing regimen whereby after a duration 
drug concentration reaches a steady state level. The measure of the capability of the body to 
eliminate a drug is defined in terms of clearance (Bent and Zia-Amirhosseini, 1995).  The 
extraction ratio (ER) of the drug which is the ratio of the rate of elimination to the rate of 
presentation is assumed to be 0.55. The latter value is considered a medium ER for AD drugs 
(Bent and Zia-Amirhosseini, 1995). This means that around 45% of the drug is absorbed in the 
blood. ER is calculated according to the following equation: 
 
A
VA
A
VA
C
CC
CQ
CCQ
ER



          (5.6) 
CA refers to concentration in the feed stream to the liver, while CV refers to the exit concentration 
from the liver. Q (CA – CV) refers to rate of elimination. 
 
Figure 5.1:  Schematic representation for Pharmacodynamics one-compartment drug and two-enzyme/ two-
compartment model 
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Table 5.1: Dimensionless forms of the ordinary differential equations of drug effect on  β- amyloid  
aggregates via choline leakage hypothesis 
Item Compartment Differential equation 
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Vm 0.068 KU2 
Ksm 9.5 
KsU 0.034 KU2 
λ 1.25 
KbA3 0.075 KL2 
KbA2 0.06 KL2 
Kabs              0.375 
Ke              0.7205 
KCl               0.125 
ʋ              0.05 
ψ              0.001 
 
Table 5.2: Values of the Kinetic Parameters 
Parameter Value Reference 
 1 5.2(0.1) Peet & Hersh (1977) 
 2 12 Peet & Hersh (1977) 
 3 1000 Peet & Hersh (1977) 
 4 5 Peet & Hersh (1977) 
 5 1 Peet & Hersh (1977) 
  0.5 Garhyan et al., (2006); Ibrahim et al., (1997);  
Elnashaie et al., (1983a), (1983b), (1984), 
and (1995) 
  1 Garhyan et al., (2006); Ibrahim et al., (1997);  
Elnashaie et al., (1983a), (1983b), (1984), 
and (1995)  
Ka(kh) 1.066*10
-6 
kMole/m
3
(µMole/mm
3
) Garhyan et al., (2006); Ibrahim et al., (1997);  
Elnashaie et al., (1983a), (1983b), (1984), 
and (1995)  
Ks1 50.33 µMole/l  Garhyan et al., (2006); Ibrahim et al., 
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(1997);  Elnashaie et al., (1983a), (1983b), 
(1984), and (1995) 
S2ref 100 µMole/l Guyton and Hall, (2000) 
S3ref 1 µMole/l Guyton Hall, (2000) 
1B  
510033.5  kMole/m
3
(µMole/mm
3
) Garhyan et al., (2006) 
2B  
510033.5  kMole/m
3
(µMole/mm
3
) Garhyan   et al., (2006) 
H
  2.25 Elnashaie et al., (1984) 
OH
  0.5 Elnashaie et al., (1984) 
1S
  1.5 Elnashaie et al., (1984) 
2S
  1.5 Elnashaie et al., (1984) 
3S
  1 Elnashaie et al., (1984) 
RV  
1.2 Elnashaie et al., (1984) 
fpH  
8.2 Guyton, 2000 
fs1  
15 Garhyan   et al., (2006) 
fs2  
1.15 Garhyan et al., (2006) 
fs3  
3.9 Garhyan et al., (2006) 
1  0.01 Garhyan et al., (2006); Ibrahim et al., (1997);  
Elnashaie et al., (1983a), (1983b), (1984), 
and (1995) 
R 0.8 Tucek (1978) 
KL2 1  
KU2 assumed  
KL1  
 
3KL2  
KL3  
 
0.035KL2  
KL4  
 
1.76KL3  
KU11 0.0425  
BAref 20 nM/l Kar et al., (2008) 
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5.3) Results and Discussion 
On the basis of Figure 5.1 and the model equations described in Table 5.1 and the kinetic 
parameters values in Table 5.2, the results illustrated from Figure 5.3 to Figure 5.8 show the 
predicted time course of all state variables in two-enzyme/two-compartment (2E2C) model 
where the impact of AD drug on 2E2C model is incorporated by solving numerically the system 
ODEs of Table 5.1. It is assumed that the patient is in pre-treatment with maximum β- amyloid 
concentration according to choline leakage hypothesis obtained at KL2 =1 as investigated in 
Chapter 3. Then, a drug is administered in order to lower the production of β- amyloid 
aggregates through the period (0-300) corresponding to (0-30 hr).   
Figure (5.2) depicts the dynamic behavior of the drug concentration at different feed drug 
administrations (KU2). It is observed that the drug administered orally takes the bell shape where 
the left branch represents the absorbance after administration while the right branch is the 
clearance part through urine or the liver. It is observed that at Ku2 = 0 which is considered as the 
control value where no drug is administered, the drug concentration (U) in the presynaptic 
neurons is zero. As Ku2 = 2.25 (corresponding to 225 mg), it is observed that the drug is absorbed 
to allow for its concentration in the presynaptic neurons to increase to reach 0.37 (after passing 
37 (corresponding to 3.7 hr) then the drug is cleared slowly to reach 0.36 (corresponding to 0.36 
µM) after passing 70 (corresponding to 7 hr). Afterwards, the drug starts to be eliminated 
completely to reach the pretreatment case where the drug content is zero after passing 250 
(corresponding to 25 hr). 
When Ku2 increases to reach 4.5 (corresponding to 450 mg), drug is absorbed to allow for 
its intracellular concentration to increase and reach 0.95 (corresponding to 0.95 µM) as a high 
level then it decreases slowly due to complete removal after passing 250 (corresponding to 25 
hr).  Furthermore, at KU2 = 9 (corresponding to 900 mg), the absorbance increases very fast to 
reach to 1.3 and the drug content (U) increases reach 1.3 (corresponding to 1.3 µM). Then the 
drug absorbance increases to reach 3.8 after passing 63 (corresponding to 6.3 hr). Then, it 
decreases fast to reach 0.5 after passing 175 (corresponding to 17.5 hr); then it is cleared slowly 
to be removed completely after passing 250 (corresponding to 25 hr). 
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Figure 5.3 shows β- amyloid dynamics in the presynaptic neurons of the brain. It is 
observed that β- amyloid aggregates concentrations are inversely proportional to drug 
concentrations as indicated in Figure 5.2. Figure 5.3 shows that after treatment with drug at feed 
rate of KU2 = 2.25, the level of β- amyloid aggregates drops to 9.89 (corresponding to 197.8 nM) 
to the value 8.2 (corresponding to 164 nM) after passing time of 63 (corresponding to 6.3 hours) 
where absorbed drug concentration increases in the same period at the same feed rate of KU2. In 
the latter period, the drug is helpful to increase the degradation rate of β- amyloid aggregates and 
inhibits the polymerization of β- amyloid. As the β- amyloid concentration drops from 9.89  to 
8.2, β- amyloid aggregates  undergoes a transient rise and then returns to the pretreatment levels 
Figure 5.2: Time course of drug concentration in the presynaptic neurons at different drug feed rates 
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in the period (63-250) corresponding to (6.3-25 hr)  indicating that β-amyloid aggregates 
production takes place in the same period that drug concentration is eliminated from the neural 
tissues.  
As drug is exposed to clearance where its levels in brain tissues decrease, β- amyloid 
aggregates concentration increases monotonically to pretreatment levels. As the feed drug rates 
increase where KU2 = 4.5, β- amyloid aggregates decreases very fast from 9.98 to 6.5 
corresponding to (197.8- 130 nM) after passing 75 corresponding to 7.5 (hr) from administering 
drug  as shown in Figure 5.2 where drug is absorbed in the same period as explained previously 
in Figure 5.1. It is observed that β- amyloid aggregates returns to the pretreatment state as drug is 
eliminated completely in the same period. While the feed drug rate increases to KU2 = 9, β- 
amyloid aggregates levels drop to the lowest level which is 3 (corresponding to 60 nM) after 
passing 6.3 hr where drug content increases due to absorbance. Then, the drug starts to be 
eliminated allowing levels of β- amyloid aggregates to return to the pretreatment level due to 
increasing the production of β- amyloid aggregates where drug content decreases significantly as 
shown in Figure 5.2. 
The potency and efficacy for lowering β-amyloid aggregates can be defined by the 
function % Xs which measures the average of β-amyloid aggregates reduction after treatment. It 
defines the intrinsic PK/PD relationship for the drug. This intrinsic PK/PD relationship is 
equivalent to the relationship between an exposure and time-weighted-average of β-amyloid 
aggregates lowering after treatment. 
In addition, the impact of drug feed rate on the percent of β-amyloid aggregates removal 
is investigated as shown in Figure 5.4 to confirm β-amyloid aggregates levels illustrated in 
Figure 5.3. In Figure 5.4, β- amyloid profiles with changing drug input rates are compared with  
that at the pretreatment case (KU2  = 0).  It is observed that the maximum β- amyloid aggregates 
removal levels increase from 15 % to 34%, and 69.5 % as KU2 increases from 2.25 to 4.5 and 9 
respectively. Our results are compatible with the experimental findings obtained by Craft et al., 
(2002) that developed mathematical models for β-amyloid aggregates fertilization and plaque 
growth. Craft e al., (2002) showed that vaccines help to inhibit accumulating β-amyloid large 
molecules (polymers) more than monomers and by the end of the period,  β-amyloid aggregates 
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return to the pretreatment steady state due to the equlibrium between a zero-order generation rate 
(Kin) and a first-order clearance rate (Kout).  
 
 
 
It is observed from pharmacodynamics aspects that the minimum peaks of β-amyloid 
aggregates concentrations of the presynaptic neurons are achieved in the range from 6-7 h after 
drug administration as shown in Figure 5.3. Furthermore, these minimum peaks in β- amyloid 
aggregates levels are lowered with increasing KU2 indicating the effective impact of AD 
therapeutics on the content of β- amyloid aggregates inside compartment 1. It is observed that the 
time required to attain the minimum β-amyloid levels differs based on the value of administered 
drug input rates.  Furthermore,   greater input drug rates are accompanied with higher percent of 
Figure 5.3: Time course of β- amyloid aggregates concentration at different drug feed rates 
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decrease in levels of β- amyloid aggregates. These results are compatible with those obtained by 
Gopu et al., (2013) and Engelhardt et al., (1995). 
The increase of β- amyloid aggregates during drug elimination could be explained by   
the increase of the activities of γ- and β-secretase relative to that of α secretase which might lead 
to disturbances in APP proteolysis.  Consequently, β- amyloid aggregates increase and become 
uncontrolled by the drug (Liu and Murphy, 2006). The latter observation shows that more 
research is needed on the level of the interaction between β- amyloid aggregates growth and the 
drug in order to enhance the PK/PD modeling and develop more effective therapeutic strategies 
for AD. 
Figure 5.5 (a) shows the time course of rate of ACh synthesis catalyzed by ChAT at 
different feed rates of drug. It is observed that at KU2 = 0, the synthesis rate (Rate 1) drops to the 
minimum  steady state value which is around 0.005 where β-amyloid aggregates cause ChAT 
activity inhibition and there is no drug to inhibit the effect of β- amyloid aggregates. As KU2 
increases to 2.25, Rate 1 increases. It is observed that Rate 1 drops fast after passing 12 (c.t. 1.2 
hr) from the initial value of 0.0165. This drop can be illustrated by the fact that in the beginning 
of drug administration, β- amyloid aggregates have still a great effect. At KU2 = 2.25, Rate1 
drops to reach 0.0062, then it rises to reach 0.0068 after passing around 60 (c.t. 6 hr), then it 
drops to reach 0.0051 at the end of the period 300 (c.t. 30 hr) where the drug at inlet rate of KU2 = 
2.25 in the last period is eliminated allowing to increase β-amyloid aggregates and leading to 
formation of pathways in the presynaptic membranes and then choline is leaked out of the 
presynaptic neuron. 
When the feed rate of the drug increases to KU2 = 4.5, it is noticed that the synthesis rate 
takes the same behavior as at KU2 = 2.25 but the level at the middle period is higher where it 
reaches 0.0085 then it decreases to reach the steady state value at the end of the administration 
period.  It is observed at KU2 = 9, Rate 1 in the middle stage increases to reach the maximum 
level compared to that at the previous values of KU2 where Rate1 reaches 0.0127, then it 
decreases as usual to reach the steady state value of 0.0052. The dynamic behavior of Rate 1 is 
expected to affect all state variables in compartment 1 as will be explained later. 
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Figure 5.4: Time course of % β- amyloid aggregates removal at different drug feed 
rates 
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Figure 5.5 (b) shows the dynamic behavior of ACh hydrolysis process by AChE enzyme 
in compartment 2 at different values of KU2. It is observed that Rate 2 at KU2 = 0 is not affected 
where it decreases monotonically to reach the steady state value of 0.061 due to consumption of 
ACh in compartment 2. AT KU2 = 2.25 and 4.5, Rate 2 takes a similar behavior where Rate2 
drops from 0.167 at the beginning to 0.062 and 0.064 after passing 7.5 (c.t 0.75 hr) then Rate 2 
increases to reach 0.063 and 0.071 respectively after passing 75 (c.t, 7.5 hr) then Rate 2 
decreases gradually due to drug elimination to reach the steady state value by the end of the 
period. When the feed drug rate increases to KU2 = 9,  Rate 2 takes the same behavior but it 
Figure 5.5: Time course of : a) Rate of ACh Synthesis (Rate 1)  , 
 b) Rate of ACh hydrolysis    (Rate 2) at different KU2 values 
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reaches the maximum level which is Rate 2 = 0.095 then it drops gradually to reach the lowest 
steady state value at Rate 2 = 0.062 as shown in Figure 5.5 (b). 
Figure 5.6 (a) depicts the time course of ACh synthesized in compartment 1 (ACh1) with 
different feed rates of drugs. At KU2 = 0, it is observed that ACh1 increases after passing 1.5 
(0.15 hr) from drug administration from 3.9 to around 5.5. The increase of ACh1 at early times 
after administration of doses could be explained as an almost instantaneous increase in the 
synthesis of ACh1. Then it decreases monotonically to reach the steady state value of 3.7 at the 
end of administration period of 300 (c.t, 30 hr). When the feed drug rate increases to KU2 = 2.25, 
ACh1 drops from 5.5 at time of 1.5 (0.15 hr) to 4.1 at a time of 13 (1.3 hr) to reach the plateau 
around 3.7 by the end of the administration period of 300 (c.t. 30 hr). 
While KU2 = 4.5, ACh1 takes the same behavior as that at KU2 = 2.25, but the levels of 
ACh1 are higher where ACh1 in the middle period of (7.5 < t < 75) corresponding to (0.75 < T < 
7. 5 hr) increases from 4.1 to 5.1.  Then, ACh1 decreases monotonically to 3.7 by the end of drug 
taking period, where the drug is eliminated completely giving the opportunity to β-amyloid 
aggregates to generate and cause leakage pathways in the presynaptic membrane and reduce the 
intracellular choline levels. Moreover, at KU2 = 9,  where the drug concentration increases due to 
absorbance,  the maximum ACh1 level is  around  7  and is reached at t = 75 (c.t. 7.5 hr), then it 
decreases continuously to reach 3.7 where the rate of ACh synthesis decreases in the relevant 
period due to drug elimination. It is noticed that as KU2 increases from 0 to 9, ACh1 increases 2-
folds from 3.5 to 7, and the increases of 2 folds of KU2 from 4.5 to 9 leads to an increase of 
ACh1 levels from 4.85 to 5. 
Figure 5.6 (b) shows the dynamic behavior of ACh in compartment 2 (ACh2) produced 
from the hydrolysis of ACh by AChE. It is observed that the dynamic behavior of ACh2 looks 
like that of Rate 2 explained in Figure 5.5(b). At KU2 = 0, it is observed that ACh2 decreases 
moronically from 0.37 at the beginning of drug administration to reach 0.11 at the end of drug 
administration.  While the drug inlet increases from KU2 = 2.25 to 4.5 and 9, the levels of ACh2 
in the middle drug administration period increase to be 0.12, 0.13, and 0.18 respectively. Then 
ACh2 decreases continuously to reach the minimum level which is 0.118 by the end of the 
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period where drug in this period is eliminated  and β-amyloid aggregates increase leading to 
reduction of ACh1 levels and thereby Rate2 as well. 
It is observed that when the drug reaches the maximum level at KU2 = 9 where Cmax = 3.8, 
ACh1 jumps 2-fold from 3.7 at maximum β- amyloid levels when there is no drug administered 
(KU2 = 0) to 7 at (KU2 = 9) while β- amyloid decreases 3-folds from 9.89 at KU2 = 0 to 3.05 KU2 = 
9. These results are compatible with those obtained by Craft e al., (2002) who developed 
mathematical models for β- amyloid  fertilization and plaque growth  and showed that the 
decrease in drug content reduces the neuronal ACh burden where  β- amyloid  grows due to  
accumulating large molecules (polymers) more than monomers (Craft e al., 2002). 
Figure 5.7 (a) shows the dynamic response of the intracellular choline concentrations in 
the presynaptic neurons in compartment 1. It is observed that at KU2 = 0 where no drug is 
administered, choline content (Ch1) decreases continuously from 3.23 (corresponding to 323 
µM) to the steady state value of 0.99 (corresponding to 99 µM) due to the choline leakage caused 
by β- amyloid aggregates. As the drug is administered with the rate of KU2 = 2.25, the drug level 
decreases from 3.23 at the beginning of administration to t = 7.5 (c.t. 0.75 hr), then it increases as 
drug is absorbed until it reaches the maximum 1.313 after passing 45 (c.t. 4.5 hr) then as drug is 
eliminated after the latter period, β- amyloid polymer is reproduced to cause pathways in the 
presynaptic neuron membrane to permit choline substrate to get out of the presynaptic neuron 
and reduces gradually to reach the value 1(corresponding to 100 µM). When the drug input 
increases to KU2 = 4.5, the drug content takes a similar behavior where it decreases in the first 
period of t = 7.5 (0.75 hr) to reach 1.37 then it increases as drug is absorbed to reach 1.682 at t = 
52.51 (c.t.  5.251 hr) then it decreases to reach the minimum level where Ch1 = 0.99 
(corresponding to 99 µM) at the end of drug administration. 
 In addition, at KU2 = 9, Ch1 takes the same behavior while it takes higher levels than that 
at low KU2. Where the maximum level of choline is attained at the maximum concentration of 
drug reached at t = 60.87 (c.t. 6.087) where Ch1 = 2.45 (corresponding to 245 µM), it decreases 
gradually as drug is eliminated and β- amyloid polymer is regenerated until the end of the drug 
administration. It is observed that the maximum content of choline in compartment 1 is reached 
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at the maximum KU2 = 9 where the high content of drug inhibits the capability of β- amyloid 
aggregates to form pathways in the membranes of compartment 1 and prevent choline leakage. 
  
 
 
 
 
Figure 5.7 (b) illustrates the time course of choline level in compartment 2 (Ch2). The minimum 
level of Ch2 is attained at KU2 = 0 where β- amyloid aggregates cause the maximum effect on 
Ch1. The low levels of Ch1 result in lowering levels of Ch2 due to the low transport Ch rate 
from compartment 1 to compartment 2. It is observed that in the time period of (7.5 < t < 75) 
corresponding to (0.75 < T < 7. 5 hr) the maxim levels of Ch2 jumps from 0.41(corresponding to 
41 µM) at KU2 = 0 to 1.021 (corresponding to 102.1 µM) at KU2 = 9 as drug concentration 
Figure 5.6:Time course of : a) ACh concentration in compartment 1 (ACh 1), 
                 b) ACh   concentration  in   compartment 2 (ACh 2)   at different KU2 values 
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increases because of absorption as KU2 increases then Ch2 decreases gradually as drug is 
eliminated to reach 0.4 as shown in Figure 5.7 (b). 
 
 
 
 
Figure 5.8(a) shows the dynamic response of the acetate concentrations in compartment 
1. It is observed that the levels of acetate are the maximum at KU2 = 0 where no drug is 
administered, and β- amyloid  aggregates cause the maximum effect and form channels in the 
membranes of compartment 1 and allow choline leakage to be  out of compartment 1. Therefore, 
acetate is accumulated in the presynaptic neurons. It is observed that the final steady state of 
Acetate 1 is around 7.863 (corresponding to 7.863 µM). It is observed in the beginning of the 
administration period that Acetate 1 decreases fast from 8.3 (corresponding to 8.3 µM) to 6.5 
Figure 5.7: a) Choline concentration in compartment 1 (Ch 1), 
              b) Choline concentration in compartment 2 (Ch 2)   at different KU2 values 
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(corresponding to 6.5 µM)  at t = 7.5 (c.t. 0.75 hr) where acetate is consumed with choline 
towards production of ACh. Then, acetate 1 increases from 6.5 to settle down around 7.863 by 
the end of the t = 300 (c.t. 30 hr), where the synthesis reaction of ACh is reversible as shown in 
Figure 5.8(c). 
At KU2 = 2.25, it is observed that Acetate 1, in the period 0 < t < 10, decreases first to 
reach 6.4 (corresponding to 6.4 µM)  at t = 2.5 (c.t. 0.25 hr) then it increases to reach 7.5 
(corresponding to 7.5 µM)   at t = 15 (c.t. 1.5 hr) then it decreases slightly to reach 7.4 due to its 
consumption with available choline where drug reaches the maximum absorption, however, it is 
observed that Acetate 1 increases to reach the final steady state of the pretreatment state which is 
7.863. At   KU2 = 4.5, Acetate 1 takes a similar behavior as that at KU2 = 2.25, however, it is 
observed that Acetate 1 is consumed more where the minimum level of Acetate1 = 7.062 is 
attained at t = 52.51 (c.t. 5.5251) then it increases again to reach the final steady state obtained at 
the end of the period: t = 300 (c.t. 310 hr). The level of acetate 1 at KU2 = 4.5 which is lower than 
that of KU2 = 2.25 and KU2 = 0 is attributed to the inhibition of β-amyloid aggregates and its 
incapability to form channels through the membranes and to the efficacy of the drug through the 
relevant period of absorbance and the abundance of choline to react with acetate to form ACh. 
While the drug input rate increases to reach  KU2 = 9, more choline becomes available  in 
compartment 1 to react with acetate leading to consumption of acetate to give lower levels of 
Acetate 1 to reach 6.34 (corresponding to 6.34 µM)   than that at KU2 = 4.5, 2.25 , and 0.  
Figure 5.8(b) shows acetate concentrations in compartment 2 (Acetate 2).  It is observed 
that Acetate2 is produced in the period (0 < t < 2.5) to increase from 4.95 to 5.4 (corresponding 
to 4.95 and 5.4 µM) respectively. Then, at KU2 = 0, it decreases to reach 4.95 at t = 5 (c.t. 0.5 hr) 
then it increases to reach 5.22 at t = 20 (c.t. 0.2 hr). When the inlet drug rate increases to KU2 = 
2.25, 4.5, and 9, acetate 2 increases in the period (20 < t < 75) to reach 5.28, 5.35, and 5.7 
respectively (corresponding to 5.28, 5.35, and 5.7 µM) respectively due to its consumption with 
the available choline prevented from leakage because of the drug inhibition of β- amyloid 
aggregates. 
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Figure 5.9(a) shows the dynamic response of the intracellular pH in compartment 1 (pH1) 
at different input drug rates. It is observed that pH1 decreases from 8.5 to 6 in the first small  
 
 
 
 
 
period (0 < t< 5). Then, at KU2 = 0, pH1 increases to 6.5 and settles down around the latter value 
until the end of period.  The behavior of pH1 looks like that of Acetate 1. At KU2 = 2.25, more 
choline will be available to consume acetate 1 and allows to pH1 to decrease to be 6.25 until t = 
44.74 (c.t. 4.474 hr) then it increases to 6.25 and stabilizes around this value. It is observed that 
at KU2 = 4.5 and 9, pH1 decreases in the same period to 5.85 and 5.55, then it increases again and 
Figure 5.8: Time course  of: a) Acetate concentration in  compartment 1 (Ac1),  
            b) Acetate concentration in compartment 2 (Ac 2)   at   different  KU2 values 
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settles down around 6.25 until the end of the period where through the last period of drug 
administration the drug is eliminated allowing choline channels in the membrane to be formed 
and giving the opportunity to choline to get out of compartment 1. Figure 5.9(b) shows the time 
course of pH2. It is observed that the behavior of pH2 looks like that of pH1. However, the levels 
of pH2 are lower than those of pH1. At KU2 = 2.25, 4.5 and 9, pH2 decreases to reach 5.85, 5.75, 
and 5.45 respectively in the period of (40 < t < 100) c.t. (4 < t  < 10) hrs.  Then pH2 increases to 
return to the pretreatment state which is 5.99. Table 5.3 shows the typical PK and PD parameters 
and their values.  From the results and Table 5.3, it is observed that t (max), at which the 
maximum absorbed drug concentration in the presynaptic neuron (Cmax) is achieved, is in the 
range from 10 to 20 h.  The results show that longer periods are needed for high drug input rates 
to achieve Cmax as shown from the high AUC values.  
 
 
 
 
 
Figure 5.9: Time course of : a) pH in compartment 1 (pH1), 
                  b) pH in compartment 2 (pH2)    at   different   KU2 values 
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Table 5.3: PK/PD parameters 
Drug input rate (KU2) (mg) 0 225 450 900 
Cmax (µM) 0 37 92.3 379.35 
tmax (h) 0 4.474 5.251 6.8655 
β-amyloid min.  (nM) 198 164 129.6 60.94 
ACh1 max. (µM) 188 215.5 255 350 
ACh2 max. (µM) 5.5 6 7 10 
Ch1max. (µM) 99 131.3 168.2 245 
Ch2 max. (µM) 41 54 70 102.1 
AUC (µMh) 0 498.2 1199 4252.2 
 
These results are compatible with theoretical and experimental results obtained by Gopu et al., 
(2013). It is observed that as the drug input rate increases, the peak of the drug increases and the 
minimum concentration of β-amyloid decreases, and the peaks of ACh and choline 
concentrations in compartments 1 and 2  increase. It is not easy to compare PK parameters with 
other different theoretical or experimental study of rats or rabbits models due to the wide range 
of drug administration doses and experimental conditions. 
 
 5.4) Summary and Conclusions 
In this chapter, a tenth-dimension nonlinear pharmacokinetic/pharmacodynamics model 
was built to evaluate the impact of AD medications on the concentrations of β-amyloid 
aggregates and levels of ACh, Ch, acetate, pH, rate of ACh synthesis and rate of ACh hydrolysis 
in both compartments based on the choline leakage hypothesis. The interaction between drug and 
β-amyloid aggregates is formulated in a one-compartment drug which is the presynaptic 
compartment  based on single doses to investigate the dynamic behavior of cholinergic system 
before and after treatment. From the profound pharmacodynamics results through high drug 
doses administration, modeling and simulation of PK/PD is a useful tool for predicting the 
dynamic behavior of the effect of therapeutics on cholinergic and β- amyloid aggregates and 
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could be helpful for selecting the appropriate dosing of AD inhibitors not just in the specific 
targets of the neurons. It is found that modeling of drugs that stop the β-amyloid aggregation is 
the main approach for developing AD diseases where β-amyloid aggregates cause channels in 
the membranes of the presynaptic neurons leading to choline leakage and disturbances in the 
neurocycle of ACh. A one-compartment PK/PD model is developed to describe the impact of 
therapeutics on complexities in the interaction between β-amyloid aggregates, drug PK/PD, and 
ACh neurocycle.  The model could predict the reduction in β-amyloid aggregates levels and the 
increase of choline and ACh, in both compartments as well as both rates of ACh synthesis 
activated by ChAT enzyme in compartment 1, and ACh hydrolysis catalyzed by AChE enzyme 
in compartment 2.  
 Our study shows that drugs or agents that inhibit β- amyloid aggregation in the brain are 
likely to cause significant reduction in β-amyloid aggregates concentrations and increase in the 
levels of ACh and choline in both compartments. The results of the PK-PD models are 
compatible with the experimental findings obtained by Craft et al., (2002), and Walsh et al., 
(2000) who suggested that β- amyloid aggregates are mainly the reasons of lowering levels of 
ACh and even the destruction of the neurons. Although some of the model parameters are not 
known accurately, the incorporation of β- amyloid aggregates and drug equations into 2E2C 
model enabled us to understand the interaction between β- amyloid aggregates, drug, and ACh 
neurocycle and could be a guide to perform clinical and physiological experiments to achieve the 
optimal drug effect and could give systematic highlights to develop future trials for AD 
medications. 
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Chapter 6 
Conclusions and Future Work 
 
The work described in this thesis has concentrated on the effect of β-amyloid peptide 
aggregates on the cholinergic neurocycle. Although many researchers focused on β-amyloid 
interactions, the mechanisms that β-amyloid aggregates affect cholinergic neurons and reduction in  
ACh levels are still unclear. The effect of β-amyloid was investigated through proposing two 
hypotheses into two-enzyme /two compartment model (2E2C): the first is choline leakage 
hypothesis, and the other is the loss of ChAT activity hypothesis.  The dynamic behavior for all 
states of the ACh neurocycle was investigated in a wide range of β- amyloid aggregate 
concentrations and was compared with healthy neurons where there is no β- amyloid aggregates in 
order to explain the physiological and dynamic phenomena occurring in brains with Alzheimer’s 
disease. In addition, the interactions between β-amyloid aggregates and a drug orally administered 
were investigated through proposing one-compartment pharmacokinetics/pharmacodynamics 
(PK/PD) model. The main outcomes of this dissertation are summarized below. 
 
6.1 Conclusions 
In Chapter 3, the effect of β-amyloid aggregates on ACh neurocycle is studied through the 
hypothesis of choline leakage. It is suggested that β-amyloid aggregates create pathways in 
membranes of the presynaptic neurons leading to choline loss outside of the cholinergic neurocycle. 
A novel nine-dimensional nonlinear mathematical model of 2E2C of the neuron terminals is built 
where the presynaptic neuron is considered as compartment 1 and both synaptic cleft and the 
postsynaptic neuron are considered as compartment 2. It is noticed that the increase of the 
production rate of β-amyloid aggregates (KL2) leads to an increase in the amount of leaked choline 
from compartment 1 resulting in a decrease in choline levels in both compartments. In addition, it is 
observed that as KL2 increases, the intracellular concentration of β- amyloid aggregates increases 
thereby the loss of choline from compartment 1 increases.   Furthermore, the rate of ACh synthesis 
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catalyzed by the enzyme ChAT in compartment 1 and the rate of ACh hydrolysis activated by AChE 
decrease with the increase in KL2. 
The concentrations of ACh in both compartments 1 and 2 decrease significantly with the 
increase of KL2. However, the acetate level in compartment 1 increases in parallel with the increase 
in KL2 but the acetate level in compartment 2 decreases. It is concluded that the choline leakage 
hypothesis gives a reasonable explanation for the reduction of levels of the neurotransmitter and 
choline in the neurocycle of ACh which are the main hallmarks in brains with AD. The results of the 
mathematical model are compatible with the theoretical results obtained by Ehrenstein et al., (1997) 
and the experimental results obtained by Kar et al., (1998, 2004), Galdzicki et al., (1994), and Allen 
et al., (1997) on PC 12 cells. The results are also compatible with those reported by Allen et al., 
(1994) who showed that β-amyloid aggregates could lead to increase in choline loss from neurons 
and negatively affected generated ACh levels.  Therefore, a therapeutic strategy based on blocking 
choline leakage channels caused by β- amyloid aggregates is a promising strategy for curing AD and 
could achieve the physiological levels of intracellular choline and ACh.   
In Chapter 4, three different kinetic mechanisms explaining the interaction between β- 
amyloid aggregates and ChAT activity are suggested and tested through the incorporation of the rate 
of ACh synthesis where ChAT activity is inhibited by β-amyloid into the 2E2C model. The 
reduction in ChAT activity is one of the symptoms of brains with AD.  In the first kinetic 
mechanism, β- amyloid aggregates attack activated enzyme complex E2H. It is found that the 
increase in KL2 to the presynaptic neuron leads to increase in β-amyloid aggregates concentrations 
inside the presynaptic neurons and reduction of ACh synthesis rate compartment 1 and ACh levels in 
both compartments. However, it is observed that all choline levels in both compartments, the rate of 
ACh hydrolysis in compartment 2, ACh levels in compartment 2, and pH2 are not affected.   
The results obtained from the second kinetic mechanism where a competitive inhibition of β-
amyloid aggregates occurs with enzyme intermediate complex X2 are similar to those achieved from 
the first kinetic mechanism where the effects of β-amyloid interaction in both kinetic mechanisms 
are similar. In the third kinetic mechanism, β- amyloid aggregates attack all species in ChAT 
enzyme; it is found that at very high input rate of β- amyloid aggregates, there is an observed new 
phenomenon which is the oscillatory behavior for all components of the neurocycle of ACh. The 
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disturbance observed in ACh levels in both compartments reflects the harmful effect of the fully 
attack of β-amyloid aggregates to all species of ChAT. The latter disturbances in ACh neurocycle are 
the symptoms of brains with AD and indicate that the fully inhibition of ChAT caused by β-amyloid 
aggregates could be a possible kinetic mechanism explaining the loss in ChAT activity due to the 
interaction with β-amyloid aggregates in  ACh neurocycle. The latter results show that protecting the 
enzyme ChAT from β-amyloid aggregates inhibition is a reasonable therapeutic approach for brains 
with AD. In comparison to the effect of β- amyloid aggregates via choline leakage hypothesis, it is 
observed that ChAT activity to be reduced significantly needs a high concentration of inlet β-
amyloid aggregates. These results are consistent with the experimental results got by Kar et al., 
(1998) who showed that the exposure for small concentrations of β-amyloid aggregates has no 
impact on ChAT activity in cortex tissues and indicated that when neurons tissues exposed to low 
concentrations of β-amyloid aggregates for a while, choline uptake reduced significantly.  
In Chapter 5, the effects of AD therapeutics are investigated through building a new PK/PD 
model by incorporating a one-compartment drug model into the two-enzyme/two-compartment 
model to give a ten-dimensional model. The drug is suggested to interact with the tissues of the 
presynaptic neurons where β- amyloid aggregate is located.  The PK/PD model is built based on the 
effect of β-amyloid aggregates via choline leakage hypothesis where the maximum generation rate 
of β-amyloid aggregates (KL2 = 1) is considered. The dynamic behavior of all concentrations of β-
amyloid aggregates, choline, ACh, acetate, and pH in both compartments in addition to the rate of 
ACh synthesis in compartment 1 and ACh hydrolysis is investigated through observing the impacts 
of drug on β-amyloid aggregates and cholinergic neurocycle in a wide range for the input rate of 
drug (KU2).  The PK/PD model could predict the reduction of β-amyloid aggregates levels and the 
increase of choline and ACh, in both compartments as well as both ACh synthesis rate activated by 
the enzyme ChAT in compartment 1, and ACh hydrolysis rate catalyzed by the enzyme AChE in 
compartment 2.  
The outcomes of PK/PD drug model such as Cmax, Tmax , AUC, and Emax are in agreement 
with that obtained by Craft et al., (2002) who showed that concentration of β-amyloid aggregates 
after adding a therapeutic agents in the brain experiences a rapid reduction in levels of β-amyloid 
aggregates then addresses a rise then returns to the pre-treatment state where at steady state there is 
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no change in the levels of β-amyloid aggregates. Our study shows that drugs or agents that inhibit β- 
amyloid aggregation in the brain are likely to be a successful therapeutic approach to give systematic 
highlights to develop future trials, new diagnostic techniques, and medications for AD.  
 
6.2 Future Work  
The development of the present work can be extended as follows:  
1) For the effect of β-amyloid aggregates, we considered two hypotheses in the presynaptic 
neurons for the impacts of the interaction with β-amyloid aggregates. The model can be 
extended to consider the interaction between β-amyloid aggregates and acetyl co-A. The 
experimental review showed that β-amyloid aggregates could affect the synthesis of acetyl 
CoA. In addition, the effect of β-amyloid aggregates on the internal diffusion for ACh vesicles 
and the effusion of theses vesicle with the presynaptic membrane to release ACh into synaptic 
cleft. Furthermore, the model can be extended to take into account the effect of β-amyloid 
aggregates on the activity of AChE and the postsynaptic receptors. In these cases, the 
outcomes of the effects of β-amyloid aggregates on compartment 2 could help understand the 
nature of the interaction between β-amyloid aggregates and cholinergic neurocycle and the 
central nervous system.  
2) Considering the polymerization (aggregation) of β-amyloid peptides from soluble monomers 
to produce aggregates accumulating in brains with AD could help understand the toxicity 
nature of β- amyloid aggregates. The rates of association, initiation and elongation of β-
amyloid and their kinetics could enrich our model and describe accurately the impacts of β-
amyloid aggregates on ACh neurocycle and could be useful for designing therapeutic agents 
that inhibit β-amyloid aggregation and toxicity. 
3) The incorporation of β-amyloid aggregates into two-enzyme/two-compartment model 
combined with experimental and clinical data could be helpful for understanding β-amyloid 
aggregates interaction and developing therapeutic agents that inhibit the agglomeration of β-
amyloid peptides or increase the rate of defragmentation of oligomers. 
4)  The pharmacokinetic/pharmacodynamics model could be developed to be a two-
compartment or a multi-compartment based models in order to take into consideration the 
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drug blood and plasma concentrations and compare between different types of drug 
administration either orally, intravenously, or intramuscularly. 
5)  Investigate the optimal drug control strategy using the developed the pharmacokinetic and 
pharmacodynamics models in order to identify the optimal drug dose giving the maximum 
efficiency and minimize the toxic effect for the drug and β- amyloid aggregates. Optimal 
control could be used to test such hypotheses. It can be performed through multi-compartment 
model in order to properly model the actions of the drugs. Both discrete and continuous 
nonlinear optimal controls for drug doses could be employed in order to investigate the 
optimal scheduling drug doses for AD and compare the effects of different processes.   
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